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Abstract 
Substrate elucidation and mutasynthesis: Characterisation of the 
biosynthetic pathway of a tripyrrolic secondary metabolite, 
prodigiosin 
Maxime Pierre Fabrice COUTURIER 
A wide variety of biological activity can be found in the realm of secondary metabolites. The 
tripyrrole prodigiosin illustrates this perfectly with activities ranging from antimicrobial to 
immunosuppressive and anticancer. Microorganisms producing the red pigment prodigiosin 
were first isolated more than 150 years ago. Yet, its structure was only elucidated in the 1960s 
and the biosynthetic pathway remained mainly unknown until the 2000s. This secondary 
metabolite results from a bifurcated pathway where monopyrrole 2-methyl-3-pentyl-1H-pyrrole 
(MAP) and bipyrrole 4-methoxy-1H,1'H-2,2'-bipyrrole (MBC) are produced independently 
before condensation. As MBC is an intermediate in the synthesis of other natural products, the 
enzymes involved in its formation have been well characterised. In contrast, the three enzymes 
– PigD, PigE and PigB – involved in the formation of MAP are specific to the biosynthesis of 
prodigiosin and less is known about them. This thesis focuses on the latter two enzymes. 
PigE was first described as a transaminase catalysing the transformation of 3-acetyloctanal into 
3-acetyloctylamine (which cyclises to form dihydroMAP) and this activity has been confirmed 
by feeding intermediates to various gene-knockout strains. However, in vitro studies have 
demonstrated that 3-acetyloctanal could not be the product of PigD. In addition, bioinformatics 
analysis of its amino acid sequence showed that PigE has two domains: a transaminase C-
terminal moiety and an unspecified N-terminal one, which we propose is a thioester reductase 
that converts a 3-acetyloctanoyl thioester to 3-acetyloctanal. Attempted chemical 
complementation of a pigD-knockout strain of Serratia using synthetic thioester, carboxylic acid 
and aldehyde substrates showed that both the thioester and the aldehyde can be used for 
pigment production, indicating that a thioester reductase is involved in prodigiosin biosynthetic 
pathway. Furthermore, the PigE protein was expressed in a heterogeneous host, purified and 
submitted to a number of activity and kinetic assays, which demonstrated that it can reduce a 
3-acetyloctanoyl thioester substrate. 
The oxidation of dihydroMAP to MAP had previously been shown to be catalysed by an FAD-
dependent oxidase PigB. The kinetics of HapB, a homologue of PigB had been studied by a 
previous group member. To take this project further we studied the substrate flexibility of the 
Preface 
iii 
 
enzyme and used it to form new analogues of prodigiosin by mutasynthesis. Ten analogues of 
dihydroMAP with modifications either in the C2 or C3 positions were synthesised. Both 
extensions and truncations in the length of the chain at the C3 position could be accepted, 
whereas alkyl chains longer than 3 carbons on the C2 position could not be accommodated. 
Similar results were found in vivo when the analogues were fed to a pigD-knockout strain of 
Serratia, showing that PigB and the condensing enzyme PigC shared similar flexibility. Eight 
analogues of prodigiosin were hence obtained and their antimicrobial activities against Gram-
positive and Gram-negative bacteria were assessed.  
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Chapter 1. Prodigiosin: structure, synthesis 
and biosynthesis  
 
1. Structure of prodiginines 
All through human history, natural products have shown numerous applications. For instance, 
indigotin extracted from plants has been used as a dye for centuries.1 Traditional medicines and 
the use of active products from plant extracts are other examples of applications of natural 
products. With the rise of the pharmaceutical industry in the 19th century, their importance was 
once again confirmed: one of the most well-known and commonly used drugs, aspirin, derives 
from salicylic acid found in willow trees.2 Between 1981 and 2014, 25% of the drugs approved by 
the FDA were either natural products or modified natural products.3 If we include synthetic 
molecules mimicking natural products, that number rises to 45%. Therapeutic areas covered by 
natural products are also very diverse: almost half of the molecules accepted for cancer 
treatment since the late 40s derived from natural products3 and 90% of the antimicrobials used 
clinically today come from microorganisms.4 Considering that cancer occurrence has increased 
by more than 10% in the UK over the last 20 years5 and the fast emergence of antibiotic 
multiresistant strains,6 discovery of new medicines is crucial and natural products represent a 
large pool of potential candidates. 
In bacteria, the genes coding for the proteins involved in the production of secondary 
metabolites are usually gathered in clusters (called biosynthetic gene clusters, BGCs). In some 
species, such as some Actinobacteria, more than a dozen such clusters can be present, and the 
understanding of these clusters and the biological assessment of their products are a potential 
source of new drugs.   
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Figure 1.1: The four groups of prodiginines 
Prodiginines are a family of secondary metabolites with a 2-pyrrolyldipyrromethene skeleton 
(Figure 1.1) and a methoxy group on ring B. The conjugated -system containing seven double 
bonds gives them a bright red colour. Prodiginines are divided into 4 groups, depending on the 
substituents on ring C (Figure 1.1 and 1.2).7 Group 1 prodiginines have only linear alkyl chains 
as illustrated by prodigiosin 1a from Serratia marcescens (Sma) and undecylprodigiosin 2 from 
Streptomyces coelicolor A(3) (Figure 1.2a).8 S. coelicolor also produces streptorubin B 3, which, 
like metacycloprodigiosin 4 from Streptomyces longisporus ruber (Figure 1.2b),9 is an example 
of a prodiginine from group 2, where position 1 and 3 of ring C are connected. An example of a 
group 3 prodigiosin, with a cyclic structure between positions 2 and 3 of ring C, is given by 
cycloprodigiosin 5 produced by Alteromonas rubra.10 Finally, in group 4, a macrocycle connects 
rings A and C, as illustrated in Figure 1.2d by Actinomadura madurae’s cyclononylprodigiosin 6 
and methylcyclodecylprodigionsin 7.11 
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Figure 1.2: Examples of prodiginines from the four groups 
2. Discovery and elucidation of the structure of prodigiosin 
Prodigiosin 1a is probably the most well-known example of a prodiginine. 
Indeed, it is famous for its alleged involvement in a number of “miracles” 
– hence its name – and it was the first prodiginine to be characterised. 
Observation of bleeding food, especially in starch rich material such as 
polenta or bread (see Figure 1.3), even religious bread, has been 
documented since the middle ages and up to the 20th century and was 
often attributed to either witchcraft or divine intervention. In the early 
19th century, recurring occurrences of this phenomenon in northern Italy triggered a scientific 
investigation and botanist Pietro Melo, pharmacist Bartolomeo Bizio and physician Vincenzo 
Sette independently concluded that the red coloration was due to fermentation and achieved 
the first isolation of Sma.12 This microorganism was at the time thought to be a fungus but was 
quickly reclassified as a bacterium. However, the molecule responsible for the pigmentation 
remained unknown for decades. The first isolation of prodigiosin was performed by Wrede and 
Figure 1.3:  
Bleeding bread 
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Hetche in 1929.13 Using degradations studies, they were able to show the presence of three 
pyrroles and a methoxy group and proposed three possible structures (Figure 1.4).14 
 
Figure 1.4: The three potential structures for prodigiosin proposed by Wrede and Hetche 
Another 30 years passed before Vogel and Wasserman used biochemical tools to rule out 
incorrect structures. In the early 50s, it was observed that some mutant strains of Sma could not 
produce prodigiosin on their own but could cross complement each other (the pigment was 
produced when the two strains were cultured together). Santer and Vogel15 hypothesized that 
an intermediate in prodigiosin production accumulated in such strains. They were able to isolate 
a compound consistent with the chemical formula C10H10O2N2 and to show it contained at least 
one pyrrole with a hydrogen on one of the carbons  to the nitrogen. Wasserman and 
coworkers16 were then able to show that prodigiosin resulted from the condensation of the 
compound isolated by Vogel and 2-methyl-3-amylpyrrole (MAP) 9, a compound that Wrede and 
Rothlaas14 had observed during their degradation studies. They also were able to demonstrate 
that Vogel’s compound was a bipyrrole with an ,’ linkage and with a methoxy on the C3 
position of one ring and an aldehyde on the C2 or C4 position of the same ring (Figure 1.5c). 
This ruled out two of the three initial proposed structures.  
 
Figure 1.5: Intermediates in prodigiosin structure elucidation a) MAP 8, isolated by Wrede and 
Rothlaas, b) synthetic precursor for structure B and C c) potential structures for the intermediate isolated 
by Santer and Vogel 
Definitive proof of prodigiosin structure was reported by Rapoport and Wilson in 1962, when 
they synthesised a molecule whose optical properties matched perfectly the ones of natural 
prodigiosin. In a series of papers17,18 they first synthesised a methoxypyrrole 1017 that would have 
been the precursor of structure B, and showed it was inconsistent with the intermediate isolated 
by Vogel. They then synthesised the two possible regioisomers of the precursors (11 and 12) 
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proposed by Wasserman et al.16 and condensed them with MAP. By comparing the UV 
absorbance of the two products with natural prodigiosin18 they were able to conclude that the 
structure of prodigiosin is the one presented in Figure 1.2. This also suggested that the final step 
for prodigiosin biosynthesis was the condensation of MAP 9 and 4-methoxy-2,2'-bipyrrole-5-
carboxaldehyde (MBC) 11. 
Hence, almost 150 years after the first isolation of a bacterium producing prodigiosin, the 
structure of the pigment was finally known. Yet, two configurations of the compound are 
possible (Figure 1.6). Considering the variety of biological activities that prodigiosin displays 
(see Section 5), structure activity tests and prediction are important for the design of new 
potential drugs and it is hence crucial to know which conformation is predominant. Rizzo et al.19 
addressed this issue and showed that the two conformational isomers always exist in equilibrium 
and the rates of interconversion – and consequently the ratio – depended heavily on the pH of 
the solution. Indeed, the -conformer is able to form an extra hydrogen bond when protonated, 
leading to a difference of pKa between the two forms. As a result, prodigiosin is almost purely in 
its  form at low pH and in its  form at high pH (Figure 1.6). 
 
Figure 1.6: The two conformations of prodigiosin 
3. Elucidation of prodigiosin biosynthetic pathway 
One of the first investigations into prodigiosin biosynthetic pathway was conducted by Williams 
and his group by isotopic labelling20 as well as by trying to enhance the production of pigment 
by adding single amino acids to the culture broth21. This showed that proline, alanine, histidine, 
acetate and serine were likely to be involved in the formation of the secondary metabolite.  
As mentioned above, Wasserman and co-workers16 showed in the 60’s that prodigiosin resulted 
from the condensation of MAP and MBC, suggesting a bifurcated pathway. However, the 
molecular biology tools necessary for a complete elucidation of the pathway were not available 
before the early 2000s when the complete sequence of S. coelicolor became available. This 
allowed Cerdeño et al.22 to attribute a function to each of the 23 genes present in the BCG (noted 
red) by sequence comparison (Figure 1.7). They were then able to support their predictions 
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through complementation experiments with knockout mutants. They concluded that two genes 
coded for regulators, six were involved in the formation of MBC 11 (Figure 1.8), eight in the 
biosynthesis of 2-undecylpyrrole 13 (Figure 1.9) and that two were involved in housekeeping 
functions. One gene was also predicted to code for the enzyme catalysing the condensation of 
11 and 13 into undecylprodigiosin 2 and another gene was forecasted to code the enzyme involved 
in the conversion to Streptorubin B 3.  
A few later years later, Salmond and co-workers23,24 managed to clone and express the 
prodigiosin BGC in an heterologous host. Whilst investigating carbapenem production by 
Serratia sp. ATCC 39006 (S39006) by cloning its genome library into E. carotovora ssp. 
carotovora, they observed production of prodigiosin in strains transformed with cosmid 
pNRT104.23,25  By comparing Sma’s and S39006’s genomes, they located the Sma cluster, cloned 
it and expressed it in E. coli.24 The clusters of the two Serratia species showed a good 
conservation of 14 genes (pigA-N), which were believed to be responsible for the biosynthesis. 
An additional gene, pigO, was present in the Serratia 39006 operon, but knocking it out did not 
prevent the production of pigment, suggesting a regulatory role.24 
Williamson et al.26 then prepared mutants of S39006 with in-frame deletions or insertions in 
every biosynthetic gene. For each mutant, the accumulation of intermediates was checked by 
Liquid Chromatography-Mass Spectrometry (LC-MS) and the order of many of the enzymes was 
determined by cross-feeding (Figure 1.8).  
As mentioned earlier, prodiginines can be produced by a variety of micro-organisms. In addition, 
a given prodiginine can be found in different strains. For example, prodigiosin 1a is produced 
not only by Sma and S93006 but also by other strains of Serratia (nematodiphila and plymuthica 
for instance), Vibrio gazogenes ATCC 43942,27 Hahella chejuensis KCTC 2396 (H2396)28 and 
Janthinobacterium lividum BR01.29  Interestingly, the BGC, noted pig, is remarkably well 
conserved among those organisms (see Figure 1.8).30 S39006 was originally believed to be a 
strain of Sma, but deeper genetic analysis contradicted this assessment.24 H2396 is a marine 
bacterium isolated from the South Korea sea and produces prodigiosin using the hap cluster. 
This cluster contains 15 genes, one more than Sma: the sequence of the homologue of pigB 
(hapB) contains a stop codon, leading to a gene coding for the N terminal domain and one for 
the rest (see Chapter 2).28 Janthinobacterium lividum BR01 is a psychrophilic bacterium found in 
Alaskan soil. Although all the other examples of prodigiosin producer are -proteobacteria, this 
one is a -proteobacterium. In addition, in this strain, the genes coding for PigB and PigC are 
fused, leading to gene pigBC.29   
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Although the biosynthetic pathways followed are similar with red and pig, the organisation of 
the BCG are different: the order of the genes is not the same and they are arranged in three 
operons in red instead of one in pig (Figure 1.7).30 A recent study showed that the pig cluster 
and its homologues in -proteobacteria descended from a common ancestor, whereas the red 
cluster shared most analogy with other actinobacterial clusters coding for pyrrole formation in 
other secondary metabolites, hinting horizontal gene transfer and convergent evolution.30 
Nevertheless, all but three genes in the pig cluster show strong homology with enzymes coded 
by the red cluster.24 The three ‘missing genes’ are pigB, pigD and pigE, suggesting a strong 
conservation of MBC biosynthesis from one prodiginine to another whereas the biosynthesis of 
the monopyrrole involves more variation.  
Combining results obtained with S. coelicolor31 and S39006, a complete biosynthetic pathway 
for prodigiosin 1a was proposed by Williamson et al. (Figure 1.8).26 
3.1. Biosynthesis of MBC24,31 
The initial precursor of bipyrole MBC is L-proline. In Serratia, PigI activates L-proline using 
adenosine triphosphate (ATP) and transfers it to the thiol group of a peptidyl carrier protein 
(PCP), PigG. PigA then catalyses the oxidation of the pyrrolidine moiety, leading to the 
corresponding pyrrole (see Figure 1.8). In a process similar to that of polyketide synthases 
(PKS), the thioester is then transferred to the active site of PigJ. A decarboxylative coupling of a 
malonyl unit carried by an acyl carrier protein (ACP) domain of PigH onto the pyrrole-2-
carboxyl thioester then yields a pyrrolyl--ketothioester attached to PigH. A pyridoxal 
phosphate (PLP) dependent -oxoamine synthase domain in PigH then catalyses a 
decarboxylative condensation of serine with the pyrrolyl--ketothioester to release the 4-
hydroxy-2,2'-bipyrrole-5-methanol (HBM) 14. According to Williamson et al.26, no accumulation 
of any of the intermediates before HBM could be detected by mass spectroscopy (MS), which is 
consistent with protein-bound intermediates. 
Flavin dependent PigM then catalyses the oxidation of HBM into 4-hydroxy-2,2'-bipyrrole-5-
carbaldehyde (HBC) 15. Interestingly, this intermediate can be accepted by the condensing 
enzyme PigC, leading to the formation of norprodigiosin 16. Finally, MBC is obtained by 
methylation of HBC by PigF, possibly in complex with PigN. A pigF knock out strain only 
produces norprodigiosin, whereas in the absence of PigN prodigiosin is produced but in lower 
amounts, which suggests that PigN is not essential for the methylation but does facilitate it.26 
Chapter 1. Prodigiosin: structure, synthesis and biosynthesis  
 
8 
 
 
Figure 1.7: Examples of prodiginines BGCs; from top to bottom: S39006, Sma, Janthinobacterium lividum BR01, H2396, S. coelicolor. Blue: synthesis of bipyrrole 
MBC; green: synthesis of monopyrrole; red: condensation; purple: cyclisation; orange: no known function. The transmembrane domain of PigB and the 
corresponding gene in H2396 are green and white. Genes with the same function in the pig/hap clusters and the red cluster are connected.  
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PCPs such as PigG need to be phosphopantetheinylated after translation to be active. Sequence 
comparisons and knock out experiments indicated that PigL was responsible for this step of the 
pathway.31 The function of the last enzyme involve in MBC biosynthesis, PigK,  is still not clear: 
knock out mutants were still able to produce prodigiosin , but the ratio between prodigiosin and 
norprodigiosn was changed compared to the wild type, which suggested that PigK is involved in 
MBC formation.32 Comparison with similar proteins suggested that PigK could be an oxygenase 
taking HBC as a substrate.33 
3.2. Biosynthesis of MAP 9 
MAP biosynthesis relies on three enzymes: PigD, PigB and PigE. They have been less extensively 
studied than the proteins involved in MBC formation because they are specific to prodigiosin 
whereas the formation of MBC occurs in a similar fashion in the biosynthesis of other 
prodiginines. 2-Octenal 17, potentially formed by the action of a thioester reductase on octenoyl 
ACP, an intermediate in fatty acid biosynthesis, was originally presumed to be the starting point 
of the pathway.26,34,35 However, Dresen et al.36, showed that thiamine pyrophosphate (TPP)-
dependent PigD, when presented with a aldehyde substrate such as 2-octenal, catalyses a direct 
attack of an acetyl anion equivalent at the carbonyl carbon instead of the  position. Yet, with 
less reactive carbonyls (ketones or thioesters) the required attack at the -carbon was 
observed.36 It is therefore now proposed that PigD catalyses the decarboxylative coupling of 
pyruvate with octenoyl ACP (or CoA) to give the corresponding 3-acetyloctanoyl thioester. 
PigE is known to be responsible for the formation of 3-(2-aminoethyl)octan-2-one 18 (which 
cyclises to give dihydroMAP 19), but its exact substrate and activity are yet to be demonstrated. 
A crystal structure,35 sequence analysis and feeding studies26 are all consistent with the C-
terminal half of PigE being a PLP-dependent transaminase, catalysing the transformation of 3-
acetyloctanal 20 into 18. Bioinformatic analysis of the N-terminal half of PigE, suggests that it 
might be a reductase which releases the aldehyde, possibly from a thioester (see Chapter 4). 
H2MAP 19 is then oxidised to MAP by PigB. Previous work in the group showed that PigB was a 
FAD dependent oxidase and that the reaction requires O2 and releases H2O2.37 
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Figure 1.8:Prodigiosin biosynthesis in S39006 Top: biosynthetic pathway; Bottom, biosynthetic gene cluster; in green: biosynthesis of monopyrrole MAP, in 
blue: biosynthesis of bi-pyrrole MBC, in red: condensation. KS: ketosynthase, ACP: acyl carrier protein, OAS: -oxamine synthase; Pig enzymes are involved in the 
formation of prodigiosin 1a by S39006; Red enzymes are involved in the formation of undecylprodiogiosin 2 by S. coelicolor  
 
 
 PigC 
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3.3. Biosynthesis of 2-undecylpyrrole 13 
As expected from genome analysis, the biosynthesis of 2-undecylpyrrole 13 is very different from 
that of MAP 9.38–40 It appears that at least 6 genes are involved in the biosynthesis of this pyrrole 
unit (Figure 1.10). It has been proposed that the biosynthesis starts with the loading of a malonyl 
group on the ACP RedQ. The malonyl group would then undergo a decarboxylative 
condensation with acetyl-CoA, perhaps catalysed by the ketosynthase RedP.38 The acetoacetyl-
RedQ would then be reduced, probably by enzymes normally involved in the fatty acid 
biosynthesis as no genes encoding enzymes fulfilling these functions have been found in the 
cluster. The chain would then be elongated by translocation onto RedR followed by 
decarboxylative condensation with malonyl-RedQ, keto-reduction, dehydration and enoyl 
reduction four times, leading to dodecanoyl-RedQ. Thioesterase RedJ then releases dodecanoic 
acid 21. Sequence analysis of the remaining enzymes, combined with LC-MS analysis of knock 
out mutants, suggested that the dodecanoic acid was then loaded on an ACP domain in RedL by 
the adjacent adenylation (A) domain. The ketosynthase (KS) domain could then catalyse the 
condensation of the malonyl group loaded on the next ACP domain with the dodecanoyl 
thioester, leading to the corresponding -ketotetradecanoyl thioester. Finally, condensation of 
the thioester with glycine, catalysed by the PLP dependent −oxoamine synthase (OAS) domain, 
would release an -oxoamine, which could spontaneously cyclise and form 5-undecylpyrrolin-
3-one 22. The final reduction is believed to be catalysed by RedK, before dehydration leads to 13. 
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Figure 1.9:  Proposed biosynthetic pathway of 2-undycylpyrrole 
3.4. Condensation: PigC 
Mutants of S39006 with an in-frame deletion in pigC (S39006 ΔpigC) showed accumulation of 
both MBC and MAP. Furthermore, this strain was able to complement mutants with a knockout 
either in the MAP pathway or in the MBC pathway, indicating that ATP-dependent PigC was 
responsible for the condensation into the final pigment.26 Interestingly, the reaction can occur 
spontaneously under acid catalysis, but the bacterial internal pH is not low enough for the 
reaction to occur uncatalyzed.41 Two regions of PigC have a strong homology with pyruvate 
phosphate di-kinase (PPDK): the N-terminal domain of PigC is similar to the ATP binding 
domain of PPDK, whilst the C-terminal domain of PigC is similar to the phosphoryl transfer 
domain.32 The central domain of PigC has no strong homology and is presumed to bind MBC 
and MAP and to catalyse the reaction, probably via the phosphorylation of the oxygen atom of 
MBC’s aldehyde group, followed by nucleophilic attack by MAP and release of the phosphate. 
PigC has also displayed a remarkable substrate flexibility for MBC as well as for MAP units (see 
Chapter 2). In undecylprodigiosin biosynthesis, the condensation step is catalysed by PigC 
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homologue RedH.42 Interestingly, both PigC (see chapter 2) and RedH can accommodate 
variations of ring A of MBC, leading to analogues of prodigiosin and undecylprodigiosin.42,43 
3.5.  Formation of cyclized prodiginines 
For group 2 prodiginines, cyclisation occurs after the condensation step. 
For instance, in S. coelicolor, it has been shown that RedG (in purple in 
Figure 1.7) catalyses the conversion of undecylprodigiosin 2 to 
streptorubin B 3 (see Figure 1.2b). Similarly, in S. longisporus, 
metacycloprodigiosin results from the action of McpG, a homologue of RedG on 2.9 These 
enzymes have been shown to belong to the family of Rieske Non-Heme Iron-Dependent 
Oxygenases.9 This family of enzymes relies on sulphur-iron complexes (Figure 1.10) to oxidise 
a variety of functionality.44 
The formation of cycloprodigiosin 5 follow a similar mechanism: Keasling and co-workers 
showed that it resulted from an oxidative cyclisation of prodigiosin 1a by the alkylglycerol 
monooxygenase-like enzyme PRUB680 in P. rubra. Yet, PRUB680 is different from the other 
enzymes catalysing the cyclisation of prodiginines as far as it is not a member of a Rieske 
oxygenase family. It is also noteworthy that this enzyme has no equivalent in Serratias’ genomes 
which explain why cycloprodigiosin could not be observed in those prodigiosin producers.45 
Similarly, the formation of the macrocycle in group 4 prodiginines is still to be explained. 
4. Related compounds 
Comparison of prodiginine BGCs against all genomes shows some genes of these pathway have 
homologues in the BGC of a wide range of other secondary metabolites. For instance, pigA, pigI 
and pigJ have shown homology with genes in Pseudomonas aeruginosa’s plt cluster, which is 
involved in the formation of the monopyrrole pyoluterin.30 Whilst this is noteworthy as the use 
of proline to produce pyrrole is relatively uncommon among -proteobacteria, those three gene 
represent only a small proportion of the cluster. Other natural products share a much stronger 
analogy with prodiginines. 
4.1. Marineosin 
Marineosins A (23) and B (24) (Figure 1.10), have been isolated and characterised by Fenical 
and coworkers46 from marine actinomyces.  
Figure 1.10: Rieske 
center 
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Figure 1.11: Structure of marineosins and their intermediate 23-hydroxyundecylprodigiosin 
Despite having a structure much more complex than most prodiginines, it has been shown that 
their BGC (mar) is highly homologous with the red cluster, apart from an additional gene, 
marA.47 Interestingly, knock-out of the redG homologue in the mar cluster led to the 
accumulation of a group 1 prodiginine, 23-hydroxyundecylprodigiosin 25, which suggested those 
compounds derived from a biosynthetic pathway similar to undecylprodigiosin and that MarA 
performs a final reduction. 
4.2. Roseophilin 
Roseophilin 26 (Figure 1.12) was first isolated from Streptomyces griseoviridis in 199248 and its 
structure49 and stereochemistry50,51 were fully elucidated a few years later. Even though it looks 
very prodiginine-like, its hydrocarbon side-chain is linked to the conjugated system by more C-
C bonds than in any other prodiginine. In addition, ring B is a furan in the case of roseophilin, 
whereas it is a pyrrole in the prodiginines. Yet, the roseophilin BGC (rph) from S. griseoviridis 
shows a strong analogy with the red cluster.52 The similarity between the two pathways was 
confirmed when prodigiosin R1 27 was isolated from S. griseoviridis52: it is believed that its 
precursor 11’-dimethylundecylprodigiosin 28 plays a role in the formation of dechlororoseophilin 
29, which has been shown to be an intermediate in roseophilin biosynthesis.53 Challis and co- 
workers proposed that after the formation of intermediate 30 through two oxidative cyclisations 
catalysed by a Reiske oxygenase-like enzyme, ring B could open via the deprotonation of the 
hydroxyl (31). After a prototropy, the oxygen could perform a nucleophilic attack on the imine 
(32). Loss of ammonia would then lead to the furan which is characteristic of roseophilins 
(Figure 1.12b).54 
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Figure 1.12: Roseophilin: a) structure and potential biosynthetic intermediates; b) proposed mechanism, 
adapted from Withall et al.54 
4.3. Tambjamines 
Tambjamines (Figure 1.12) are a family of yellow secondary metabolites which shares the 
bipyrrole moiety (rings A and B) of the prodiginines, but where the cycle C is replaced by a 
substituted imine. They were first isolated from marine invertebrates but in the last decade 
several compounds from this family have been isolated from soil and marine bacteria such as 
Pseudomonas tunicata. The BGC for tambjamine YP1 33 was elucidated by Burke et al.55 and it 
seems the bipyrrole structure results from a similar pathway to the one leading to the formation 
of MBC in a prodiginine biosynthesis. The analogy between the two pathways goes further: very 
recently, analysis of the cluster of cyclic tambjamine MYP1 34 showed the presence of a gene 
similar to redG which could play the same role in the final cyclisation of the molecule.56  
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Figure 1.13: Tambjamines a) General structure, b) Examples 
5. Biological properties of prodiginines 
Interest in prodiginines has been renewed in the past 20 years as their biological activities and 
potential therapeutic applications were discovered. Some of these properties are described here 
along with proposed mechanisms of action. 
5.1.  Antimalarial 
Papireddy et al.57 conducted in vitro tests of prodigiosin along with three other natural 
prodiginines and a range of synthetic ones against the malaria parasite P. falciperum pansensitive 
D6. They concluded that they were all extremely potent with IC50 value between 8 and 1.7 nM 
for the natural compounds and were more active than their reference drug, chloroquinine. The 
best value was obtained with metacycloprodigiosin.  This was consistent with the finding of  
Isaka et al.58: they reported an IC50 of 12 nM for metacycloprodigiosin against P. falciperum. 
Finally, Kim et al.59 investigated cycloprodigiosin and reported a similar IC50 value. These 
promising in vitro assays can be translated into animal models: prodigiosin has for instance been 
shown to effectively treat monkeys infected with malaria.60 Castro also managed to double the 
survival time of mice infected by Plasmodium berghei by injecting them with 40 mg/kg of 
prodigiosin.61 This quantity was much lower than the toxicity threshold as no death due to 
toxicity seemed to appear before 160 mg/kg. Most studies, with the exception of Papireddy et 
al.,57 reported no toxicity against mammalian cells at antimalarial dosage.58,59 Interestingly, 
structure-activity relationship (SAR) studies showed that ring C had little influence on the 
activity, which might explain why metacylcloprodigiosin and cycloprodigiosin had similar IC50 
values.62 This also meant that tambjamines shared prodiginines’ potential against malaria.62 In 
conclusion, these studies suggested that prodiginines seem an interesting lead in the fight 
against malaria. Interestingly, prodigiosin has recently been shown to be able to affect 
Trypanosoma cruzi, another protozoan.63 
Chapter 1. Prodigiosin: structure, synthesis and biosynthesis  
 
17 
 
5.2.  Antifungal 
Although less common than viral and bacterial infections, fungal infections are also an 
important risk both for human health – Cryptococcus sp. leads to 600,000 mortalities every 
year64 – and the environment.  The fungal disease aspergillosis is responsible for wiping out sea 
fan coral.65 This highlights the importance and the urgency to find methods to prevent fungal 
propagation. 
Prodigiosin has been shown to enhance fungicidal effect of other compounds.66–68 Moreover, 
Sma has been used by itself on several occasions to control fungal proliferation. It has also been 
shown that the supernatant from prodigiosin producing Serratia sp. had a growth inhibitory 
effect against Pythium myriotylum, Rhizoctonia solani, Sclerotium rolfsii, Fusarium oxysporum 
and oocycete Phytophthora infestans .69 
5.3. Anti-bacterial 
Emergence of multi resistant strains makes the development of novel classes of antibiotic a 
priority. The activities of prodiginines, in particular prodigiosin 1a, have been tested against a 
number of bacteria, both Gram-positive and Gram-negative.63,70–72 Prodigiosin showed growth 
inhibition against Staphylococcus aureus, Enteroccocus faecalis, Streptococcus pyogenes71, 
Salmonella typhimurium, E. coli, C. albicans  and Bacillus subtilis.73 The activity of prodigiosin 
against oxacillin resistant S. aureus71 is noteworthy as those strains are a growing concern in 
health care facilities where they are responsible for many hospital infections.72 Borrelia 
burgdorferi is another strain of interest inhibited by prodigiosin. This strain, responsible for 
Lyme disease, is resistant to multiple antibiotics but is affected by prodigiosin both in its 
stationary phase and when it is actively growing.74  
Besides its growth inhibition capacity, prodigiosin is also able to induce programmed cell death 
in Bacillus cereus, Pseudomonas aeruginosa, S. aureus and E. coli and to reduce the motility  of 
B. cereus and E. coli.75  
These studies tend to show that prodigiosin is able to affect both Gram-positive and Gram-
negative bacteria, but some discrepancies are to be noted. For example, Lapenda et al. did not 
observed any effect on Gram-negative strains.71 Different mechanisms of actions have also been 
proposed: Stopar and co-workers70 claimed that prodigiosin affected growth, cell division, 
protein and RNA synthesis and overall metabolic activity whilst cytoplasmic membrane and 
chromosomal DNA remained intact; whereas Suryawanshi et al.76 suggested a chaotropic 
behaviour, with disruption of the plasma membrane and loss of essential metabolites 
responsible for the activity. In addition, it is possible that mechanisms of action of prodigiosin 
Chapter 1. Prodigiosin: structure, synthesis and biosynthesis  
 
18 
 
on cancer cells (proton transport, DNA cleavage, see section 1.5) would also contribute to the 
antibacterial effect. It is worth noting that no information on the mechanism could be gathered 
from the analysis of a resistance gene as none has been found to date.  
Recently, Klein et al. tested prodigiosin along with a range of group 3 prodiginines (See Figure 
1.1) against E. coli, B. subtilis, Corynebacterium glutamicum, Saccharomyces cervisiae and 
Komagataella phaffii. It appears that the size of the chain between the C2 and C3 position of the 
ring C has little influence on the antibacterial activity.77 Interestingly none of the compounds 
showed activity against the producing organism, P. putida. 
5.4. Immunosuppressive 
As mentioned above, prodiginines, like most secondary metabolites were first screened for their 
antimicrobial activity. More recently, the interest shifted toward their immunosuppressive 
properties,78 leading to promising results against some auto-immune diseases. This is of 
importance as the existing treatments, cyclosporin A, rapamycin or FK-506 are known for their 
toxicity and low efficacy.78 Undecylprodigiosin 2 is probably the prodiginine which has been the 
most extensively investigated.79–82 These studies revealed that, in mice, 2 was able to inhibit T 
cell proliferation81 without affecting antibody production82 or cell death. It appeared that 2 
inhibits both Ca2+ dependent and Ca2+ independent mitogens, with a preference for cytotoxic T 
lymphocytes, hence preventing their proliferation. Interestingly, results about its effects on B 
lymphocytes were contradictory from one study to another: Tsuji et al.81 observed a selective 
inhibition of T-cells whereas Songia et al.79 observed effects on B-cells. This could be of 
importance as B-cell lymphoma is a major side-effect in immunosuppressed patients treated 
with cyclosporin A. However, the toxicity observed in mice makes 2 a very unlikely drug 
candidate.79 
Cyclic prodiginines have also been investigated.83–85 Despite being slightly less potent than 2, 
metacycloprodigiosin 3 showed a good specificity to inhibit T cell proliferation in vitro. A 
massive drawback was its severe toxicity in vivo.85 Similarly, cycloprodigiosin 8 salts showed 
inhibition of murine T cell proliferation83 and helped prevent graft rejection in rats.84 However, 
it displayed important side effects in rats84 and led to cell death at inhibition concentration,83 
which renders modifications necessary to make the compound druggable. 
A few studies on prodigiosin 1a have also been conducted.86–88 Han et al.87 isolated prodigiosin 
from culture broth of Sma B and showed that it could inhibit the proliferation of T-cells 
efficiently at 30 nM in vitro, whereas cell death could not be induced at concentration lower 
than 100 nM. They also demonstrated a strong specificity: B-cell proliferation was not affected 
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at all by prodigiosin.87 Prodigiosin inhibits interleukin 2R receptor expression, which disturbs 
the interleukin 2 signalling pathway and prevents the proliferation of the cells.88 These in vitro 
results were applied in vivo: prodigiosin showed promising results to delay the progression of 
autoimmune diabetes and collagen induced arthritis.88 Moreover, it also has a positive effects 
against graft-versus-host disease and can enhance the effects of current drugs such as 
cyclosporin A.86 Interestingly, and contrary to the other bacterial prodiginines, none of the 
studies reported toxicity against rats. 
To overcome the limitation presented by natural prodiginines’ toxicity at inhibition 
concentrations, a number of synthetic analogues were also screened for immunosuppressive 
effects.89 It resulted in a lead compound, PNU 156804 35 (Figure 1.14), which supressed T cell 
activation as well as 2, but with a decreased toxicity.90 Further in vivo 
studies showed it was as efficient as the reference cyclosporin A to 
extend rats’ lives after a heart transplant.91 Interestingly, 35 did not 
seem to affect the same target as prodigiosin but instead inhibited 
Janus kinase 3, a cytoplasmic tyrosine kinase associated with the  
chain of the interleukin 2 receptor.91 As of today, this molecule still 
seems to be the most promising candidate for an immunosuppressive 
drug with a prodiginine scaffold.  
5.5.  Antitumour 
The potential of prodiginines in the fight against cancers has been 
widely explored. For instance, prodigiosin 1a has been tested by the 
National Cancer Institute against more than 60 cell lines and 
showed an average inhibitory concentration (IC50 ) of 2.1 µM.92 1a 
gave particularly promising results against breast cancer93 and 
neuroblastoma cell lines94 and was potent enough to be tested a 
preclinical trial against pancreatic cancer.32 However, a number of 
other analogues have also been tested. Undecylprodigiosin 2 was 
effective against human breast carcinoma95 whereas cycloprodigiosin 5 induced apoptosis in rat 
liver cancer.96 Besides their activity against cancer cell lines, prodiginines do not seem to be toxic 
against noncancerous cells.78,97 Moreover, none of the multidrug resistance mechanisms 
examined up to now seem to affect prodiginines.96,98 Those interesting properties of prodiginines 
led to the development of obatoclax 36 (Figure 1.15), which was tested against multiple types of 
cancer. For instance, it has reached phase II against different blood cancer (leukemia99 and 
lymphoma100) and was in combination with other drugs against lung cancer.101,102 
Figure 1.14: PNU 156804 
Figure 1.15: Structure of 
anticancer agent obatoclax 
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Prodiginines seem to have several modes of action against cancers cells (Figure 1.16). They have 
been shown to prevent cell invasion and migration, which is key against metastasis. For instance, 
1a decreases the expression of RhoA, a GTPase regulating transduction pathways involved in cell 
adhesion and migration and inhibits matrix  metalloproteinase-2, an enzyme  playing a key role 
in invasion as it degrades extracellular matrix proteins.98  More recently, Wang et al.93 obtained 
very good results using 1a and 36 to treat breast cancer: by acting on the Wnt/-catenin 
signalling pathway, the two prodiginines not only reduced the amount of migration but also 
triggered apoptosis. This could explain how 1a and 5 increase the survival in pulmonary 
metastasis melanoma.96 Prodiginines also can prevent proliferation by arresting the cell-cycle. 
This has been particularly well studied in the case of lymphocytes: T lymphocytes are blocked 
before entry into S phase but do not die. Treatment with prodigiosin leads to a decrease in 
known cell-cycle regulatory genes expression such as cyclin A, cyclin D2, cyclin E, cdk2 and cdk4, 
leading to an arrest in mid-late G1.78,79,90 Yet, the predominant effect of prodiginines against 
cancer cells is the triggering of apoptosis. Li et al.103 recently illustrated this phenomenon by 
showing that 1a up-regulated the production of apoptosis related proteins such as Caspase 9 and 
Bax in human carcinoma and prostate cancer cell lines. The mechanisms leading to programmed 
cell death can be divided in three main categories.  
5.5.1. Mitogen- activated Protein Kinases (MAPKs) 
Studies have shown that prodigiosin could induce apoptosis both in a caspase dependent103 and 
independent manner.104 MAPKs control many physiological processes and are divided into three 
families: JNKs, p38 MAPKs and ERKs.78 All three can be targeted by prodiginines. For instance, 
metacycloprodigiosin 4 activated a JNK, leading to the increase of an apoptotic signal.85 
Prodigiosin 1a can target p38 MAPKs, but not JNKs.105,106 Phosphorylation of ERKs by prodigiosin 
has not been observed but prodigiosin-induced apoptosis can be prevented by adjusting this 
pathway.107 Prodiginines can target other crucial cellular cascades.  The Wnt/-catenin cascade93 
was mentioned above, but Hong et al.108 also shown that prodigiosin could rescue p53 deficient 
cells by up-regulating p73. The diversity of cascades that prodiginines can affect could be related 
to their ability to inhibit the specificity of some tyrosine phosphatases.109 
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5.5.2. pH regulation 
It is essential that pH in cells and specialised organelles remains in an appropriate range. 
Changes in the intracellular pH can trigger apoptosis.110 Many examples of prodiginines 
disturbing this equilibrium have been reported.111 Prodiginines can act as ionophores and help 
the symport of H+ and Cl- across membranes. This leads to a decrease in pH without changing 
the membrane potential.112 An indirect consequence of the relocalisation of H+ by prodiginines 
is an ATPase uncoupling effect, either in bacteria and mitochondria (F0F1-ATPases)111 or in 
eukaryotes (V-ATPases).112–117 Structure-activity relationship on H+/Cl- transport concluded that 
the presence of the three pyrroles rings118,119 as well as the alkyl chain on the C2 position of the C 
ring120 are necessary to observe the activity. It is likely that this chain helps in getting the 
prodiginine into the membrane.  
5.5.3. DNA cleavage 
In the presence of copper, prodiginines are able to bind and cleave dsDNA.92 Melvin et al. studied 
extensively the interaction between prodigiosin and dsDNA and were able to show that 
prodigiosin intercalates in the minor groove via hydrogen bond, electrostatic and van der Waals 
contacts.121–123 In terms of mechanism, prodigiosin binds in a 1:1 ratio to Cu(II) and gets into the 
dsDNA.124 A Cu(I)-Cu(II) cycle then generates the H2O2 responsible for DNA cleavage.122 Even 
though DNA cleaving activity has been demonstrated, its influence on the cytotoxicity remains 
unclear. Indeed, dsDNA cleavage does not lead to anticancer activity with all prodiginines.125 
Yet, Cu concentration being higher in cancer cells than in healthy ones, this activity could 
explain why prodiginines have a stronger cytotoxic effect on cancer cells than healthy ones. 
Actual cleavage is not necessary to observe apoptotic activity. Indeed, prodigiosin has been 
shown to bind to DNA G-quadruplexes,126 which can prevent telomerase from working 
efficiently. Studies on the effect of substituents on the C-ring on the DNA-binding effect showed 
that a methylation on the C4 position was not detrimental. In addition, when the C3 position 
was substituted with different esters and amino groups, a loss of activity was observed with 
amino groups whereas esters retained their activity. Yet, no clear relationship between the 
structure and the activity has been established.127 
5.5.4. Mitochondrial induced apoptosis 
Mitochondria outer membrane permeabilization (MOMP) is a central event in apoptosis: 
apoptosis signals trigger a conformational change in proteins such as Bax which result in the 
formation of a channel in the mitochondrial membrane, leading to the release of cytochrome c 
in the cytosol.128 Prodiginines can affect different aspects of this process. For instance, 
prodigiosin 1a can trigger a conformational change in Bax.103 In addition, obatoclax 36 has been
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Figure 1.16: Examples of mechanisms of action for prodiginine anticancer activity Adapted from Williamson et al.109 
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 shown to antagonise several member of the B-cell lymphoma (BCL) protein family, such as BCL-
2, BCL-XL, BCL-W and MCL-1.129–131  These proteins are found on the mitochondrial membrane 
and prevent MOMP.132   
It is difficult to establish which of these mechanisms is primarily responsible for the apoptosis. 
Location studies of prodiginine did not lead to an answer to that question: in some studies 
prodiginines have been shown to accumulate in the cell nucleus, which would suggest that the 
DNA cleavage is the predominant mechanism, while other reports claimed that it was most 
concentrated in the cytoplasm or in mitochondria membrane, which would indicate a 
prevalence of the pH deregulation and the MAPKs mechanisms. 
In conclusion, prodiginines have shown anticancer properties against a variety of cell lines, 
whilst being relatively harmless for non-malignant cells at the same concentrations. Yet, effects 
vary from one prodiginine to another and from one cell line to another. Prodiginine have been 
shown to affect many biological targets and it is likely that a combination of all the mechanisms 
described above is responsible for the overall biological effect. 
6. The role of thioester in biosynthesis 
Thioesters are common intermediates in many biosynthetic pathways, including the one of 
prodigiosin. As this project was particularly focused on demonstrating the existence of thioester 
intermediate in the formation of MAP (see section 7 and Chapter 4), this section aims to give a 
fez notions about the role of these compounds in biosynthesis. 
Nature has used the fact that thioesters are less stabilised by resonance than their oxygen ester 
and carboxylic acid counterparts to drive reactions in many biosynthetic pathways. This is 
illustrated, for example, by the building of carbon-carbon bonds through Claisen condensation 
by the use of coenzyme A (CoA) 37 acyl thioesters (Figure 1.17). This phenomenon plays a crucial 
role in terpene and steroid biosynthesis.  
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Figure 1.17: Coenzyme A a) structure; b) example of biosynthetic step where CoA is involved 
Fatty acid and polyketide biosynthesis are further biological processes where thioesters play a 
crucial role (Figure 4.2). In the first step, the thiol of the 4-phosphopantetheine moiety of an 
acyl carrier protein (ACP) is charged with a malonyl unit, derived from malonyl CoA, and an 
active-site cysteine residue of the -ketoacyl synthase is similarly charged with an acyl unit. The 
-ketoacyl synthase then catalyses a decarboxylative Claisen condensation of the malonyl unit 
with the acyl unit, giving a -keto-butanoyl ACP thioester. In fatty acid biosynthesis the ketone 
carbonyl is then reduced by action of NADPH. The (E)-unsaturated thioester obtained after 
dehydration can then undergo further reduction through NADPH, leading to the saturated 
thioester. This intermediate is then reloaded on the -ketoacyl synthase active site cysteine 
residue ready for condensation with a further malonyl unit brought by the ACP.133 The Claisen 
condensation, the ketone carbonyl reduction, the dehydration and the enol reduction are then 
repeated and the chain gains two carbons at every cycle. It is worth noting that octenoyl-ACP, 
the proposed precursor of MAP in the prodigiosin biosynthetic pathway, is formed by this 
process. The cycle ends when the chain reaches 14 to 18 carbons and a thioesterase hydrolyses 
the thioester of the acyl-ACP (see Section 1.1.3). 
Polyketide biosynthesis involves the same steps as fatty acid biosynthesis except some of the 
reduction/dehydration steps are omitted, so that each two-carbon chain-extending unit can be 
left as the ketone or the alcohol or the C=C double bond instead of the fully reduced -CH2-CH2-
. 
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Figure 1.18: Fatty acids biosynthesis, pant= phosphopantotheine 
  
7. Aims of the project  
This project aimed to study the three enzymes – PigD, PigE and PigB – involved in the formation 
of MAP. As mentioned earlier, these enzymes have been less extensively characterised than the 
ones involved in the formation of MBC and little is known about their substrate specificity, 
enantioselectivity, or kinetics. 
Here, the substrate flexibility of PigB and its homologue HapB was investigated through protein- 
and cell-based assays with analogues of its natural substrate with various alkyl substituents. The 
substrate flexibility was then applied to the formation of novel prodiginines whose biological 
properties were then explored. 
Out of the three enzymes, PigE is the one that has been characterised the least. In particular, its 
ability to reduce a thioester substrate to an aldehyde and then to catalyse the transamination of 
the aldehyde is still uncertain. This project aimed to use a cell-based assay to demonstrate the 
thioester reductase activity and protein assays to determine the cofactors involved and the 
kinetic parameters of PigE. 
Finally, a demonstration of PigD’s capacity to catalyse the acylation of ,-unsaturated 
thioesters was attempted.  
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Chapter 2. Mutasynthesis of new prodiginines 
by exploiting the substrate flexibility of 
dihydropyrrole oxidase PigB 
 
1. Objectives 
Total synthesis is a powerful tool but also has many drawbacks. For instance, a high number of 
steps and the use of harsh conditions are not always compatible with large scale reactions. 
Mutasynthesis provides an alternative to this method. The technique relies on the ability of a 
strain unable to produce the natural product of interest, often because of a mutation in a gene 
coding for a protein responsible for the formation of a biosynthetic intermediate, to accept a 
synthetic intermediate later on in the biosynthetic pathway.134 Furthermore, if the enzymes 
present some substrate flexibility, this can give access to analogues of the natural product with 
a minimum of synthetic steps. 
Since Vogel’s15 work, it is known that some Serratia mutants unable to produce prodigiosin can 
have their pigment production restored by adding an intermediate to the culture broth. 
Furthermore, some mutant strains can cross-complement, which means that one strain 
produces and releases an intermediate that the other strain can use to produce prodigiosin (and 
vice versa in some cases). As mentioned earlier, this property was exploited by Salmond and co-
workers for the elucidation of the biosynthetic pathway to prodigiosin26 as well as in their study 
of the substrate flexibility of the condensing enzyme PigC.43 In the latter study, a S39006 mutant 
with an in frame deletion in PigH was constructed, hence presenting a white phenotype as MBC 
could not be produced (see Figure 1.9).26 This strain was fed with analogues of MBC having 
variations in ring A (Figure 2.1b). Considering the structure of anticancer agent obatoclax 36, 
modifications in those positions had the potential to lead to biologically active compounds. New 
prodiginines were obtained with all analogues with only one ring. The enzyme was less flexible 
toward bigger structures, but the indole substrate was accommodated, leading to the formation 
of 36. 
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Figure 2.1: Modifications on prodigiosin ring A a) Obatoclax; b) MBC analogues; adapted from 
Chawrai et al.135 
Recently, the specificity of PigC for its other substrate, MAP, was explored by Klein et al.136,137 
They worked on a Pseudomonas putida strain which had been engineered to heterologously 
express the Sma pig gene cluster and constructed a strain with an in frame deletion in pigD (P. 
putida ΔpigD), the first enzyme involved in MAP biosynthesis (see Figure 1.9). After showing 
that this strain could still produce MBC,136 they investigated the flexibility of PigC for analogues 
of MAP with different alkyl chains  on the C2 and C3 positions (Figure 2.2b). It appeared that 
modifications in the C3 position were well accommodated whereas the size of the chain on the 
C2 position could not be changed without a loss of activity. It is worth noticing they obtained 
most of the precursors, including MAP 9, using the Trofimov reaction. This reaction leads to the 
formation of disubstituted pyrroles from an oxime precursor, meaning that MAP and its 
analogues could be obtained in a one-pot two-step reaction from the appropriate ketone (Figure 
2.2a).138 However, analogues with hydrogen in either C2 or C3 position could not be obtained 
this way and the use of hydroxylamine limits the range of the substituents. In addition, 
regioselectivity problems are observed with unsymmetrical ketones when R1 is larger than a 
methyl group.  Despite these limitations, Klein et al.77 managed to use this method to prepare 
analogues of MAP with rings of five to twelve carbons between the C2 and the C3 positions 
(Figure 2.2c). They were all accommodated by PigC and led to the formation of group 3 
prodiginines in just two synthetic steps and one fermentation step with P. putida. This method 
was more efficient than classic isolation and shorter than total synthesis of the compounds, but 
limitations remain: isolation and purification of the prodigiosin from the culture broth can be 
difficult and the yields are often lower than chemical synthesis.  
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Figure 2.2: Analogues of MAP tested by Klein et al. a) Trofimov synthesis of pyrroles; b) analogues 
with alkyl substituents; c) bi-cyclic analogues of MAP 
This project aimed to prepare prodiginines by feeding analogues of 19a into a S39006 mutant. 
To do so, it intended to extend previous work in the group that had identified which regioisomer 
of H2MAP is the substrate for PigB. The substrate flexibility and the enantioselectivity of PigB 
and its homologue HapB were also to be investigated. In addition, the synthesis of new analogues 
of 19 was explored. 
2. Elucidation of the structure of PigB’s substrate 
As mentioned in Chapter 1, Williamson et al.26 showed that PigB and its homologues were 
responsible for the last step in MAP 9 biosynthesis (see Figure 1.9). However, they were not able 
to determine which of the two possible regioisomers (Figure 2.3, compound 19a and 38) was 
the natural substrate.  
 
Figure 2.3: Formation of two possible substrates for PigB 
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Chawrai subsequently synthesised both 19a and 38 and showed that only 19a could be taken in 
as a substrate by a mutant of S39006 with an in-frame deletion in pigD (S39006 ΔpigD) (Figure 
2.4a).139 
In the course of this project, bacterial H2MAP was analysed to corroborate this finding: extracts 
were prepared from a 200 ml culture of S39006 with an in-frame mutation in pigB (S39006 
ΔpigB) and its LC-MS chromatogram was compared to one of synthetic 19a (Figure 2.4 b). 
 
Figure 2.4: Study of PigB regioselectivity a) top: S39006 ΔpigD + 19a, bottom S39006 ΔpigD + 38; b) 
Extracted chromatograms at 154.16 (19a + H+), top to bottom: S39006 ΔpigD extract, S39006 ΔpigB 
extract, synthetic 19a 
A small peak at 1.50 min was noticed in the chromatogram of the synthetic sample. The 
experiment was repeated several times at different concentrations, but two peaks were always 
obtained. The NMR spectrum of the sample though showed a good purity. It is possible that this 
second peak is due to one of the enamines in equilibrium with 19a (see Figure 2.5). Because the 
LC-MS experiment was conducted in a mixture water/acetonitrile, these products can be more 
stable than in the CDCl3 used for NMR analysis. 
 
Figure 2. 5: Imine/enamine equilibrium of 19a 
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The chromatograms showed the accumulation of an intermediate in S39006 ΔpigB with a mass 
consistent with H2MAP and with the same retention time as synthetic 19a. As expected, no such 
peak was seen with S39006 ΔpigD. This is consistent with Chawrai’s results and confirms that 
19a is the natural substrate of PigB. 
3. Synthesis of novel analogues of H2MAP 
3.1.  Modifications in the C2 and the C3 position 
 
Figure 2.6: Synthesis of H2MAP analogues with modification on the C2 and C3 positions 
In Chawrai’s work, H2MAP 19a was obtained in two steps from N-vinyl-pyrrolidinone 39 (Figure 
2.6). After formation of the enolate of 39 by treatment with NaHDMS, it was alkylated with 1-
iodopentane at low temperature, giving intermediate 40a. MeLi was then added to attack the 
carbonyl, and, after a couple of hours, the mixture was acidified, triggering deprotection of the 
amine and dehydration (Figure 2.7).139  
 
Figure 2. 7: Mechanism of acid-catalysed deprotection of the vinyl amine. 
A similar method could be used to get analogues 
with modifications either on the C3 or C2 
positions (Table 2.1). For modifications on the 
C3 position, another halogenoalkane than 1-
iodopentane could be used in the first step 
(compounds 19b-g). These six analogues of 
H2MAP were previously made by Hiral Bhalara in 
the group20 but were all resynthesized in the 
current work. Similarly, other organolithium 
compounds were used in the second step to change the Table 2.1: Analogues of H2MAP 
Compound R1 R2 Yield (%) 
19a C5H
11 
Me 58 
19b Et Me 52 
19c Pr Me 42 
19d Ally
l 
Me 45 
19e C6H
13 
Me 47 
19f C7H
15 
Me 47 
19g iPr Me 47 
19h C5H
11 
Et 20 
19i C5H
11 
Pr 7.5 
19j C5H
11 
C4H
9 
25 
19k C5H
11 
Ph 55 
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substituent in the C2 position (compounds 19h-k). For 2-propyl-dihydroMAP 19i, propyl-
lithium (which is not commercially available) was generated in situ by addition of an excess of 
t-BuLi to 1-iodopropane at -80°C followed by stirring at room temperature in Et2O. This allowed 
the consumption of t-BuLi through a deprotonation of the solvent, leading to the formation of 
isobutane, ethylene and lithium ethoxide,140 hence avoiding side reactions. Indeed, despite being 
less nucleophilic than other organolithium reagents, t-BuLi is a strong base and a reducing 
agent, which led to side products. The drawback of this approach is the loss of some of the newly 
formed propyl-lithium, decreasing the yield. An excess of 19a was then added and the reaction 
could proceed as for commercial alkyl lithiums, leading to the isolation of the desired H2MAP 
analogue. 
Another issue with this procedure is the formation of side products during the first step. For 
instance, 3,3-dipentyl-N-vinylpyrrolidin-2-one 41 (see Figure 2.8) could be isolated from the 
reaction mixture during the preparation of 40a. Yet, such double addition products could be 
easily separated by column chromatography with an eluent of low polarity.  
 
Figure 2. 8: An example of by-product obtained during the synthesis of analogues of 19a 
Even though this synthetic route is compatible with a number of different alkyl substituent, it 
suffers important scope limitations. For instance, hindered organolithium reagents are poor 
nucleophiles and may reduce 40 instead of nucleophilically attacking it. Furthermore, addition 
of an aromatic moiety on the C3 position would generally not be possible as SN2 reactions do 
not work on aryl halides, preventing the formation of compounds like 3-phenyl-N-
vinylpyrrolidin-2-one with this method. However, activated aromatic rings can undergo a SNAr. 
Thus, the enolate of 39 successfully reacted with 2-bromopyridine.  The analytical data of the 
resulting product were consistent with the formation of the adduct. However, minor peaks were 
visible in the NMR spectrum, suggesting that the presence of the aromatic ring  to the carbonyl 
stabilised the enol tautomer 42 enough that it represents 20% of the mixture. The exchange 
between the two tautomers (Figure 2.9) could explain why the proton next to the aromatic ring 
was not visible in the NMR spectrum. MeLi was added to the compound in a similar fashion as 
for the synthesis of 19a-h, but no reaction was observed. It is likely that the proton next to the 
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carbonyl is more acidic than in 40a-g, and MeLi here behaved as a base instead of a nucleophile. 
However, time did not permit any options to circumvent this to be explored.  
 
Figure 2.9: Putting an aromatic ring in the C3 position of H2MAP analogues a) enol equilibrium of 
103h; b) A possible way to circumvent and get the wanted enamine 
3.2. Preliminary study of modifications of the substituent on the C4 
position 
These analogues could be interesting to study the enantioselectivity of PigB regarding the C4 
position. These analogues can theoretically be obtained by adapting the method described above 
with variations on the starting material. Furthermore, the nitrogen atom can be protected by 
any protecting group stable in basic conditions and labile in acid. As such compounds are not 
necessary commercially available, a small scale “proof of concept” synthesis of the Boc-protected 
lactam with a 4-ethyl group 43 was attempted (Figure 2.10) 
 
Figure 2.10: Synthetic route toward analogues of H2MAP with substituents on the C4 position 
Oxidation of pyrrole with hydrogen peroxide in the presence of barium carbonate141 was carried 
out as a first attempt to prepare 1,5-dihydro-2H-pyrrol-2-one 45, but after several hours at reflux 
no reaction was observed. Amide 45 was finally prepared via the conversion of 2,5-dimethoxy-
2,5-dihydrofuran 44 in the presence of ammonium chloride.142 Even though the yield of that step 
was very low, enough of 45 was isolated so the Boc protection could be performed, giving 46. 
This was then treated with diethyl copper lithium. Monitoring the reaction by TLC showed the 
appearance of a number of new spots. 1H NMR analysis of the crude mixture was consistent with 
the formation of 43, but it was only a minor component and the scale was too small to isolate 
the desired product. This process would require optimisation, in particular for the first step, but 
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it presents an interesting way to prepare precursors of H2MAP analogues with substituents on 
three positions of the pyrrole. 
3.3. Toward a general methodology 
The methods described above suffer strong limitations on the substituents as they need to be 
compatible with the final organolithium addition, hence preventing the incorporation of most 
electrophilic or acidic groups. 
A route (Figure 2.11) overcoming these limitations was investigated. 
 
Figure 2.11: Synthetic route giving analogues of H2MAP with substituents on all four positions 
This synthesis would also give the possibility to change the substituents on all four positions of 
the ring. This would allow a larger understanding of PigB, but only compounds where R4 is a 
hydrogen atom could be converted to a prodiginine. 
As illustrated in Figure 2.12a, 2-octanone 47 was chosen as the starting material as it would 
allow us to get the same C2 and C3 substituents as in H2MAP. Numerous procedures for -
bromination of carbonyls using N-bromosuccinimide (NBS) can be found in the literature.143,144 
An acid catalyst activates the carbonyl, leading to the formation of an enol, which then quickly 
attacks NBS. The problem with most of the procedures is a lack of regioselectivity as they are 
usually performed on symmetrical ketones. Hence a few conditions were attempted (Table 2.2). 
This is particularly relevant because the polarities of the two regioisomers are very close, making 
separation by flash column chromatography too difficult. 
Solvent Catalyst Temperature Time 
Selectivity 
(1-bromo:3-bromo) 
Yield 
 (% reacted carbonyl) 
CHCl3 pTSA 0 °C then r.t. 16 h 3:4 70% 
CCl4 NH4OAc 80 °C 1 h 1:3 53% 
CHCl3 NH4OAc 80 °C 16 h 1:9 27% 
It appeared that the best regioselectivity was obtained with NH4OAc as a catalyst and 
chloroform as a solvent, but this was accompanied with an important decrease in the yield. This 
could be due to ammonium acetate being a weaker acid than pTSA, leading to a slower activation 
Table 2.2: Conditions for -bromination of ketones 
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of the carbonyl. As a result, the formation of the enol was under thermodynamic control, leading 
to the desired regioselectivity, but the yield was decreased. Considering the importance of the 
regioselectivity for the rest of the route and the fact that the starting materials can be recovered 
and are cheap, the third set of conditions was preferred. Yet, about 10% of the product was still 
1-bromooctanone 48b, which reacts faster than the 3-bromooctanone 48a for downstream 
reactions, leading to the formation of unwanted products such as phosphorane 49b. Fortunately, 
this kinetic property could be used to remove this regioisomer: the crude product was reacted 
for 2 h with dimethyl malonate 50 and potassium carbonate at 60 °C. In these conditions, the 
malonate addition only occurs on the 1-bromooctanone, leading to the formation of 51 and pure 
3-bromooctanone, which could be recovered by flash column chromatography. 
 
 
Figure 2.12: Initial steps in the general methodology a) Conversion of 2-octanone 47 into 
phosphorane 49a; *the yield for the first step represents the conversion in 48a and 48b; b) kinetic 
resolution of regiosimers of 48; c) phosphorane obtained by reacting 48b with PPh3 
48a was reacted with triphenylphosphine to from the phosphonium salt 52. The precipitate was 
collected and placed in basic conditions. The resulting ylid 49a was stabilized by the presence 
of the carbonyl and could hence be isolated. The yield of this reaction sequence was very low, 
probably partly because the phosphine oxidised very readily and, despite our best attempts, a 
lot of it did not participate the reaction. The pentyl chain might also make the phosphonium 
salt more soluble in toluene and EtOAc than anticipated and a lot of it may have been lost during 
the washing of the salt.  
Before trying to scale up or to screen for different conditions, the Wittig reaction was attempted 
with another stabilized ylid 53 (Figure 2.13). 
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Figure 2.13: Preliminary study for Wittig reaction and Michael addition of a nitroalkane 
Vanillin 54 was chosen as the substrate for the reaction because as it is more reactive than a 
ketone. After 16 h at r.t. in THF, a mixture 3:1 of E and Z isomers ((E)-55 and (Z)-55) was obtained. 
The two isomers were separated by column chromatography, allowing the testing of the addition 
of nitroethane on a pure sample of (E)-55. The (E)-55 was stirred with nitroethane and DBU in 
acetonitrile at r.t. and the reaction was monitored by TLC. After 24 h a new spot was visible 
under UV, but the starting materials were still predominant in the reaction mixture. After an 
acidic wash to remove DBU, an NMR of the crude confirmed that (E)-55 was still the main 
component of the mixture, but 10% of the mixture was consistent with 56. More work needs to 
be done to improve the reaction rate (changing the concentrations, the temperature, the 
reaction time or the base) before going forward with this reaction.  
4. In vitro characterisation of PigB homologue, HapB  
4.1. Comparison between HapB and PigB 
As explained in Chapter 1, proteins fulfilling the same function in prodigiosin biosynthesis in 
different organisms share a high level of homology. Here, direct comparison using Artemis 
ACT145 and EBI’s Clustal Omega146 between PigB and its homologue in H2396, HapB, indicated 
that the two proteins share 41% identity. BLAST analysis showed they both presented a strong 
homology with flavin-dependent amine oxidases. This was supported by Phyre147 analysis of 
HapB (Figure 2.14): the structure of the protein could be modelled based on its homology with 
the FAD dependent lysine specific histone demethylase 1b (LSD1).148 This result was in 
agreement with the role Williamson et al.26 attributed to the protein. Furthermore, HapB and 
PigB presented a high degree of identity in residues 53-65 of HapB (166-178 of PigB), which are 
predicted to be the FAD binding site (in orange in Figure 2.14). Two other regions (residues 
266-307 and 528-544 of HapB) are also highly conserved, which could mean they form part of 
the active site (in red in Figure 2.14). Interestingly though, alignment with LSD1 showed that 
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only one of the residues aligned with amino acids involved in the catalytic pocket of LSD1 is 
found in these regions (in blue in Figure 2.14). This could be explained by a difference of 
function between the two proteins and by the fact that LSD1 has extra domains that form part 
of the active site.148 A major difference between HapB and PigB is to be noted though: the first 
113 residues of PigB have no equivalent in HapB. They are predicted to be a transmembrane 
domain. A protein homologous to this transmembrane domain is found in Hahella’s genome 
(gene HCH_06023), located at the 5’ end of hapB. 
 
Figure 2.14: Predicted stucture of HapB (Phyre) orange: predicted FAD biding site; red: other highly 
conserved regions, blue: catalytic residue from LSD1. 
Bhalara expressed both hapB (plasmid pHDB1) and pigB (plasmid pHDB4) in S39006 ΔpigB and 
pigmentation was observed in both cases (Figure 2.15a), suggesting both proteins could catalyse 
the oxidation of H2MAP into MAP. The expression of the two genes could be induced with 
IPTG.20  
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Figure 2.15: Comparison of HapB and PigB activity a) growth on PGM, b) growth on LB, c) UV spectra 
of prodigiosin culture extracts; Red: No IPTG, Blue: IPTG (1 mM), d) MS analysis of the prodigiosin extracts 
(i) S39006, (ii) S39006 ΔpigB pHDB4, (iii) S39006 ΔpigB pHDB1; Norprodigiosin 16+H+: 310.19; 
Prodigiosin 1a+H+: 324.21 .For a) and b), the labels are on the pictures 
We noticed that the colonies with the plasmids presented a more purple aspect than the red 
wild type when cultured on LB (Figure 2.15b). Therefore, in the current work, we decided to 
check that the pigment obtained with the complemented strains was authentic prodigiosin. 
Prodigiosin extracts were prepared from liquid cultures of S39006, S39006 ΔpigB pHDB1 and 
S39006 ΔpigB pHDB4, with and without IPTG induction. UV spectra of the extracts were 
measured (Figure 2.15c) and they were also analysed by MS (Figure 2.15d). 
All six extracts had the same UV profile, indicating that the pigments in the samples were 
similar. Pigment production in S39006 ΔpigB pHDB4 was significantly enhanced by adding 
IPTG: without IPTG, the pigment level was slightly below the WT, whereas with IPTG it was 
more than twice as much. This suggests a by-pass of the regulatory mechanism of pigment 
production in that strain. On the other hand, the production of pigment in S39006 ΔpigB pHDB1 
was low and unaffected by the presence of IPTG. Several explanations are possible for this 
phenomenon: HapB is a heterogeneous protein, and hence may not interact properly with 
S39006’s proteins. It also might have solubility issues and overexpression could lead to the 
formation of inactive inclusion bodies. Finally, HapB activity might be lower in those 
circumstances because of the absence of the transmembrane domain corresponding to the N 
terminal domain of PigB. MS results showed the extracts contained mixtures of prodigiosin and 
norprodigiosin. Norprodigiosin results from the same biosynthetic pathway but instead of using 
MBC, PigC catalyses the condensation of MAP with HBC, the preceding intermediate which 
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lacks the O-methyl group. This confirmed that both PigB and HapB catalysed the oxidation of 
H2MAP into MAP. This means that characterisation results obtained for one are likely to be 
similar for the other. 
4.2. Substrate flexibility of HapB 
Bhalara isolated soluble HapB but, probably because of the transmembrane domain mentioned 
above, active PigB could not be purified. She then characterized its kinetic parameters in vitro 
(Figure 2.16b), using an Ehrlich’s assay: pyrroles with a free -position quantitatively react with 
p-dimethylaminobenzaldehyde 57, also known as Ehrlich’s reagent to form a red complex 58 
(Figure 2.16a). She also demonstrated this enzyme was FAD and O2 dependent and produced 
H2O2 as a by-product.20 
 
Figure 2.16: a) Principle of the Ehrlich’s assay used to measure the activity of HapB b) Michaelis-Menten 
curve of HapB (work performed by Dr Bhalara) 
As changing the alkyl chains on the C2 and C3 positions has little influence on the Ehrlich’s 
assay, it can be used to assess the specificity of HapB for analogues 19b-k. HapB was incubated 
with each of the ten potential substrates for 15 min before stopping the reaction and assessing 
the presence of pyrrole. The assays with modification in the C3 (compound 19b-g, Figure 2.17a) 
position were performed by Bhalara149 whereas modifications in the C2 position (compounds 19 
h-k, Figure 2.17b) were assessed in this study.  
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Figure 2.17: Results of Ehrlich's assays with H2MAP and analogues 19a-k. a) modifications in the C3 
position (performed by Dr Bhalara), b) modifications in the C2 position. Each absorbance value is 
normalised with respect to the absorbance obtained in the parallel experiment with H2MAP 19a. c) 
Positions on H2MAP anologues 
It appeared that all modifications in the C3 position could be accommodated. Chains up to three 
carbons could be accommodated in the C2 position, but longer chain length lead to very little if 
any pyrrole formation. 
5. Mutasynthesis  
5.1. Qualitative results of complementation assay 
Growing S39006 on low phosphate media has been shown to enhance prodigiosin production.150 
Hence, two streaks of S39006 ΔpigD were grown on peptone glycerol agar (Figure 2.18a). Next 
to the streaks, 5 µl of H2MAP and analogues at 0, 10 or 100 mM in DMSO were spotted. The 
bacteria were incubated for a further 16 h and the presence of pigment was assessed (Figure 
2.18b). As expected, H2MAP led to strong pigmentation as did all analogues with modification 
on the C3 position. High concentrations of 19h and 19i gave some pigmentation, even though it 
remained very faint with the latter. Other modifications on the C2 position gave no observable 
pigment. These results, which are testing the substrate flexibilities of both PigB and PigC were 
in good agreement with the in vitro results obtained with HapB. This suggests that PigB and 
HapB have similar substrate specificities. 
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Figure 2.18: Chemical complementation assays on agar plates a) scheme of the plate; b) Results with 
H2MAP analogues. Assays with compounds 19b, 19c, 19d and 19g were performed by Bhalara.20 
5.2. Quantitative results 
Pigment production by bacteria in liquid culture can be quantified by centrifuging the cells and 
extracting the pigment from the cell-pellet by vortexing in acidified (4% HCl) EtOH and, after 
further centrifugation, measuring the quantity of prodigiosin by recording the absorbance at 535 
nm (see Figure 2.15).150 
Strains with in-frame deletions in pigD and pigE are both potential candidates for the 
mutasynthesis experiments. Hence a complementation assay was performed by feeding H2MAP 
to strains S39006 ΔpigD and S39006 ΔpigE. The quantity of prodigiosin recovered is presented 
in Figure 2.19. 
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Figure 2.19: Complementation assay of S39006 ΔpigD and S39006 ΔpigE with H2MAP 
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It appeared that complementing S39006 ΔpigD led to a higher pigmentation than 
complementing with S39006 ΔpigE. These results were consistent with qualitative observations: 
when complemented on agar, the red colour appeared in a matter of minutes with S39006 ΔpigD 
whereas hours were necessary in the case of S39006 ΔpigE. There is no clear explanation for this 
phenomenon, but it is possible that PigE and PigB form a complex and that the absence of PigE 
decreases the activity of PigB. 
A range of H2MAP concentrations were also tested with S39006 ΔpigD, leading to Figure 2.20. 
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Figure 2.20: Complementation assay of S39006 ΔpigD with a range of concentrations of H2MAP. 
Restoration of pigmentation could be observed for concentrations of H2MAP as low as 1 µM. Yet 
the highest pigmentation we observed was with 10 µM. Interestingly, increasing the 
concentration further led to a decrease of the final pigmentation. This is consistent with the 
inhibition of PigC in presence of excess MAP observed by Chawrai et al.135 
Following these two experiments, it was decided to conduct the in vivo flexibility assays of PigB 
with   S39006 ΔpigD at 10 µM of substrate. Using the same process as previously, pigment was 
extracted from S39006 ΔpigD fed with the four analogues of H2MAP with a modification on the 
C2 position and the five with a modification on the C3 position. Because of equipment limitation, 
five distinct experiments had to be performed to cover all the substrates. Variations from one 
experiment to another were compensated by normalising the results to the reading obtained 
with the positive control H2MAP for each experiment. As the final compounds only differ in 
their alkyl chain, it was assumed that the max of the prodiginine was not significantly affected 
by the change in the structure. Furthermore, once the culture reached a certain optical density, 
ethanolic extracts of uncomplemented S39006 ΔpigD were visibly coloured, leading to 
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background absorbance at 535 nm. This was probably due to the production of carotenes or 
other such compounds so the value of prodigiosin absorbance was corrected by subtracting the 
baseline (see experimental). The results are shown in Figure 2.21. 
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Figure 2.21: Complementation of S39006 ΔpigD with H2MAP and its analogues a) Analogues with 
modification on the C3 position; b) Analogues with a modification on the C2 position 
The results were congruent with the in vitro experiments and the qualitative tests. Pigments 
could be recovered with all analogues with a modification in the C3 position whereas only chains 
up to 3 carbons on the C2 positions led to pigmentation. Furthermore, the pigmentation 
obtained with the latter two compounds (19h and 19j) was much weaker than with natural 
substrate.  
The fact that 19g-i gave lower than expected pigmentation, considering their in vitro results, can 
be explained by compatibility issues with PigC. Indeed, to get to the final pigment, the substrate 
needs to be accommodated both by PigB and PigC. As mentioned earlier, it has been shown that 
modifications in the C2 positions led to an significant decrease in PigC activity.137 Similarly, it is 
likely that 9g, with an isopropyl chain on the C3, cannot be accommodated well by the 
condensing enzyme.  
This experiment also demonstrated the possibility of using analogues of H2MAP for 
mutasynthesis of new prodiginines (compounds 1b-i), whereas all mutasynthesis methodologies 
to date have relied on analogues of the PigC substrates. This is particularly important as, to the 
best of our knowledge, 1g is the first example of a group 1 prodiginine with a branched side chain 
on ring C. 
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6.  Enantioselectivity of PigB 
PigD has been shown to favour the formation of the S product.36 However, the asymmetric centre 
introduced by PigD is adjacent to an imine bond in H2MAP. Hence, it may racemise though an 
imine/enamine equilibrium (Figure 2.22). 
 
Figure 2.22: Racemisation of H2MAP 
The question of the enantioselectivity of PigB is only relevant if the rate of racemisation of 
H2MAP is slower than the enzymatic reaction. When in solution in deuterated water, H2MAP 
would incorporate deuterium as a result of the imine-enamine equilibrium, and this can be 
monitored by NMR spectroscopy. This experiment was run at pH 4 with a phosphate buffer and 
at pH 7 in pure D2O. The main difficulty with the experiment was the low solubility of H2MAP 
in water, leading to poor sensitivity compared to spectra recorded in CDCl3 as well as shifting of 
most of the peaks compared to reference spectra. The proton of interest was associated with the 
peak at 2.8 ppm and the integral of this peak was monitored. In parallel, the integral of the peak 
at 3.5 ppm, associated with the protons of the CH2 next to the nitrogen, and the signals due to 
the protons of the methyl group at 2.0 ppm were also monitored. The peak at 3.5 ppm was not 
expected to change during the experiments and hence its integral was set as for two protons in 
all spectra, whereas protons corresponding to the peak at 2.0 ppm may also be involved in an 
imine/enamine equilibrium (Figure 2.23) and thus the integral of this peak might decrease. 
 
Figure 2.23: Two possible imine/enamine equilibria 
Surprisingly, the peak at 2.8 ppm did not seem to change in the course of the experiments, 
whereas the one at 2.0 ppm showed a slight decrease. It is interesting to note that similar results 
were obtained at both pH values (Figure 2.24). This result was supported by the comparison of 
spectra acquired 24 h apart: H2MAP was dissolved in D2O along with a few drops of d6-DMSO 
to help the solubilisation and spectra were recorded just after dissolution and 24 h later. Again, 
the experiments were conducted at pH 4 and 7. In both cases, the peak at 2.0 ppm underwent a 
large decrease whereas the 2.8 ppm area was barely affected (Figure 2.25). It can be concluded 
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that H2MAP was indeed in slow equilibrium with an enamine form. However, this equilibrium 
does not affect the asymmetric carbon, probably for steric reasons, and racemisation of an 
H2MAP solution is not a problem. The enantioselectivity of PigB was hence investigated. 
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Figure 2.24: evolution of the NMR signal of the protons involved in imine/enamine equilibrium 
a) pH=4, b) pH=7; Green: 2.8 ppm, Blue 2 ppm 
 
Figure 2.25: Evolution of the NMR spectra of H2MAP in D2O over 24 h, a) pH=4, b) pH=7; in blue: 
t=0, in red t=24 h, square in blue peak corresponding to the proton of the methyl group, squared in green: 
peak corresponding to the proton of the stereocenter 
H2MAP does not have any chromophore. However, an absorbance maximum can be observed at 
275 nm. This is presumably due to a n → * transition – promotion of one of the non-bonding 
(lone pair) electrons on the nitrogen to the * orbital. Contrary to most UV absorbances which 
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are due to  →  transitions, this n → * transition is formally forbidden by quantum mechanics, 
and hence the absorbance is weak. A relatively high concentration of H2MAP is therefore 
necessary to observe it (Figure 2.26). 
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Figure 2.26: UV spectrum of H2MAP at 100 mM in MeOH 
The synthesis of H2MAP, as described in section 3, leads to a racemic mixture. The isolation of 
each enantiomer by HPLC was attempted with a Supleco Analytical Chiral column. As illustrated 
in Figure 2.27, two peaks (retention time: 5 min 50 s and 6 min 45 s) were visible at 210 nm and 
275 nm, but the first one looked weaker at 275 nm. A TLC of the collected fraction showed that 
the first contained a product with the same Rf as H2MAP whereas the second one looked empty. 
This suggested that the second peak was actually an impurity: a mixture of only isopropanol and 
hexane was run on the HPLC in the same conditions and this peak was still present, indicating 
that those conditions were not suitable to separate H2MAP enantiomers. Consequently, the 
polarity of the eluent in the HPLC method was decreased, but the two peaks were only shifted: 
the impurity was still there whereas the enantiomers of H2MAP still coeluted. It was concluded 
that the available column was impractical for the separation of H2MAP enantiomers. However, 
even if conditions to separate the two enantiomers by HPLC had been found, the UV absorption 
of H2MAP is very weak and the quantity of H2MAP that can be extracted from S39006 ΔpigB is 
very low, so detection of the compound by HPLC would have been very challenging. 
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Figure 2.27: HPLC trace of synthetic run on a chiral column 
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This led to the investigation of a method to enhance H2MAP detectability by addition of a chiral 
chromophore (Figure 2.28). This should also facilitate the analysis as the diastereoisomers thus 
obtained should have different retention times on an achiral HPLC column. 
 
Figure 2.28: Enhancement of H2MAP detectability 
A diastereoselective reduction of the imine would be preferable for the first step because it would 
lead to only one pair of diastereoisomers after the second step. First a hydrogenation catalysed 
by palladium-on-charcoal was tried. H2MAP in EtOH was stirred with fresh Pd/C under H2 at 
room temperature. Unfortunately, after 4 days, no formation of the product was observed.   
As a consequence, other approaches were investigated. For instance, the use of DIBAL as a 
reducing agent was investigated: a test reaction with 2 eq. of DIBAL at -10 °C for 15 min produced 
a mixture of the desired amine and starting material. Purification of the amine by silica 
chromatography was impossible as a 2D TLC showed that 59 degraded on silica. However, the 
difference of pKa between the amine and the imine could be exploited to purify 59 by extraction 
with a solution of adapted pH (8-9). 1H NMR analysis of 59 showed a characteristic doublet at 
1.15 ppm (see experimental and appendix), but a smaller doublet at 0.99 (ratio 5:1) ppm. In the 
13C spectra as well, a set of small peaks were observed alongside the main peaks. This indicated 
the presence of two diastereomers, but, surprisingly, they were not formed in a 1:1 ratio. It is 
likely that steric hindrance of the pentyl group favours attack from the opposite face, leading to 
the cis isomer (R,R and S,S) preferentially. Test reactions with a large excess of DIBAL and 
different reaction times were conducted (Table 2.3) in the prospect of using it on a biological 
extract where an excess of DIBAL would compensate for remaining traces of water and where 
the actual quantity of H2MAP would be hard to estimate. 
Time Conversion (% amine) 
30 min 70% 
45 min 75% 
1 hrs 100% 
Table 2.3: Stirring time with an excess of DIBAL 
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As illustrated in Table 2.3, this resulted in an improvement of the conversion. Interestingly, the 
ratio cis/trans also remained similar from one experiment to another. 
Unfortunately, removing the water from biological extracts can be challenging and is likely to 
lead to some loss of H2MAP as it is volatile. Furthermore, variability between one bottle of DIBAL 
and another was observed. NaBH4, could provide a viable alternative, especially because it can 
be used in a MeOH/H2O solvent system.151 Some diastereoselectivity was observed with NaBH4, 
but the ratio between the cis and trans isomers suffered a lack of repeatability, probably because 
NaBH4 is less sterically hindered than DIBAL. In addition, changes in the chemical shift of the 
methyl doublet in the 1H NMR spectrum were observed from one experiment to another. In 
conclusion, these approaches were promising and led to the formation of enough 59 to 
investigate the amine coupling, but they require optimisation. 
 
Figure 2. 29: Mosher's acide and the equilvalent acyle chloride 
Amide coupling with Mosher’s acid was then investigated. Activation of (R)-Mosher’s acid 61 
(Figure 2.29) with EDC and DMAP prior to the addition of 59 was tried but without success. 
Instead, activation of the carboxylic acid by formation of the acyl chloride 62 was investigated.152 
Excess thionyl chloride could be removed under reduced pressure and the amine dissolved in 
DCM could then be added. It was observed that a poor yield was obtained when the initial 
activation was only performed for two hours. Therefore, the reaction between Mosher’s acid and 
thionyl chloride was investigated using NMR spectroscopy. In the proton NMR spectrum, the 
hydrogen of the methoxy group underwent a shift from 3.57 to 3.77 ppm whereas in the 19F NMR 
spectrum the CF3 peak is shifted from -71.77 to -70.68 ppm. An NMR tube was charged with 0.4 
ml CDCl3, 0.3 ml SOCl2 and 17 mg (R)-Mosher’s acid and heated at 80°C. Spectra were recorded 
over an 18 h period, leading to Figure 2.30. 
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Figure 2.30: Formation of the acyl chloride of Mosher's acid 62 a) Evolution of the 19F NMR spectrum, 
b) evolution of the 1H NMR spectrum, c) Monitoring of the acylation Blue: 1 h, red 2 h, green; 4 h, purple 
9 h, yellow, 18 h 
It was hence decided to do the acylation overnight instead of in 2 hr as stated in the original 
procedure.  
The final amide 60 was obtained, and its UV spectrum was recorded (Figure 2.31). 
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Figure 2.31: UV spectra of 60 
60 showed an absorbance maximum at 260 nm. Hence, different HPLC conditions were 
investigated to separate the 4 diastereomers present in the mixture. Even though the reduction 
was stereoselective to some extent, the trans isomers of the amine were still present, leading to 
a total of 4 diastereomers after coupling with (R)-Mosher’s acid. It appeared that the best results 
were obtained with a gradient of ACN (0.1% formic acid) from 50 to 90% in water with a 
Phenomenex Jupiter 5µ C18 300A analytical column (Figure 2.32). 
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Figure 2.32: HPLC trace of a mixture of isomers of 60 
Two major peaks could be observed at 2.48 and 4.09 min, probably related to the cis isomers 
while two smaller peaks were observed at 7.98 and 8.34 min. 
7. Conclusion and future work 
Comparison of the LC-MS traces of extracted H2MAP and synthetic standards confirmed the 
structure the of H2MAP. We also established that the equilibrium between the imine and 
enamine form of H2MAP is slow enough compared to an enzymatic reaction to make the 
investigation of the stereoselectivity of PigB and its homologue relevant. The methodology for 
this investigation still requires optimisation, in particular, the conditions for the reduction need 
to be improved whilst more procedures should be tried for the amide coupling. A repeatable 
process with a good yield must be achieved before trying the procedure on a biological extract. 
The flexibility of H2MAP oxidases PigB and HapB around the C2 and C3 positions was studied, 
leading to the formation of analogues of prodigiosin by mutasynthesis. This study could be 
completed by trying side chains with heteroatoms and aromatic rings as well as substitution on 
other positions. The synthetic route described in section 3.2 gave promising results, but the final 
steps of the sequence are yet to be confirmed and its scope must be explored.
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Chapter 3. Antimicrobial activity of prodigiosin 
analogues 
 
Chapter 2 described how 8 analogues, compounds 1b-i, of prodigiosin 1a were obtained by 
mutasynthesis. Here, we aimed to assess their biological potential and in particular their 
antimicrobial activity, both against Gram-positive and Gram-negative bacteria. 
1. Construction of a prodigiosin producing strain suitable for 
antibiotic assays 
 
Figure 3. 1: Carbapenem 
S39006 is known to produce not only prodigiosin but also the antibiotic carbapenem 63 (Figure 
3.1). As a result, extracts for S39006 ΔpigD complemented with H2MAP contain a mixture of two 
antibiotics. The possibility that carbapenem effect was small enough to be masked by 
prodiginines activity was investigated through the preparation of extracts containing 1a-i and 
from S39066 ΔpigD without complementation. The samples were concentrated to the same 
concentration and the uninduced sample was concentrated to the minimal possible volume. 
Discs were then charged with the extracts and placed on a lawn of S. aureus (in triplicate). The 
plate was then incubated at 37°C, and inhibition halos were observed leading to Figure 3.2.  
 
Figure 3.2: Antibiotic activity of S39006 extracts Top three rows: column 1: uninduced, 2: 1a, 3: 1b, 4: 
1c, 5: 1d, 6: 1e; bottom three rows: column 1: solvent, 2: 1f, 3: 1g, 4: 1h, 5: 1i 
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The biggest halos were obtained for the most concentrated samples. This was particularly 
noticeable for the negative control, which did not contain any prodiginines. It meant that the 
carbapenem had a more important antibiotic effect than the prodiginines under these 
conditions and that direct extraction from induced S39006 ΔpigD was not suitable for an 
assessment of prodiginine antimicrobial activity. It was hence decided to construct a Serratia 
strain producing neither PigD nor carbapenem. 
Phages are viruses specifically infecting bacteria. They have been the driver of a number of recent 
biological advancements such as CRISPR-Cas9.153 Schematically, a phage infection follows these 
steps: the phage adsorbs onto its host, injects its DNA which is then replicated by the bacterial 
machinery, leading to the formation of new phages which finally encapsulate their DNA and exit 
the cell. During the encapsulation, a phage sometimes acquires bacterial DNA instead of its own. 
When this phage infects its next host, homologous recombination can happen. This process, 
called transduction, is a motor of genetic diversity in bacterial populations and can be used to 
transfer mutations. 
Serratia MCA54 (here called S39006 carA-) was constructed by Thomson et al.23 so that a 
transposon carrying resistance to kanamycin was inserted in carA, a gene coding for an enzyme 
necessary for carbapenem biosynthesis. A phage lysate was prepared (see experimental) by 
infecting top lawns of S39006 carA- with different concentrations of phage OT8 and extracting 
the phages present in plates presenting confluent plaques after an overnight culture. A culture 
of S39006 ΔpigD was then mixed with the resulting lysate for a short time.154 After washing off 
the phages, the cells were plated on LB supplemented with kanamycin. Some of the colonies 
thus obtained were then tested in a carbapenem assay along with S39006, S39006 ΔpigD and 
S39006 carA- (Figure 3.3). 
 
Figure 3.3: Carbapenem assay ΔpigD: S39006 ΔpigD, carA-; S39006 carA-, WT: S39006; the 16 other 
colonies resulted from the transduction experiment 
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As expected, large halos were visible surrounding S39006 and S39006 ΔpigD. Interestingly, 
those halos were also of similar sizes, indicating that prodigiosin had little antibiotic effect 
compared to carbapenem under these conditions. A small halo was observed around S39006 
carA- which tends to reinforce that the antimicrobial effect of the prodigiosin was present but 
weaker than that of the carbapenem. No halo could be seen around the 16 colonies resulting 
from the transduction experiment and they were all white, confirming a phenotype unable to 
produce prodigiosin or carbapenem. They are noted S39006 ΔpigD carA-. 
2. Antibiotic assay 
2.1. Preliminary studies 
Prodiginine extracts were prepared with this new strain. Restoration of pigmentation was 
observed in the same manner as with S39006 ΔpigD, indicating that the new mutation did not 
affect prodigiosin biosynthesis. Cells from 25 ml of cultures inoculated with H2MAP in LBS 
(LB+0.25 M sorbitol, see section 5) were extracted with 1 ml of acidified EtOH (Table 3.1). The 
quantity of prodiginine was estimated by measuring the absorbance at 535 nm, with 535 = 139 
800 ± 5100 M-1.cm-1 for prodigiosin.136 
Compound 1a 1b 1c 1d 1e 1f 1g 1h 1i Ne
g A535 (corr) 1.57 1.71 0.505 2.49 2.18 2.19 2.33 2.87 0.377 0
mprod (µg) 3.611 3.933 1.1615 5.727 5.014 5.037 5.359 6.601 0.8671 0 
Table 3.1: Quantity of prodiginine obtained from complementing 25 ml of S39006 ΔpigD carA- The 
absorbances were corrected for non-prodigiosin secondary metabolites by subtracting the value of the 
negative control 
These extracts were concentrated under reduced pressure and redissolved in DMSO so that the 
concentration was 36 µg/ml in all cases. Filter paper discs were inoculated with the extracts and 
placed on lawns of S. aureus. The plate was incubated overnight at 37 °C leading to Figure 3.4. 
 
Figure 3.4: Antibiotic assay of prodiginines extracted from 25 ml of S39006 ΔpigD carA- culture  
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Only a small halo with prodigiosin 1a was visible. This indicated that the concentrations of 
antibiotic were too low to observe any activity. It was hence decided to scale up the production 
to 400 ml of culture. 
Such a culture was inoculated with 19a and about 80 µg of pigment 1a were obtained. The sample 
was then concentrated, and filter paper discs loaded with approximately 7.7 µg of prodiginine. 
Results of the antibiotic assay against S. aureus are shown in Figure 3.5. 
 
Figure 3. 5: Antibiotic assay of 1a extracted from 400 ml of S39006 ΔpigD carA- culture Neg: extract 
from 400 ml of a S39006 ΔpigD carA- culture without 19; solvent: EtOH 
Unsurprisingly, a small halo was observed around the disc only inoculated with ethanol. The 
negative control also displayed a significant halo, which suggest that other secondary 
metabolites produced by S39006 could have an antibiotic activity. However, this halo was 
noticeably smaller than the one obtained with 1a, which suggests that the effect observed in this 
case was due to the pigment. This validated the procedure for the preparation of extracts for 
further antimicrobial experiments. 
2.2. Disc diffusion assay 
Prodiginine extracts from 400 ml of culture of S39006 ΔpigD carA- inoculated with H2MAP 
analogues were prepared (see experimental). The samples were then evaporated to dryness and 
resuspended in 0.5 ml of acidified EtOH. Filter paper discs were then charged with 50 µl of 
extract and placed on an agar plate with a lawn of E. coli ESS. This strain displays enhanced 
susceptibility to some antibiotics155 and was hence used to obtain halos as big as possible, making 
the interpretation of the assay easier. A positive control with ampicillin (10 µg) and a negative 
one with only EtOH were also put on the top lawn. A fourth disc was charged with 0.4 µmol of 
H2MAP or the corresponding analogue: this represented the maximum quantity of that could be 
present on a disc charged with 10% of the total extract. Results after overnight growth at 37°C 
are presented in Figure 3.6.  
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Figure 3.6: Antimicrobial assay of 1a-i against a Gram-negative bacteria  in reading order: scheme of 
the plate, 1a, 1b, 1c, 1d, 1e, 1f,1g, 1h and 1i 
A negative control was prepared from an extract from S39006 
ΔpigD carA- cultured in absence of any H2MAP 19a analogues 
(Figure 3.7). As expected, in this plate only ampicillin displayed 
a halo. In the other plates, both positive and negative controls 
gave the expected results whilst halos were observed with all the 
extracts. Interestingly, prodigiosin itself gave the smallest halo 
whilst extracts that looked barely red gave halos of similar size 
to ampicilin’s (1h and 1i). Most discs impregnated with H2MAP 
analogues did not lead to a visible halo. Compounds 19e and 19f 
did, but the size of these halos was smaller than the size of the ones obtained with the extracts. 
Activity against S. aureus was also tested (Figure 3.8). Here again all prodiginines seemed to 
have activity. Yet, when the experiment was repeated with a fresh batch in an attempt to imitate 
Figure 3.8, almost no activity could be observed. To rule out the presence of mutations or 
contamination in the strains used for the assay, the experiment was repeated against bacteria 
freshly taken out of the glycerol stock, but it gave similar results. The discrepancies could be due 
to difference of concentration in prodiginine from one batch to another (A535 was twice as high 
in some cases in the original batch) or to the effects of other molecules present in the extract. 
These variations from batch to batch were also observed with E. coli. 
Figure 3.7: Negative control 
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Figure 3.7: Antimicrobial assays of 1a-i against a Gram-positive bacteria   
 
Another limitation of these experiments was the lack of comparability between the compounds 
as all the discs are charged with a different quantity (Table 3.2).  
Compound 1a 1b 1c 1d 1e 1f 1g 1h 1i 
A535 (corr) 1,57 1,71 0,505 2,49 2,18 2,19 2,33 2,87 0,377 
nmol 11.16 12.88 7.62 20.21 14.66 7.87 2.36 1.79 0.72 
µg 3.6 3.6 2.5 5.9 4.9 2.6 0.7 0.6 0.3 
 
Table 3.2: Quantity of prodiginine obtained from 400 ml cultures 
To get a suitable comparison, the concentration of the prodiginine in all the samples were 
brought to 0.21 mM (as judged by their A535 values). Filter discs were then inoculated with 50 µl 
of the sample (approx. 3 µg) or 0.4 µmol of the 19 precursors (this represent the maximum 
quantity of precursor that could have been spotted on the disc from an extract). They were then 
all placed on a single plate to compare their antibiotic effects (Figure 3.9). The sample used for 
1h was purified by HPLC beforehand.  
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Figure 3.8: comparison of the antibiotic activities of compounds 1a-I a) Scheme of the plate, C+: 
ampicillin, C- EtOH, N: extract from S39006 ΔpigD carA- cultured without an H2MAP analogue ; b) 
Activity against E. coli; c) Activity against S. aureus 
The results for the two strains were similar (Table 3.3). The strongest halos were observed with 
1e, but its precursor 19e gave a similar result. As observed earlier, 19f also gave halos, but, 
interestingly, no visible halo was observed with 1f. Prodiginine 1d gave halos consistently bigger 
than its precursor, but they were still small compared to the positive control. Prodiginines 1b 
and 1c also seemed to have some activity against E. coli. The purest compound, 1h had mainly a 
surfactant effect.  However, after the HP-LC purification, the ethanolic solution seemed less 
viscous than when the cells extracts were directly concentrated and resuspended in ethanol, 
probably because there were less impurities. It was hence hard to tell if the observed effect was 
due to antimicrobial activity or surfactant pushing the bacteria away.  
Extract  C+ C- N 1a 1b 1c 1d 
E. coli 4.6 ± 0.5 <1 1 ± 0.0 1.4 ± 0.6 <1 1.5 ± 0.7 <1 1.3 ± 0.1 <1 2 ± 0.9 <1 
S. aureus 7.1 ± 0.1 <1 <1 1.3 ± 0 <1 <1 <1 <1 <1 1.8 ± 0.0 <1 
 
Extract 1e 1f 1g 1h 1i 
E. coli 2.9 ± 1.5 3.7 ± 0.4 <1 4.5 ± 0.7 <1 <1 NA 1.0 ± 0.0 <1 <1 
S. aureus 3.7 ± 0.7 5.0 ± 0.6 <1 4.1 ± 0.2 <1 <1 NA NA 1.0 ± 0.0 <1 
 
Table 3.3: Halo sizes C+, C- and N as above; left: 1; right 19 
Considering the results presented in Figures 3.6 and 3.8, and even allowing for the fact that less 
material was used than in some literature reports,71 the halos were smaller than expected. This 
could be due to degradation of the samples either during the concentration process or during 
storage. 
The quality of the data as well as the repeatability of these experiments needs to be improved. 
Using only purified prodiginines in more concentrated solutions so that the discs can be 
saturated with a higher quantity of compounds whilst minimising the amount of solvent could 
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be a way to do so. Yet, as a preliminary test, these experiments confirmed the antimicrobial 
potential of the mutasynthesised prodiginines.  
2.3. Half maximal growth inhibition (GI50) experiments 
Fresh prodiginines (1a, 1e, 1g and 1h) extracts were prepared from 1 L of culture. The ethanolic 
extracts were sterile-filtered before concentration and resuspension in 1 ml of H2O/ACN. 
Prodiginines were then purified by HPLC. The pink fractions were gathered, the solvent removed 
under reduced pressure, and the residue was resuspended in the minimum volume of EtOH. 
Unfortunately, the quantity of 1g – estimated by measuring the A535 – hence purified was too low 
for any downstream applications. 
Growth inhibition assays were conducted with maximal concentrations of 1.4 µg/ml (4.3 µM) for 
1a and 7 µg/ml (21 µM) for 1e and 1h (Figure 3.10a): 96-well plates were charged with E.coli ESS 
or S. aureus (OD600 = 0.06) and a serial 2-fold dilution of prodiginine and the plates were 
incubated at 37 °C for 16 h. Ampicillin was used as a positive control (Figure 3.10a). The plates 
were then inspected for growth and the OD600 was recorded with a plate reader. At 1e and 1h 
concentrations, the absorbance of prodiginines still had to be taken into account when the 
OD600 was measured: the absorbances were hence corrected (see experimental) and normalised 
by the mean absorbance of wells charged with bacterium but not with antibiotic. The data were 
finally submitted to a non-linear analysis (Figure 3.10b-f).  
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Figure 3.9: GI50 assays a) Scheme of the plate, b) 1a against S. aureus; c) 1h against S. aureus; d) 1e against 
S. aureus, e) 1h against E. coli; f) 1e against E. coli 
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It appeared that the concentrations were not high enough to see the complete inhibition profiles 
in some cases. In particular, all the concentrations tested with 1a were lower than the GI50. 
Furthermore, the curve obtained for 1h against E. coli did not follow the expected sigmoid and 
the end growth was sometimes higher than without the antibiotic (Figure 3.10b and e). Despite 
these problems, GI50 could be estimated in all cases. Interestingly, both 1e and 1h are more potent 
than prodigiosin 1a against S. aureus. It is possible that the extra methyl group on 1e and 1h 
improved the lipophilicity of the molecules, hence enhancing any membrane disturbing effects 
or cell permeability. The difference between 1e and 1h is harder to explain, especially without 
knowing for certain what the mechanisms of action of prodiginines in the cells are. For both 
compounds, a better activity against the Gram-positive strain was observed, possibly because of 
the absence of an outer membrane in that case.  
3. Preliminary anti-cancer activity assay 
This part of the project was done with the help of Lavinia Dunsmore. Prodiginine 1h was 
inoculated to cultures of HeLa cervical cancer cells at concentrations between 1 µM and 62.5 nM 
with 1% DMSO. The cells were cultured two days and the cell viability was measured and 
normalised to controls cultured with 1% DMSO only, leading to Figure 3.11. 
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Figure 3.10: Cell viability assay of HeLa cell in presence of 1h (1% DMSO) 
It appeared that the concentrations were higher than the LD50. A non-linear analysis of the data 
was nevertheless possible, but the confidence interval around the predicted value of the LD50 
(40 nM) was very wide. Yet, these data indicate that the LD50 for 1h is lower than the reported 
values for 1a (about 1 µM).156,157 However, it would be necessary to try a wider range of 
concentrations for precise determination of the LD50. Finally, it would be interesting to also test 
activity against non-cancer cell lines to assess for cancer cell selectivity.  
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4. Investigation of a hyper-producing strain for yield 
improvement 
Even with an increased culture volume, the quantity of pigment obtained remained low. The 
construction of a mutant of S39006 ΔpigD with the capacity to produce more prodigiosin was 
hence investigated. Serratia rop2 was prepared by Slater et al.150 by transposon mutagenesis. 
Plasmid pUT-miniTn5 Sm/Sp158,159 was used to insert the transposon with resistance to 
streptomycin and spectinomycin into pstS, a gene involved in phosphate transfer during a 
random transposon mutasynthesis experiment aimed to study the regulation of prodigiosin and 
carbapenem production. The mutant hence obtained was visibly extra-red. Using the same 
transduction procedure as for the construction of S39006 ΔpigD carA- (see experimental and 
section 2), colonies with deletion in pigD and the insertion in pstS were obtained (strain S39006 
ΔpigD rop2). Resistance to streptomycin and spectinomycin confirmed the presence of the 
transposon whilst the deletion was checked by colony PCR. 
The hyper productivity of the strain was then checked by measuring the quantity of pigment per 
cell for 11 h after addition of H2MAP to a culture of S39006 ΔpigD rop2. The effects of the 
variations of the media volume – which is reduced by more than half because of the sampling 
when the experiment is conducted in  25 ml cultures – were first assessed (Figure 3.12a), 
followed by the effect of supplementing the media with sorbitol (Figure 3.12b), with the wild 
type strain. 
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Figure 3.11: Prodigiosin production time curves Black: OD600, Red: A535, a) influence of the media 
volume b) Influence of sorbitol supplementation 
Growth curve of S39006 in 25 and 250 ml cultures were similar, even though slightly higher 
OD600 and prodigiosin levels were obtained in 25 ml, probably because of  better oxygenation. 
It was hence decided to perform future growth curves in 25 ml. As expected, the addition of 
Chapter 3: Antimicrobial activity of prodigiosin analogues 
60 
 
sorbitol led to a longer exponential phase, and hence a large increase of OD600 and of prodigiosin 
production. Interestingly, the amount of prodigiosin per cell was also six times higher in the 
presence of sorbitol. This justified the use of sorbitol as a complement for growth curve and 
complementation assays. A535 increased also slightly in S39006 ΔpigB in the presence of sorbitol, 
probably because the higher OD600 triggered the formation of other secondary metabolites. 
The hyper productivity of pigment in S39006 ΔpigD rop2 was then assessed and compared to 
the pigment production in S39006 ΔpigD (Figure 3.13) when these strains are cultured in the 
presence of H2MAP. Here, H2MAP was added after 12 h of incubation and the OD600 and the 
pigmentation were monitored for a further 12 h. 
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Figure 3.12:Effects of an insertion in pstS on pigment production 
The amount of pigment per cell was indeed higher with the rop2 mutation. However, it seemed 
to decrease as time went on, probably because of the faster consumption of the precursor.  
For mutasynthesis and complementation assays, the total amount of pigment is more relevant 
than the quantity per cell. Because of differences in the growth and in the rate of consumption 
of the precursor, it was observed that less total pigment was actually obtained with S39006 
ΔpigD rop2 than with S39006 ΔpigD after 16 h with H2MAP (Figure 3.14). Shortening the time 
would lead to lower OD600 and hence decrease the overall pigmentation as well.   
Chapter 3: Antimicrobial activity of prodigiosin analogues 
61 
 
Dp
ig
D
Dp
ig
D
 r
op
2
0
2
4
6
8
A
5
3
5
 (
A
U
)
 
Figure 3.13: Pigment production S39006 ΔpigD and ΔpigD rop2 after 16 h of culture with H2MAP 
in LBS 
In conclusion, even though rop2 mutation gives a hyperproducer phenotype, optimisation of the 
feeding assay would be necessary to get a better yield using this strain.  
5. Other potential applications of prodigiosin analogues 
Indirect applications of these new prodiginines can be imagined. For example, compound 1d 
contains an allyl group, with can be used for electrocyclization (as a dienophile in a Diels-Alder 
reaction for instance), metathesis, and many other things. A potential application could be to 
follow the prodiginine inside a cancer cell. As mentioned in Section 1.5, studies about the 
location of prodiginine in cancer cells gave contradictory results. Treating cancer cells with 1d 
and then coupling it with a tetrazine attached to a fluorophore would provide a way to conduct 
this kind of investigation. Coupling between tetrazines and allyl tagged protein have been 
reported in the literature.160 In addition, the formation of a coupled product could be observed 
by LC-MS when 3,6-dipyridyltetrazine (Py2Tz) 64 was stirred with 19d in PBS buffer at room 
temperature (Figure 3.15). Even though this is still very far from an imaging process, this 
illustrates the possibility. 
Another idea would be to replace the terminal alkyl group by an alkyne. This would make click 
reactions with biotin-azide possible and would hence give a way to investigate what protein 
prodigiosin binds to. In summary, this process to prepare functionalised prodiginine combined 
with biorthogonal chemistry techniques could lead to a variety of new assays. 
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Figure 3.14: Coupling of 19d and a tetrazine a) Reaction scheme of the coupling b) LC-MS 
chromatogram after 48 h. The peak at 1.12 min has the correct m/z value for [19d+H]+ and the peak at 1.40 
min has the correct m/z value for [65+H]+. 
 
6. Conclusion and future work 
Initial testing of the prodiginines obtained by mutasynthesis gave promising results. The 
antimicrobial potential was demonstrated, and two compounds proved more potent than 
prodigiosin 1a against S. aureus and showed activity against E. coli. However, the repeatability 
of the disc diffusion assays needs to be improved: the surfactant effect observed with 1h needs 
to be resolved and the assay should be repeated with purified compounds for more quantitative 
results. The growth inhibition assays also need to be repeated with higher starting 
concentrations to get the full inhibition curves and MIC values.  
Prodiginines have many biological properties and only two of those have been investigated here. 
Hence, it would be interesting to assess the antifungal potential of these compounds. More in 
depth analysis of the anticancer activity would also be interesting: the precise value of the LD50 
against HeLa cells still needs to be determined and other cell lines could be investigated. 
Preliminary experiments also showed that some prodigiosin analogues may have applications 
beyond their biological properties.   
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Chapter 4. Characterisation of PigE 
 
1. Overview and aims of the project  
1.1. Overview of potential characteristics of PigE 
1.1.1. Substrate channelling 
PigE is likely to be a bifunctional enzyme (see section 1.2). It might hence be an example of 
substrate channelling, a phenomenon where the intermediates in an enzymatic sequence are 
prevented from freely diffusing. Indeed, diffusion of substrates from one active site to another 
is slow and can lead to the degradation of the intermediate. Different mechanisms preventing 
diffusion have been observed. The most obvious one is the localisation of the entire reaction 
cascade in a single organelle – a chloroplast for instance161 – hence reducing the volume in which 
the diffusion might occur. In bifunctional enzymes and enzymes clusters, structural mechanisms 
such as intramolecular tunnels, electrostatic guidance or chemical swinging arms have been 
observed.  
As their names indicate, intramolecular tunnels will connect two active sites within a single 
protein or complex, preventing the intermediates from escaping into the cytoplasm. This is 
illustrated by the last two steps of catechol degradation: 4-hydroxy-2-ketovalerate aldolase 
DmpG and acetaldehyde dehydrogenase DmpF form a complex that will catalyse a retro-aldol 
reaction producing acetaldehyde followed by oxidative thioesterification of the acetaldehyde. 
Crystal structures of the complex showed that the active sites of the two enzymes are connected 
by a 29 Å long tunnel, which the acetaldehyde travels along.162 
If the intermediates are charged, a charged pathway on the protein surface can guide the 
diffusion from one site to another. This is illustrated by the malate dehydrogenase-citrate 
synthase complex, where a positively charged surface of the protein guides the diffusion of the 
negatively charged oxaloacetate intermediate.163  
Chemical swinging arms, as illustrated by the ACP, are probably the most frequent channelling 
mechanism as they are used in Type I PKSs as well as in Type I fatty acid synthases. In the case 
of fatty acid synthesis, the ACP, the  ketoacid synthase, the  ketoacyl reductase, the hydrolase 
and the enoyl reductase are arranged in a megaenzyme; and the phosphopantetheine moiety of 
the ACP – or the entire ACP – can translocate to reach the active sites of the different 
domain.161,164 
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1.1.2. Thioester reductase (TR) 
The most common mechanism for the release of the chain from the ACP domain of PKSs and 
non-ribosomal peptide synthetases (NRPSs) is thioesterase-catalysed hydrolysis, leading to the 
formation of a carboxylic acid. Yet, the release can also occur in an reductive manner and, in 
these cases, it is catalysed by a thioester reductase (TR).165,166 All the reported thioester reductase 
domains are NAD(P)H dependent and present a Rossman fold where the cofactor can bind at 
the N-terminal end (Figure 4.1). In addition, threonine, 
tyrosine, and lysine are always present in the catalytic site.167 
These two features make TRs very similar to short chain 
dehydrogenases/reductases. Depending on the number of 
electrons involved (two or four) in the reduction, the TRs are 
divided into two main classes. When four electrons are involved, the reaction goes all the way 
to the alcohol, which is the final product in most cases. When only two electrons are involved, 
the TR gives aldehyde products, but those often undergo further transformations, leading to a 
variety of functional groups.  
TRs catalyse a hydride transfer from NAD(P)H to form a thiohemiacetal intermediate covalently 
bound to the enzyme and stabilised by H-bonding with tyrosine. Cleavage of the thioacetal then 
gives the aldehyde (Figure 4.2).168  
 
Figure 4.2: Mechanism of action of TR T: ACP or PCP thiolation domain  
In some rare instances, the release mechanism of thioester can follow yet another mechanism: 
in MBC biosynthesis, PigH catalyses the liberation of an -oxoamine by reaction of a thioester 
bound to an ACP domain with serine in a PLP-dependent fashion. 
1.2. PigE: a potential bifunctional thioester reductase - aminotransferase 
As mentioned in Chapter 1, PigE is the second enzyme in MAP biosynthesis (Figure 4.3).  
Figure 4.1: Scheme of Rossman 
fold, red:  helix, yellow:  
strand 
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Figure 4.3: Simplified prodigiosin biosynthetic pathway 
In their original elucidation of prodigiosin pathway, Williamson et al.26 described PigE as a PLP 
dependent transaminase taking the aldehyde product of PigD and catalysing the transformation 
of one of the carbonyl groups into an amine, making a spontaneous cyclisation possible. The 
transaminase activity was investigated by Bhalara, who observed an increase in the absorbance 
at 330 nm when purified PigE was incubated with L-ornithine, suggesting the formation of a 
pyridoxamine phosphate (PMP) species (see Figure 4.4) and consistent with a PLP-dependent 
transaminase.20 A crystal structure of the transaminase domain was obtained by Lou et al.35 They 
were also able to show that residue Lys645 binds to PLP, via an aldimine (Figure 4.4)  
 
Figure 4.4: Mechanism of transamination by PLP dependent aminotransferase  
However, this crystal structure was only partial, no electron density was visible from residue 
Mat1 to Ala371, probably because of degradation. Consequently, this structure might not be an 
accurate representation of the native state of PigE. 
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It is highly unlikely that PigE has only a transaminase activity. Indeed, that would mean that the 
product of PigD is a free aldehyde. These compounds are very reactive and are known to react 
with nucleophilic sites in macromolecules,169–172 for instance the cysteine170 and lysine171 residues 
of enzyme active sites, but also DNA.172 This leads to the formation of adducts impairing the 
function of essential macromolecules and thus to cytotoxicity.169,173 In addition,  aldehydes can 
trigger oxidative mechanisms and the release of free radicals within the cell, causing damage to 
DNA, proteins and membranes.174,175 Furthermore, Dresen et al. showed that PigD 
regioselectivity on aldehyde substrates was not consistent with the rest of prodigiosin 
biosynthesis (see Chapter 5).36 On the other hand, PigD showed the appropriate regioselectivity 
with thioester substrates. 
We hence hypothesised that the natural substrate of PigE was a thioester, either 3-
acetyloctanoyl-CoA 66 or more likely a 3-acetyloctanoyl-ACP 67. 
The aim of this project was to prove that there is a thioester intermediate in MAP biosynthesis, 
which is reduced to give 3-acetyl octanal 20. The thioester reductase activity of PigE was to be 
investigated both in cells and on purified proteins. 
2. Bioinformatic analysis of PigE 
2.1.  NCBI Basic Local Alignment Search Tool (BLAST)176  
When PigE DNA sequence was submitted to blastx (see appendix), the protein sequences 
matching the best with PigE’s were unsurprisingly from prodigiosin producing organisms. To 
the best of our knowledge, the predicted functions of those protein have never been 
experimentally established. 
Two domains (residue 1 to 335 and 391 to 854) were predicted. The C-terminal domain belongs 
to the family of acetylornithine PLP-dependent transaminases. This was in agreement with the 
studies on PigE mentioned earlier. The BLAST results were also consistent with Lou et al. and 
predicted Lys645 to be the residue that formed the Schiff base. It also indicated that residues 
Gly424, Thr425, Tyr530, His531, Glu583, Asp616 and Gln619 were also likely to be involved in 
binding with PLP. 
The N-terminal domain did not give any specific hits but showed some homology with Acyl ACP 
reductases, which catalyses the reduction of fatty acyl ACP thioesters to the corresponding 
aldehyde in cyanobacteria.177 It also shared some similarity with PRK14982, which is also 
believed to be an acyl-ACP reductase.177  
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2.2.  PHYRE147 
Two algorithms can be run with PHYRE software: normal or intensive. The intensive mode uses 
multiple templates and ab initio technique to cover the entire protein. PigE was analysed using 
both setups.  
In both cases, PHYRE first aligned the sequence against other proteins. Here only two proteins 
that matched the entirety of the sequence (see appendix): HapE, PigE’s homologue from H2396, 
and a putative aminotransferase form Saccharospora erythraea. The other proteins matching 
PigE’s sequence either matched the N-terminal domain or the C-terminal one. This was an issue 
because the software uses already solved structures as the basis for the 3D model. As a 
consequence, the normal algorithm only gave a model based on the best hits, which are, as 
expected from the BLAST results, covering only the C-terminal domain. 
The software was able to predict that PigE C-terminal domain (residues 394 to 848) was most 
similar to putrescine aminotransferase, a class III PLP dependent aminotransferase.178  This  led 
to the predicted structure presented in Figure 4.5. All but two of the residues predicted by 
BLAST to interact with PLP (in orange in Figure 4.5) were on the outside of a pocket, which was 
consistent with a cofactor binding site. 
 
Figure 4.5: Predicted structure of PigE C-terminal domain by PHYRE Orange: residue predicted to 
be involved in the PLP binding site  
However, the intensive algorithm circumvents that limitation: by mixing templates covering 
both domains of PigE, it was able to model 77% of the structure with more than 90% confidence 
(Figure 4.6). A drawback of this approach was that the prediction about the orientation of one 
domain compare to the other was unreliable. The template used to model the N-terminal 
domain was Methanopyrus kandleri’s glutamyl tRNA reductase, a V-shaped enzyme catalysing 
the transformation of glutamyl-tRNA into glutamate-1-semialdehyde through the formation of 
a thioester intermediate which is then reduced by NADPH.179 
Chapter 4: Characterisation of PigE 
68 
 
With both algorithms, the software predicts the secondary structures for the whole sequence. 
Estimates from both algorithms were consistent and predicted a structure with approximately 
42% of -helices, 16% of -strands, 6% of transmembrane domain (TM), and 16% of disordered 
domains. 
 
Figure 4.6: Predicted structure of PigE Blue: C terminal domain, Orange: PLP binding site, Light blue: 
PLP; Green: N terminal domain, White: low level of confidence  
In addition, at the end of the pipeline, the model is submitted to 3DLigandSite,180 a binding site 
predictor. After the intensive run, a PLP pocket (in orange in Figure 4.6) was identified. Its 
location is in good agreement with the BLAST results, other than Gly424 and Thr425, as 
observed with the normal run. 
A PHYRE analysis of the N terminal domain alone (residue 1 to 426) was performed: the best hit 
was tRNA glutamate reductase. Other hits included NAD(P)-binding Rossman fold domains and 
oxidoreductases, which was consistent with a thioester reductase activity. Unfortunately, most 
of these proteins have not been crystallised, so despite good alignments (see appendix), they 
were not used for the modelling. Yet, 63% of the sequence was modelled with more than 90% 
confidence (Figure 4.7). This was not high enough to get reliable results from 3DLigandSite. 
Interestingly, the model hence obtained differed significantly from the one obtained with the 
whole protein (Figure 4.7). This could be due to the inability for the software to predict the 
orientation of disordered domains.  
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Figure 4.7: Superposition of the PHYRE predicted model for PigE N terminal domain only (green) 
and the N terminal domain of the predicted structure of the complete PigE (blue) 
2.3.  Comparison with TamH 
In tambjamine biosynthesis, TamH has the same function as PigE in prodigiosin biosynthesis, 
but with a -ene substrate instead of a -acetylated one.55  Unfortunately, the sequence of 
TamH from Pseudomonas tunica was not readily available for comparison.  
PigE protein sequence was blasted against Pseudomonas tunica whole genome, leading to 7 hits, 
6 of whom were aminotransferases of approximately 400 amino acids, whereas the last was 941 
amino acid long. The entire prodigiosin biosynthetic gene cluster was then compared with this 
gene’s surrounding using Artemis Comparison Tool (ACT), showing homologues of genes 
involved in MBC formation, confirming that it belongs to tambjamine’s biosynthetic cluster (see 
appendix). 
Comparison of TamH and PigE sequences via BLAST and ACT showed (see Figure 4.8) that both 
displayed two domains: one predicted transaminase region and one putative reductase. 
Interestingly, the order of the domains was the reverse. This suggests some flexibility in the 
region between the two domains. 
 
Figure 4.8: Comparison of TamH and PigE sequences. The comparison of the orientations was done 
using ACT 
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3. Synthesis of PigE potential substrate(s) 
Figure 4.9: Potential substrates of PigE 
The synthesis of three different molecules (Figure 4.9) was necessary for the study of PigE. 3-
Acetyloctanal 20 was the most likely substrate and it was important to make so it can play the 
role of positive control. 3-Acetyloctanoyl-CoA 66 and 3-acetyloctanoyl-ACP 67 could be 
synthesised, but they were unlikely to get into the cells, making complementation assays 
impossible. Hence, the synthesis of mimic 68 was undertaken. Interestingly, this compound has 
previously been made by  PigD-catalysed reaction of thioester octenoyl-S-NAC 70 and pyruvate  
in vitro.36 Finally, thioesters are labile and can hydrolyse in culture broth. Consequently, it was 
important to prepare carboxylic acid 69, which is the result of the hydrolysis of 68. If the 
hypothesis on the function of PigE is correct, 69 should not be accepted as a substrate. The three 
molecules share the same carbon skeleton and only differ in one functional group. Once one of 
the three has been synthesised, the other two can be obtained by functional groups 
manipulation. 
3.1.  Method A: from ethyl acetoacetate to 3-acetyloctanal 
 
Figure 4.10: Chawrai’s synthesis of 20 
This method (Figure 4.10) was adapted from Williamson et al. who synthesised 20 and showed 
it could complement a S39006 ΔpigD mutant .26 After formation of the enolate of ethyl 
acetoacetate 7 by treatment with sodium ethoxide, it was alkylated with 1-iodopentane at reflux 
to give intermediate 72. As often with this kind of procedures, double-addition product 72b 
could sometimes be observed but could easily be removed by column chromatography. 
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Figure 4.11: Side products observed during the synthesis of 20 a) Structures, b) Mechanism of 
formation of 74b 
The second step followed the same principle: after formation of the enolate, alkylation was 
performed with allyl bromide at reflux, leading to 73. A few conditions were tried before getting 
the hydrolysis-decarboxylation product 74. When the reaction was conducted in MeOH/H2O 
1:4 and 5% NaOH at 80 °C overnight, no product at all could be detected. Changing the base for 
KOH did yield some 74 but the main product of the reaction was a side product 74b, the product 
of a retro-Claisen condensation followed by hydrolysis (Figure 4.11b). Finally, doing the reaction 
in MeOH/H2O 4:1 instead of 1:4 gave the desired product. In these conditions the retro-Claisen 
reaction was less likely to happen as the available quantity of hydroxy anion was decreased. 
Alkene 74 could be converted to 20 by ozonolysis. 
Several procedures were attempted to convert 20 into 68 and 69 (Figure 4.12). Carboxylic acid 
69 was obtained directly by oxidising 20 in presence of sodium chlorite and H2O2.181 A direct 
synthesis of the thioester from the aldehyde was attempted following a procedure developed by 
Huang et al.:182 20 was dissolved in water along with tert-butyl hydroperoxide (TBHP) and N-
acetylcysteamine (H-SNAC) 75 before pouring on catalyst FeBr2. After stirring at 110 °C for 1 h, 
no trace of the thioester could be detected. A more classic way to get thioester is through the 
coupling of a carboxylic acid and a thiol. In a first two-step attempt, synthesis of the activated 
species 76 was tried by coupling carboxylic acid 69 and NHS, and DMAP and EDC as coupling 
agents. Unfortunately, this intermediate could not be isolated. In a one-step approach, the same 
reaction was tried with H-SNAC instead of NHS, this time successfully, giving the last wanted 
product 68. 
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Figure 4.12: Conversion of 20 into 68 
3.2. Method B: From 2-octanone to 3-acetyloctanoic acid 
 
Figure 4.13: Formation of 69 from 3-bromooctanone 
A shorter approach to 69 was also investigated (Figure 4.13). Focusing the synthesis on the 
carboxylic acid allowed us to get either the thioester with the coupling reaction or the aldehyde 
through a redox process without having to make one to get the other.  
3-Bromooctan-2-one 48a was obtained from 2-octanone following the method developed in 
Chapter 2. Dimethyl malonate addition could then be carried out on 48a at 60 °C overnight, 
leading to the formation of 77. 
The synthesis of 69 then required hydrolysis of 77 and decarboxylation. To avoid incomplete 
hydrolysis, a large excess of KOH in MeOH/H2O 4:2 was added to 77, leading to diacid 78 
(Figure 4.14).  
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Figure 4.14: Methods investigated to convert 77 into 69; a) saponification followed by decarboxylation 
in acidic conditions (second step unsuccessful) b) Krapcho decarboxylation followed by saponification  
However, even upon acidification of the reaction mixture, no decarboxylation was observed. A 
few conditions were tried (Table 4.1) but 69 could not be isolated in any cases. The formation 
of 69 was assessed by NMR spectroscopy by looking for doublets of doublet at 2.39 ppm and at 
2.76 ppm (proton  to the carboxyl group). In some cases, proton NMR only showed peaks 
around 0.8 and 1.2 ppm, which suggests degradation of the products as none of the expected 
peaks of 69 or 78 were present. 
Table 4.1: Screen of decarboxylation conditions 
Hence it was decided to perform decarbomethoxylation first, followed by hydrolysis. Following 
Krapcho’s conditions,183 77 was dissolved in wet DMSO with NaCl and the mixture was heated 
up at 160°C overnight. DMSO was then washed away, leading to the intermediate 79 which could 
then be used without further purification. Carboxylic acid 69 could then be obtained by 
hydrolysis (see experimental). 
Acid Time temperature Results 
H2SO4 5 min r.t. Degradation 
HCl 4 h r.t. Diacid 78 
HCl 6 h 60°C then 80°C Degradation 
HCl 16 h 60°C Traces of 69 but mainly degradation 
acetic acid 3 h 60°C Partial degradation; 69 present but could not be 
isolated 
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Figure 4.15: Two steps conversion of 69 into 20 
68 was then synthesised following the same procedure as in section 3.2. Mild reduction 
conditions were tested to transform carboxylic acid 69 into aldehyde 20 without affecting the 
ketone. Carboxylic acid 69 was reacted with TMSCl before addition of DIBAL-H at -78 °C184 but 
after workup, no aldehyde could be detected. A two-step procedure was hence investigated, with 
first the reduction of both functional group to the alcohol followed by a mild oxidation to the 
dicarbonyl compounds.  Test reactions were conducted with borane-dimethyl sulphide (BMS) 
as a reducing agent and pyridinium chlorochromate as an oxidant185 as well as with LiALH4 as a 
reducing agent and Swern conditions for the oxidation.186 The latter gave the most promising 
results and was investigated further.  After treatment with LiAlH4, NMR spectroscopy analysis 
of the crude mixture was consistent with a mixture of diastereomers of diol 80 with very little 
impurities, confirming that it could be used without direct purification (Figure 4.15). The most 
noticeable impurity was BHT, a solvent stabiliser which fortunately does not significantly affect 
the reactions. Swern oxidation could be performed on the diol leading to the formation of the 
desired aldehyde 20. 
4. Complementation experiments 
4.1. Qualitative assay 
Similarly to the qualitative assays performed with H2MAP analogues in Chapter 2, the capacity 
of aldehyde 20 and thioester 68 to restore pigmentation in S39006 ΔpigD was first assessed. 
Two lines of the bacterium were streaked on Peptone Glycerol Media (PGM, see experimental 
for the composition) agar and cultured for two days. Aldehyde 20 or thioester 68 (2µl, 1M in 
DMSO) were then spotted next to the streaks and the plate was incubated a further 16 h at 30 
°C. As illustrated in Figure 4.16, red colour was obtained in both cases, meaning that both 
compounds could be accepted as substrates.  
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Figure 4.16: Chemical complementation of S39006 ΔpigD with aldehyde 20 (left) and thioester 68 
(right) Colour and contrast were digitally enhanced for better visualisation 
4.2. Conditions for quantitative complementation assay with PigE 
substrate 
Due to the position of the PigE-catalysed step in prodigiosin biosynthesis, chemical 
complementation with potential substrates of this enzyme can only be done on S39006 ΔpigD.  
4.2.1. Influence of the media 
As shown in Chapter 3, culture in LBS supplemented with 0.25 M sorbitol (LBS) leads to an 
increase in pigment production. However, low phosphate media have also been shown to induce 
prodigiosin production150 which explains why complementation assays on agar are performed 
with PGM. To compare the results with these two broths, prodigiosin produced by S39006 was 
extracted in both cases (Figure 4.17): 
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Figure 4.17: Prodigiosin production in different media 
PGM is far less rich than LB, especially when an additional sugar like sorbitol is present. It was 
hence unsurprising that the final OD600 would be lower in the case of PGM. The total 
pigmentation was lower as well (data not shown), but even the quantity of pigment per cell was 
about ten times lower in PGM that in LBS. The following experiments were therefore performed 
in LBS.  
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4.2.2. Influence of the substrate concentration  
Uptake of molecules from the culture medium by the cells can vary a lot from one compound to 
another. Hence, before hoping to see pigmentation with 68, it was important to determine what 
concentration was best with its aldehyde analogue 20, which is known to be accepted as a 
substrate of PigE. The importance of this test was reinforced by the weakness of pigmentation 
obtained during agar qualitative complementation experiments (see Figure 4.16). 
Pigment extracts were prepared from cultures of S39006 ΔpigD supplemented with different 
concentrations of 20 (Figure 4.18). For these experiments, the aldehyde was added to the 
culture at the same time as the inoculation with bacteria. 
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Figure 4.18: Effect of 20 concentration on growth (right) and pigment production (left) of S39006 
ΔpigD 
No effect was visible for concentrations lower than 100 µM. Yet, even at this concentration, both 
the total pigmentation and the quantity of pigment per cell remained relatively low. The real 
threshold was at 1 mM: at this concentration the pigmentation per cell was 10 times higher. 
However, the total pigmentation remained quite low. At 10 mM, both quantities were higher. It 
is important to make the distinction between these two quantities as the overall pigmentation 
needs to be high enough for good detection, whereas the pigmentation per cell indicated if the 
concentration was high enough for prodigiosin to be produced. In conclusion, both need to be 
high for a successful complementation assay. Figure 4.18 (right) shows the final OD600 obtained 
with the different concentrations of 20. The threshold observed for prodigiosin production was 
also visible here: from 1 mM the final OD600 was 10 times lower than in normal circumstances. 
This could be due to toxicity induced by the aldehyde 20.  
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4.2.3. Influence of the OD600 at the time of inoculation 
As 20 seemed to prevent the growth of S39006 at concentrations of interest, a “pre-culture” 
approach was investigated. The growth curve (see chapter 3, Figure 3.12) indicated that once 
OD600 was around 4, the quantity of prodigiosin that can be expected was enough for satisfactory 
detection. LBS was inoculated with S39006 ΔpigD and cultured until OD600 was around 4. Then 
1 mM of 20 was added and the cells were cultured a further 16 h. Controls without 20 or where 
20 was added at the same time as the bacteria were also prepared. OD600 and pigmentation were 
measured in all three cases (Figure 4.19). 
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Figure 4.19: Effects of a preculture on pigment production (left) and growth (right) of S39006 
ΔpigD complemented by 20 
The quantity of pigment per cell was the same in both samples inoculated with 20, which meant 
that the uptake of the substrate was barely affected by the OD600. However, the final OD600 of 
the culture treated with 20 later was similar to a culture without 20 and much higher than the 
one treated with 20 at the same time as inoculation. Hence, pre-growing the cells until an OD600 
of around 4 is reached is a way to overcome toxicity issues and for pigmentation to be easily 
detectable. These conditions were chosen for further experiments with the other substrates. 
4.3. Complementation assays with thioester 68 
4.3.1. Recovery of pigmentation 
Following the procedure described above, extracts were prepared from S39006 ΔpigD 
supplemented with aldehyde 20, thioester 68 and carboxylic acid 69 (Figure 4.20). 
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Figure 4.20: Complementation assays a) Pigment extracts, WT: S39006, ΔpigD: S39006 ΔpigD 
(negative control) unsupplemented, the number indicates which substrate were added, b) Pigmentation 
per cell 
As illustrated in Figure 4.20a, both 20 and 68 triggered pigmentation, whereas both 
unsupplemented cultures and the ones supplemented with carboxylic acid 69 remained 
colourless. The absorbance at 535 nm confirmed this observation, with a quantity 3 times as high 
with bacteria fed with 68 than with the negative control or the carboxylic acid (Figure 4.20b). 
Yet, the results remained much lower than with the aldehyde. This might be due to a poorer 
uptake of the thioester or due to partial degradation of the thioester or because the NAC 
thioester is a poor mimic of the natural thioester. The absence of pigmentation in the case of the 
carboxylic acid proved that the thioester itself, rather than its hydrolysis product, was 
responsible for the pigmentation.  
The results obtained with the negative control illustrated once again the capacity of S39006 to 
produce compounds other than prodigiosin absorbing at 535 nm. As a result, it was necessary to 
prove that the pigment obtained by feeding with 68 was indeed prodigiosin 
4.3.2. Time-course of pigment production 
As in Chapter 3, pigment production was monitored after addition of 20 or 68 into 10 ml cultures 
of S39006 ΔpigD (Figure 4.21). Pigment was visible in S39006 ΔpigD fed with 20 after 2 hr, 
whereas pigment started to appear with the thioester only 12 h after the inoculation and the end 
level was much lower. 
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Figure 4.21: Kinetics of pigment production after complementation with 20 and 68. 
This could be linked to a lesser capacity of the thioester to get into the cell or a lesser availability 
of the enzymatic domain responsible for its reduction. 
4.3.3. Analysis of the pigment  
Unfortunately, extracts of S39006 ΔpigD complemented with 68 were too dilute to detect 
prodigiosin by MS.  
4.3.3.1. UV spectrometry 
UV spectra of ethanolic extracts from S39006, S39006 ΔpigD and S39006 ΔpigD complemented 
with 68 were recorded (Figure 4.22). Because the absorbance was too high, the extracts from 
S39006 were diluted 100 times. Extracts from S39006 ΔpigD complemented with 68 presented 
a peak at the same wavelength as the one from the wild type (WT). This peak was absent from 
extracts of unsupplemented S39006 ΔpigD and is consistent with prodigiosin. 
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Figure 4.22: UV spectra of pigments extracts 
4.3.3.2. HPLC 
The pigment is known for its bright colour, and the UV/visible spectra above shows this method 
is viable to detect it. HPLC instruments usually have UV-Vis detectors, so comparing the HPLC 
traces at 500 and 535 nm of an extract from S39006 and one from a complementation assay 
would indicate if prodigiosin was present in the extract or not. 
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Using the conditions described by Eckeman et al. for the purification of  pigment from Sma on 
extracts from S39006 led to two peaks (Figure 4.26).187 This could be explained either by a 
difference of retention time between prodigiosin’s rotamers or the presence of two prodiginines. 
To discriminate between these two possibilities each peak was collected, concentrated and 
analysed by HPLC using the same solvent gradient (Figure 4.27a). 
 
Figure 4.23: HPLC traces of S39006 extracts a) detection at 500 nm, b) detection at 5353 nm 
Each peak gave a single peak when re-run on the HPLC (Figure 4.23a), which meant they were 
not rotamers but two distinct prodiginines. MS analysis (Figure 4.23b) showed that the first 
fraction contained a molecule with mass of 310.19, consistent with norprodigiosin 16+H+ (see 
Chapter 1) while the second fraction had one of mass 324.21, consistent with prodigiosin 1a+H+. 
 
Figure 4.24: Analysis of the prodigiosin extract a) HPLC trace of the two peaks (top, peak at 17.3 min, 
bottom, peak at 21.3 min, detection at 535 nm); b) MS analysis, top left: crude extract, top right, peak at 
17.3, bottom, peak at 21.3) 
Pigment extracts from S39006 ΔpigB supplemented with 68 were concentrated to dryness and 
re-dissolved in H2O/ACN before being analysed on the HPLC using the method developed above 
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(Figure 4.25). The two peaks corresponding to the prodigiosin and norprodigiosin were present. 
This meant that MAP production was restored by the addition of 68, which proves that S39006 
can reduce the thioester and incorporate it into prodigiosin biosynthesis. 
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Figure 4.25: Superposition of HPLC traces of prodigiosin extracts from S39006 (black) and S39006 
ΔpigB supplemented by 68 (red). 
4.4. Investigation in the role of PigE in the thioester reduction 
According to bioinformatics analyse (see Section 2), and previous work, PigE N-terminal domain 
(PigE-N) should be responsible for the reduction of thioester 68 whereas the C-terminal domain 
(PigE-C) catalyses the transamination of the resulting aldehyde 20 with ornithine. To 
demonstrate the role of the N-terminal domain, a strain expressing only PigE-C was constructed. 
Such a strain should be able to recover pigmentation when complemented with 20 but not with 
68. 
4.4.1. Construction of a pQE80L::oriT pigE-C (pPigE-C) plasmid 
pigE-C (from Met405 to Asp853) was amplified using primers MC01 and MC02 by PCR (see 
experimental). pBluescript (pBS) (see appendix) contains a multiple cloning site between lacZ 
and its promoter, thus preventing the expression of lacZ when a sequence with a stop codon is 
inserted. LacZ, which catalyses the hydrolysis of X-gal, producing a blue pigment, is not normally 
expressed by E. coli DH5. This makes the visualisation of successful insertion easier. PigE-C 
amplicons were cloned into pBS using SacI and PstI as restriction enzymes (see experimental) 
and E. coli DH5 was transformed with the ligation mixture, leading to plasmid pBS-PigE-C. 
Five white colonies were obtained, and in all cases analysis of their plasmids was consistent with 
the desired construct: the double digested products showed two bands whose size corresponded 
to the insert (1.4 kb) and the vector (3 kb), while mono-digested product showed a single band 
whose size was consistent with the size of the vector and the insert ligated together. The 
sequence of the insert was confirmed by sequencing using primers oBS-F and oBS-R.  
The construction of that intermediate plasmid was useful for the next steps, as it allowed us to 
be sure that the inserts were digested for the following ligations. This was used to clone pigE-C 
into pQE80L::oriT to give pPigE-C, a plasmid coding for PigE-C with a N-terminal His6 tag which 
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was then used to transform E. coli DH5, leading to 14 colonies. Analysis of their plasmids 
showed that only one was consistent with pPigE-C, which was confirmed by sequencing using 
primers oQE-F and oQE-R.  
4.4.2. Preparation of strain S39006 ΔpigE pPigE-C 
Transformation of S39006 and its mutants is challenging. Attempts to transfer plasmid either 
by electroporation or chemical transformation were unsuccessful. However, S39006 has been 
shown to incorporate plasmids readily by conjugation,188 i.e. direct transfer of DNA from one 
bacterium to another. pPigEC was used to transform E. coli 2163 (noted 2163) leading to the 
formation of strain 2163 pPigE-C.  is diaminopimelic acid (DAPA)-dependent, which 
drives the selection after the conjugation. Cultures of S39006 ΔpigE and 2163 pPigE-C were 
mixed in a LB+DAPA broth and, after an overnight culture, plated on LBA supplemented with 
ampicillin but without DAPA (see experimental). Sixteen colonies hence obtained were replated 
on LB with ampicillin and cultured overnight. Their plasmids were then extracted, and digestion 
and sequencing analysis showed they were all consistent with the desired pPigE-C. 
 Verification of S39006 ΔpigE pPigE-C 
S39006 ΔpigE was constructed to have a deletion of nucleotides 9 to 2553 in pigE (pigE is 2561 
bp long).26 Primers MC04 and MC05 were designed to match the sequence 250 bp before and 
after the deletion. One colony each of S39006, S39006 ΔpigE and newly formed S39006 ΔpigE 
pPigE-C were analysed by colony PCR using these primers (see experimental) (Figure 4.26). 
 
Figure 4.26: Agarose gel of the colony PCR of S39006 ΔpigE pPigE-C (A), S39006 ΔpigE (B)  and 
S39006 (C)  using MC04 and MC05 as primers. Ladder from Henrici et al.189 
As expected, the two ΔpigE strains showed a strong band at 500 bp whereas the S39006 strain 
showed an amplicon around 3 kb. A faint band around 3 kb was also observed in S39006 ΔpigE 
pPigE-C, but sequencing was inconclusive, meaning this was probably just non-specific 
amplification. Sequencing of the 500 bp band, on the other hand, was consistent with the 
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sequence on each side of the deletion. This experiment confirmed that the strain is indeed 
unable to produce full length PigE. 
Conditions for efficient protein expression were then investigated: S39006 ΔpigE pPigE-C was 
cultured in LBS at 30°C and was inoculated with different concentrations of IPTG when OD600 
reached 2. Aliquots were taken before the induction and at the end of the experiment and cell 
concentrations were equalised before lysing the cells by boiling. The proteins contained in the 
cell lysates were separated by SDS-PAGE before being analysed by Western blot using a mouse 
anti His6 primary antibody (Figure 4.27). 
 
Figure 4.27:Western blot of lysates of S39006 ΔpigE pPigE-C induced with different 
concentrations of IPTG (concentrations shown in M) C: S39006 ΔpigE lysate 
Bands could be observed in the Western blot at sizes consistent with PigE-C. It is to be noted 
that nothing was visible before the induction (data not shown) or at IPTG concentrations lower 
than 100 µM. The solubility of the protein was also assessed:  S39006 ΔpigE pPigE-C was 
cultured at 30°C in LBS to OD600 = 1 and 1 mM or 100 µM of IPTG was added. For each 
concentration, one sample was then cultured at 16 °C whereas the other remained at 30°C. E. 
coli BL21 pPigE-C and, as negative control, S39006 ΔpigE were also cultured, with the 
appropriate IPTG induction. After 16 h cell lysates were prepared. Soluble and insoluble fractions 
were separated by centrifugation and the insoluble fraction was resuspended in 1 ml of water. 
Two SDS-PAGE gels of the different fractions were run, and one was used for Western blot 
whereas the other was directly stained with Coomassie blue (Figure 4.28). 
 
Figure 4.28: SDS-PAGE analysis of PigE-C a) Coomassie staining, b) Western blot 
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It appeared that PigE-C was mainly in the insoluble fraction, meaning that isolation and 
purification would be difficult. Hence, it was decided to use the strains primarily for in vivo 
testing. Furthermore, the intensities of the bands were similar with all four conditions tried with 
S39006 ΔpigE pPigE-C, meaning that the temperature of incubation had little importance. This 
will allow the chemical complementation experiments to be conducted as before. Interestingly, 
the bands were stronger than when the IPTG was added after OD600 had reached 2, suggesting 
these conditions were more suitable for protein expression. The bands obtained with BL21 were 
weak, but this might be because the OD600 was too high when IPTG was added. This also showed 
that the formation of insoluble aggregates was not simply due to the high concentration in 
S39006, as no band was visible in the E. coli soluble fraction despite the lower concentration. 
In conclusion, the strain that was constructed cannot express full length PigE but, when induced 
with IPTG, can produce the PigE C-terminal domain, although in insoluble form. 
4.4.4. Complementation assay with S39006 ΔpigE pPigE-C 
Qualitative agar assays were conducted with ΔpigE and ΔpigE pPigE-C and 20 and 68 as 
substrate (Figure 4.29). 
 
Figure 4.29: Complementation of S39006 ΔpigE (a) and S39006 ΔpigE pPigE-C (b) with 20 and 68 
Thioester 68 seems unable to trigger pigmentation in either ΔpigE or ΔpigE pPigE-C strains. 
Strangely, aldehyde 20 seemed to be accepted by both S39006 ΔpigE pPigE-C and S39006 ΔpigE 
despite the absence of the transaminase. 
To get quantitative results, prodigiosin extracts were prepared from LBS cultures of the strains 
mentioned above as well as S39006 ΔpigD, inoculated with 1 mM of 20 and 68 (Figure 4.30). 
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Figure 4.30: Pigmentation of different S39006 strains supplemented with 20 or 68 a) Results with 
20 and 68, a picture of the well is given on top of the bar, b) Focus on the results with 68 
The results were congruent with the qualitative assays: as expected pigmentation was observed 
with both substrates in the case of S39006 ΔpigD. On the other hand, 68 did not trigger any 
pigmentation with strains not expressing pigE. Finally, 20 restored pigmentation to the same 
low level in S39006 ΔpigE and S39006 ΔpigE pPigE-C. It is likely that a non-specific 
transaminase was responsible for the formation of H2MAP in both strains. Alternatively, the 
aldehyde might have been transformed into MAP by action of the ammonia generated during 
bacterial growth.190 Unfortunately, this phenomenon hides any potential activity of PigE-C. This 
preliminary experiment had been run without IPTG as pQE vectors are known to be leaky and 
at least low levels of PigE-C expression were expected. S39006 ΔpigE pPigE-Cwas fed with 20 in 
presence of different concentrations of IPTG (Figure 4.31). No significant difference in 
prodigiosin production was observed, meaning that, even if it expressed, PigE-C was either 
inactive or at least not as active as the non-specific transaminase. 
 
Figure 4.31: Influence of IPTG on pigment production in S39006 ΔpigE pPigE-C 
Conclusion: a non-specific transaminase hides any potential effect of PigE-C and it is hence 
impossible to conclude about the transaminase activity of that protein. Thioester 68 did not lead 
to the recovery of pigmentation with S39006 ΔpigE in any of the attempts, but it did with 
S39006 ΔpigD, suggesting that PigE was necessary for the reduction of that thioester. 
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5. In vitro characterisation of pigE 
In vivo experiments suggested that PigE was a bifunctional protein, responsible for both the 
reduction of a thioester and the subsequent transamination of the resulting aldehyde. Yet, those 
experiments have limitations, for instance it is impossible to use them to determine the cofactor 
involved in the thioester reductase activity with this method. Two approaches were followed to 
overcome these challenges: isolation and purification of PigE and the use of cell-lysates. Cell 
lysates are relatively complex mixtures and the quantity of protein of interest cannot be 
accurately assessed in those conditions. However, proteins in cell lysates are more likely to be 
active as they undergo less steps between the lysis and the assay. In addition, the activity of 
transmembrane proteins can be tested in cell lysates. Cell-lysates also give the possibility to 
perform coupled assays, using several proteins which would have been difficult to isolate 
together. Using pure proteins, on the other hand, gives a perfect knowledge of the reaction 
mixture, including the concentration of the protein, which is necessary for kinetic studies. 
5.1. Construction of BL21 pPigE and expression of the protein 
A similar approach to the construction of plasmid pPigE-C was followed: pigE was first amplified 
by PCR from S39006 gDNA using primers MC01 and MC03. After cloning into pBS and using 
the resulting vector to transform E. coli DH5, white colonies had their plasmid extracted and 
digested (Figure 4.32). 
 
Figure 4.32: Agarose gel of digested plasmids from some white colonies M: miniprep, D: double 
digest, S: digestion with SacI, P: digestion with PstI 
It appeared that a number of colonies were false positive. Yet, some colonies gave results 
consistent with the desired plasmid: the monodigested samples (S and P in Figure 4.32) were 
bigger than the double digested one and all digested plasmids were different from the miniprep, 
proving that the restriction enzymes were active. Only one band was visible with the double 
digest but pBS is 3 kb long whereas pigE is 2.5 kb long, so the two bands were supposed to come 
close to each other and it is likely that, in the settings for this particular gel, they actually 
superposed. This plasmid was sent for sequencing and the results were consistent with a pigE 
insert, confirming the formation of plasmid pBS-PigE 
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pBS-PigE was digested by SacI-HF and PstI-HF along with pQE80L::oriT, and the digested 
products were run on an agarose gel until a clear separation of the pBS and pigE bands was 
observed. The relevant bands were extracted and used for ligation. After transformation, 
plasmids were extracted from colonies resistant to ampicillin and plasmids consistent with 
pPigE were sent for sequencing with primers specific for pQE (oQE-F and oQE-R) and pigE 
(MC01 and MC03), which confirmed they had a pQE vector with a pigE insert. This plasmid was 
then used to transformed E. coli BL21. 
5.2. Protein expression and purification 
Preliminary experiments to determine expression conditions were conducted. On the one hand, 
BL21 cells were grown in LB until OD600 = 1 and 10 mM of IPTG was added before growing the 
cells for a further 1 h at 37 °C. On the other hand, IPTG was added at OD600 = 0.8 and the cells 
were grown a further 16 h at 16 °C. Aliquots were taken before the addition of IPTG and at the 
end of the experiment. Quantities of cell were normalised, and the samples boiled to lyse the 
cells. They were analysed on an SDS-PAGE gel (Figure 4.33). Bands at a size corresponding to 
PigE (95 kDa) could clearly be seen in the second set of conditions and not in the first.  
 
Figure 4.33: SDS-PAGE of cell lysates obtained with different protein production conditions a) 
Incubation for 1 h, b) incubation 16 h; the gels are Coomassie stained 
pPigE codes for the expression of PigE with an N-terminal His6-tag, it can therefore be purified 
by affinity column with a Ni-NTA resin. PigE was hence isolated from one litre of culture. The 
proteins in the different fractions were analysed by SDS-PAGE (Figure 4.34). Figure 4.34a 
confirmed that the protein expression was successful. It also indicated that PigE seemed to partly 
be in the insoluble fraction, either because of the formation of aggregates, the presence of a 
transmembrane domains or simply because of a poor cell lysis. Yet, the soluble fraction showed 
a band in the proper region and some elution fractions also showed a band at the proper size, 
indicating that some of PigE still goes into the soluble fraction and could be purified. Excess 
imidazole was then removed by dialysis. 
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Figure 4.34: SDS-PAGE of fractions from purification of PigE by affinity column a) L: Molecular 
weight markers, UI: uninduced sample, I induced sample, IF: insoluble fraction, SF: soluble fraction, LW: 
Lysis wash, LF: lysis flow through, WF: wash flow through, b) elution fractions 
Bio-Rad DC protein assay showed that 0.4 mg of protein had been isolated. A UV spectrum was 
also recorded (Figure 4.35). The characteristic absorbance peak of proteins (280 nm) was 
present; but no peak was visible between 300 and 800 nm.  
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Figure 4.35: UV spectra of PigE purified without PLP in the buffers 
As PigE is a PLP-dependent transaminase, it should absorb at 410 nm because of the Schiff’s base 
it forms with its cofactor (see Section 1). It seemed that PLP was not incorporated in this batch. 
To circumvent this problem, 0.05% pyridoxine HCl was added to culture media and 1 mM of 
PLP was added to all purification buffers. PigE was purified under those conditions and its 
UV/Visible spectrum was measured after a dialysis removed the excess pyridoxine (Figure 4.36): 
it indicated the presence of PLP. 
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Figure 4.36: UV spectra of PigE (1 mg/ml) purified with additional PLP in the buffers 
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Yet, only 1 mg of protein was obtained from 1 L of culture, so other conditions were explored to 
improve the yield: different concentrations of IPTG were tested, as well as the addition of 1% 
Triton X100 in the lysis buffer. As illustrated in Figure 4.37, no obvious differences could be 
seen between the soluble fractions arising from these conditions.  
 
Figure 4.37: SDS PAGE of soluble fraction obtained with different PigE production conditions  A: 
pQE80L, [IPTG]= 1 mM (negative control), B: pPigE [IPTG]=1 mM, C pPigE [IPTG]= 0.1 mM, D: pPigE, 
[IPTG]= 1 mM, 1% Triton X100 
Triton X100 is supposed to affect mainly the efficiency of the lysis and the solubility of proteins, 
which should result in an increase of concentration of the soluble fraction, confirmed by DC 
assay. Unfortunately, when purification was carried all the way in those conditions, two bands 
at 35 kDa and 70 kDa appeared, suggesting a degradation of the protein. To investigate this 
phenomenon, two samples were lysed, one with Triton X100 (T+) in the buffer and the other 
without (T-). Furthermore, 2 tablets of protease inhibitor were added to T+. Analysis of the 
elution fraction after the Ni-NTA column on SDS-PAGE (Figure 4.38) showed that, in both 
cases, these extra bands were present, but their intensity compared to the band of interest was 
very low.  
 
Figure 4.38: Elution fraction when Triton X was used for lysis a) T-, b) T+ 
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Furthermore, a Western blot showed that only the band corresponding to PigE had the His6 tag. 
Purification of PigE with addition of Triton X100 in the lysis buffer and proteases inhibitor tablet 
in the elution buffer worked, but the improvement in the total quantity of protein obtained was 
marginal. To get more protein, the purification process was scaled up four-fold. The amount of 
resin had to be increased accordingly: as more protein was loaded on the Ni-NTA column with 
this approach, some unspecific binding occurred and the resin could saturate, leading to the loss 
of some PigE when the soluble fraction was flowed through the column. Using a gradient during 
the elution was a way to tackle unspecific binding: by increasing the concentration of imidazole 
progressively, most of the impurities were washed off before the desired protein, justifying the 
use of mixtures of wash buffer/elution buffer. Using this method, 14 mg of PigE was isolated. 
The yield was similar to the previous smaller scale culture, but the total quantity of protein 
obtained was enough for downstream applications. 
5.3. Protein characterisation 
5.3.1. Circular dichroism191–193 
Circular dichroism (CD) measures the difference in absorbance of the two directions of 
circularity of circularly polarised light. In proteins, secondary structures such as  helixes and  
sheets have signature CD profiles in the far UV. Hence recording such a spectrum allows the 
proportion of the different secondary structures in the overall folding to be estimated and 
indicates if the proteins are correctly folded.  
CD spectra of a fresh batch of PigE and an older one were recorded.  This confirmed the 
impression given by SDS-PAGE gels, that PigE was not stable enough to be kept any extended 
period of time, even at 0°C. The results were much better with the fresh batch (Figure 4.39). 
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Figure 4.39: PigE CD spectra 
This proved that the purification process does give a folded protein. Further analysis using 
Dichroweb website gave the following results (Table 4.2):  
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Algorithm Set Helix 1 Helix 2 Strand 1 Strand 2 Turns Unordered 
Selcon 3194 4 0.607 0.211 -0.017 -0.002 0.097 0.125 
Contin195 4 0.549 0.156 0.009 0.009 0.075 0.202 
Table 4.2: Fitting of PigE CD spectra 
Fitting with the Contin algorithm match the data best, but the values were in the same range 
with the two algorithms. The values extracted from the CD spectra did not match PHYRE 
predictions (see section 2) exactly, but were relatively close, and both PHYRE predictions and 
curve fitting results present some uncertainty. The high percentage of -helixes is noteworthy 
as it is consistent with a folded protein. 
5.3.2. Thermal shift assay 
This assay monitors the stability of a protein as a function of temperature. A fluorescent dye, 
here SYPRO orange, binds to the hydrophobic regions of the protein. When the protein starts 
to unfold because of temperature elevation, more hydrophobic regions become exposed, leading 
to an increase of fluorescence. As the temperature continues to increase, vesicles start to form, 
decreasing the exposed surface of the protein and the fluorescence decreases. The inflexion point 
in the increase of the fluorescence (or the maximum of the derivative curve) corresponds to the 
melting temperature (Tm) of the protein. The presence of ligand often increases the stability of 
a protein, leading to an increase of Tm. Thermal shift is hence a quick way to characterise the 
stability of a protein and to screen for potential ligands. 
PigE was subjected to this assay (see experimental) against a range of potential substrates:  68, 
NADH, NADPH and a number of amino acids (Figure 4.40).  
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Figure 4.40: Examples of the derivative of the thermal shift curves obtained with PigE.  The 
substrates represented here are the one which were most likely to bind 
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The profile of the curve obtained was unusual: most proteins have their Tm around 40-50°C, 
whereas here a Tm around 71.25 °C was obtained. An inflexion at 47 °C was visible, which would 
be more consistent with a protein Tm, but its intensity was much lower than the one at 71.25 °C. 
Another unusual aspect was that the fluorescence decreased before the increase leading to the 
melting point. These observations might have been the result of different phenomena: for 
instance, PigE is rather unstable and even though the quality of the sample was checked shortly 
before the assay, degradation cannot be excluded. It is also possible the two domains of PigE 
have different melting points, the first one unfolding at 47 °C, leading to the formation of vesicles 
which explains the decrease in fluorescence until the second very stable domain unfolds at 71 
°C. 
Compound 
Control 
DMSO 
Control 
buffer 
68 NADH Ala Asn Cys Glu Gln Gly Ser 
DTm 47°C 0 -0.25 -0.50 -0.25 -0.75 0.25 -0.5 -1.5 -0.5 0 -1 
DTm 71.25°C 0 -0.5 0 -0.5 -1.25 -0.5 -1.25 -1.75 -1.38 -0.88 -1.25 
 
Compound Tyr His Orn Ile Lys Phe Thr Val NADPH 
DTm 47°C -0.25 -1.25 -2.5 -1.5 NA -1.75 -0.75 -0.5 0.5 
DTm 71.25°C -1.25 -2 -1.88 -0.88 -0.88 -1.75 -1.75 -1 -0.75 
Table 4.3: Thermal shifts 
No significant thermal shifts at 47 °C or at 71 °C were observed with the added ligands (Table 
4.3) and none of them led to an increase of Tm. The thioester reductase activity necessitates 
binding of either NADH or NADPH whereas the transaminase domain requires the presence of 
an amino acid, ornithine according to previous studies. This casts some doubt on the validity of 
this assay. 
5.3.3. NAD(P)H monitoring 
NAD(P)H absorbs at 340 nm whereas its oxidised counterpart 
does not (Figure 4.41).196 Monitoring the absorbance of a 
mixture hence allow one to follow the quantity of reduced and 
oxidised cofactor. Interestingly, NAD(P)H present the same 
profile in TRIS, KPi, citric acid and HEPES buffers. 
Stock solutions of NADH and NADPH at 2 mM in 0.02 M 
aqueous NaOH were prepared following Sigma’s 
recommendations. These solutions were supposed to maximise 
the stability of the reduced cofactor. After checking that NAD(P)H was still in its reduced form, 
Figure 4.41: UV absorbance 
spectra of NAD+ and NADH196 
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the different components - including at least the thioester substrate 68, NAD(P)H and ornithine 
( see experimental)- were mixed and the absorbance at 340 nm was monitored (Figure 4.42).  
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Figure 4.42: Evolution of A340 Black: NADH, Red NADPH, plain: control, dotted: Complete mixture, 
[PigE] = 1 µM.  
Two different concentrations of enzyme were tried (1 µM and 10 µM), but the evolution of the 
absorbance did not seem to be different from the control with cofactor only in any of the cases. 
NAD(P)H monitoring experiments were carried with and without metal ions in the mixture, but 
no difference could be observed. Even though the concentrations of protein were relatively low, 
they were in the same range as some literature examples.40 Hence it appeared that no thioester 
reductase activity could be observed under these conditions. Similar results were obtained when 
the experiment was performed in other buffers (KPi, citric acid and HEPES). 
This set of experiments was disappointing: either NAD(P)H was not the cofactor involved in the 
thioester reduction, or PigE was simply inactive under the conditions chosen for the experiment.  
It is also possible that the kinetics of PigE were slower than NAD(P)H atmospheric oxidation 
either because the concentrations were too low or because the N-acetylcysteamine thioester 68 
was a poor mimic of the natural substrate. It is also possible that PigE forms a complex with 
some other protein(s) or ligand(s) that are removed in the purification process and hence it loses 
its activity. Finally, it was mentioned that PigE was visible in the insoluble fraction and it is 
possible that it needs to be inserted in a membrane to be active.   
5.4. Cell extracts assays 
By choosing carefully the strain used to prepare a cell extract, a wide variety of assays can be 
performed. For instance, PigE activity can be assessed indirectly, by monitoring the activity of 
enzymes further down the line in prodigiosin synthesis. PigE thioester reductase activity could 
also be monitored using the NAD(P)H technique described above. 
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5.4.1. Coupled assays 
5.4.1.1. Following MAP production 
 
Figure 4.43: Method to follow MAP formation using Ehrlich's assay 
In Chapter 2, we described a way to quantify the formation of MAP (or an analogue) by reacting 
it with the Erlich’s reagent (p-N,N-dimethylbenzaldehyde 57), leading to the formation of a red 
compound 58 with  a maximum absorbance at 555 nm. This allowed to measure the activity of 
HapB in presence of different analogues of H2MAP. As illustrated in Figure 4.43, the aim here 
is to use MAP as an indirect indicator of PigE activity. The cell extracts contained both PigE and 
PigB, hence it was hypothesised that, in those conditions, the product of PigE could be accepted 
by PigB and transformed into MAP. 
To make sure that no substrate of PigE would be present in the lysate, the extracts were prepared 
from S39006 ΔpigD. The procedure to prepare the lysates was very similar to protein 
purification, but without the purification step (see experimental). 
The activity of PigB in the soluble fraction was checked before going forward with the coupled 
assay. The extract was diluted in MES buffer and H2MAP was added (1 mM) before incubating 
for 10 min. The reactions were then stopped, and Ehrlich’s reagent was added. UV/Vis spectra 
of the samples were recorded, leading to Figure 4.47. 
400 500 600 700 800
0.00
0.05
0.10
0.15
0.20
Wavelength (nm)
A
 (
A
U
) 1 mM
Negative control
 
Figure 4.44: UV/Vis spectra of cell extract reacted with H2MAP and Ehrlich’s reagent 
After 10 min, it appeared that when the extracts and H2MAP were incubated together, the 
mixtures turned pink after the addition of Ehrlich’s reagent, whereas, in the control without 
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protein the sample remained colourless. However, the increase of absorbance remained low. 
Nevertheless, this shows that, despite it being mainly insoluble, PigB activity could be observed 
in this sample. 
As complementation assays were consistent with PigE transaminase activity, the coupled assay 
was tested by incubating the extract with a mixture of 20, ornithine and PLP before performing 
Ehrlich’s assay (Figure 4.45).  
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Figure 4.45: Two replicates of coupled assays using Ehrlich's reagent 
The results obtained were extremely variable. In particular, the UV/Vis spectra often showed 
two peaks at 530 and 570 nm. Ornithine can react directly with 20 without enzyme catalysis, 
leading to the formation of amine 81 (Figure 4.46). Then, in presence of strong acid such as 
perchloric acid, 81 can be converted into pyrrole 82, which would react with Ehrlich’s reagent. 
This might be the cause for the second peak that was observed during the coupled assay. This 
side reaction, combined with the observed lack of repeatability of the test, made this assay a 
poor solution to study PigE. 
 
Figure 4.46: Ornithine can lead to a false positive with the Ehrlich's reagent 
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5.4.1.2. Following prodigiosin production 
Cell extracts have been used to study PigC by measuring the production of prodigiosin.137 
Furthermore, cofactors needed by PigE, PigB or PigC have a strong absorbance in the near UV 
but almost none at 535 nm, making the monitoring of even very a small quantity of pigment 
possible. Another advantage of this approach was the very low risk of false positive as it relies 
on a direct measurement of prodigiosin. 
The method to prepare the cell lysate was slightly different from the one described above. 
Protein production was induced for 16 h in S39006 ΔpigE pPigE and S39006 ΔpigE before 
freezing the cell pellets until the assay. The pellets were then thawed and resuspended in a 
phosphate buffer before lysis (see experimental). Because of the opacity of the suspension hence 
obtained, only the soluble fraction was used. A 96-well plate was charged with the soluble 
fraction, thioester 68, ornithine, PLP, MBC, ATP and FAD (see experimental). A535 was 
monitored for 200 min (Figure 4.47).  
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Figure 4.47: Monitoring of prodigiosin formation Plain extract from S39006 ΔpigE, Dotted: extracts 
from S39006 ΔpigE pPigE 
The curves shown in Figure 4.47 were smoothed as the noise was substantial, making the results 
unreliable. The plate was kept overnight at room temperature and a deposit was present in some 
wells: supernatant was pipetted out and the deposit resuspended in acidified EtOH to be 
compared with prodigiosin, but none of them showed a peak at 535 nm.  
It is possible that this assay failed because some of the enzymes involved in the process are 
transmembrane proteins and were not in the soluble fraction or were in an inactive form. Hence, 
microcentrifuge tubes were charged with cell lysates containing both the cell debris and the 
soluble fractions as well as the substrates and cofactors listed above and incubated overnight at 
30 °C. The mixtures were then centrifuged and the pellets extracted with EtOH. The 
supernatants were discarded because they were visibly not red and prodigiosin has a very low 
solubility in water. The UV/Vis spectra of the ethanolic extract obtained from the cell pellets 
were recorded, but once again no peak at 535 nm could be observed. 
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It seems prodigiosin could not be produced in these conditions. This might result from an 
inappropriate ratio of protein/cofactor, too low a concentration of the necessary proteins, or 
simply one of the three enzymes required to transform 68 into prodigiosin was inactive in the 
assay conditions. 
5.4.2. Ninhydrin assay 
 
Figure 4.48: Principle of the ninhydrin assay. 
Ninhydrin is a common indicator for amines because when they react a purple product is 
formed. In addition, the transaminase activity of PigE is supposed to generate enamine 85, which 
has a nitrogen susceptible to react with ninhydrin. Hence, as illustrated in Figure 4.48, this 
assay relies on the formation of a coloured product 83 when ninhydrin 84 reacts with the by-
product of PigE transamination.197 To check that side-reactions would not lead to product also 
absorbing at 510 nm, PigE’s product H2MAP and ornithine were submitted to the assay (see 
experimental) (Figure 4.49). 
300 350 400 450 500 550 600
0.0
0.1
0.2
0.3
0.4
Wavelength (nm)
A
 (
A
U
)
ornithine
H2MAP
 
Figure 4.49: UV spectra of the reaction mixture of ornithine and H2MAP with ninhydrin 
In both cases, the absorbance at 510 nm remained low. Interestingly a small increase at that 
wavelength was visible with ornithine. Perchloric acid was present in the reaction mixture as it 
was to be used to stop the enzymatic reaction. This might have led to the oxidation of ornithine 
into 85, which could then react with ninhydrin. However, this effect remained low. 
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The assay was then conducted on lysates of S39006 ΔpigB and S39006 ΔpigD incubated with 
20, PLP and ornithine. A control without 20 was also performed (Figure 4.50). 
DpigB DpigD control
0.0
0.1
0.2
0.3
0.4
A
5
1
0
(A
U
)
 
Figure 4.50: Results on the ninhydrin assay on different cell extracts 
Unfortunately, the results obtained with both extracts were close to the control, probably 
because of the reaction between ornithine and perchloric acid mentioned above.  
As a conclusion, this assay lacked reliability and could not be used to study the thioester 
reductase activity of PigE. No further optimisation was attempted and assays giving insights in 
both activities of PigE were investigated. 
5.4.3. NAD(P)H monitoring 
Two different conditions were investigated for monitoring NAD(P)H disappearance with cell 
extracts from S39006. The cells extracts were both lysates but in one they were in lysis buffer 
(A) and in the other they were in phosphate buffer (B). Furthermore, with A the samples were 
diluted in a Tris buffer and the mixture was supplemented with metal ions, whereas in B no 
additional buffer nor metal ions were used and some PLP was added (see experimental).  
In both conditions the concentrations of the different mixture components were in a similar 
range. In conditions B, PLP concentration was chosen to be 0.125 mM because any higher 
concentration led to a significant increase in absorbance at 340 nm and prevented any 
monitoring at that wavelength. Cell debris were removed from the mixtures for a similar reason. 
In both cases the absorbance at 340 nm was recorded at 30°C (Figure 4.51). Conditions B were 
tried not only on S39006 and S39006 ΔpigE but also with S39006 ΔpigE pPigE. 
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Figure 4.51: NAD(P)H monitoring with S39006 extracts a) conditions A; b) conditions B; Black NADH, 
Red: NADPH, Blue: no cofactor, Plain: S39006 ΔpigE, Dashed: S39006, Dotted S39006 ΔpigE pPigE 
In conditions A, NADH seemed to decrease whereas NADPH did not. However, this decrease 
happened both in extracts from S39006 and S39006 ΔpigE, meaning that PigE was probably not 
responsible for that effect. The experiment was done again without adding thioester 68 and a 
similar curve was obtained (data not shown). It could hence be deduced that, in these 
conditions, another reductase uses NADH but PigE thioester reductase activity could not be 
observed.  
In conditions B, decrease of A340 can be observed in all cases, without significant variation of the 
rate. As above, this effect was present in the strains expressing PigE but also in the strain not 
expressing it, indicating that the consumption of NAD(P)H was not due to PigE. As before, 
performing the experiment without 68 gave similar results. Yet, here again, the oxidation was 
faster than if it was only caused by atmospheric oxygen, implying the involvement of another 
NAD(P)H dependent enzyme. 
It is interesting to notice that modifications of the conditions caused a major change in the shape 
of the absorbance evolution. It might be because the proteins responsible for NAD(P)H 
consumption in conditions B were not the same as in conditions A as both NADPH and NADH 
are affected. These experiments highlighted one of the main limitations of cell extracts assays: 
the lack of control on the composition of the mixtures. Here the desired phenomenon was 
observed, but it was not caused by the protein we were investigating. 
PigE was also overexpressed in E. coli BL21 and cell lysates in phosphate buffer were prepared. 
The same process was applied to BL21 without plasmid as a control and these two extracts were 
analysed by Western Blot (Figure 4.52a) and submitted to the NAD(P)H assay following 
conditions B (Figure 4.52b).  
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Figure 4.52: BL21 extracts with PigE a) Western blot of the cell extract (left lane= soluble fraction, right 
lane: insoluble fraction); b) NADPH monitoring Black NADH, Red: NADPH, Plain: BL21, Dashed: BL21 
pPigE 
The evolution of the NAD(P)H absorbance was very different here than with S39006 extracts. 
This suggested that one or more active reductases are present in the S39006 extract but not in 
the E. coli samples. Both strains behaved the same with NADH, with a fast decrease followed by 
a plateau. With NADPH, in both cases a slow decrease started after a transition period. The rate 
of decrease from t = 80 min was slightly higher in BL21 pigE than in BL21  
(1.2 × 10-3± 15 × 10-6min-1 against 0.9 × 10-3 ± 18 × 10-6min-1). This difference could suggest that 
NADPH was consumed faster in the presence of PigE but the rate remains extremely low and 
there is only a 25% difference between the two rates. In addition, the behaviour before t = 80 
min was not consistent with a continuous oxidation of NADPH. 
In conclusion, PigE contained in cell extracts did not trigger decrease in NAD(P)H over the 
course of the experiments. For opacity reasons, the experiments were conducted only with the 
soluble fraction of the lysate. Furthermore, protein purification experiments showed that the 
concentration of PigE in such extracts was low. Hence it is possible that the protein was active 
but that the rate of the reaction could not be distinguished from the O2 driven oxidation. 
5.5. LC-MS 
Following the lack of success in monitoring PigE activity by spectrophotometry and the 
difficulties encountered to develop coupled assays, a MS method was investigated. 
Cell lysates of S39006 ΔpigE, S39006 ΔpigE pPigE, E. coli BL21 and BL21 pPigE were prepared in 
a KPi buffer, and the cell debris were kept in suspension. Microcentrifuge tubes were charged 
with this mixture along with ornithine, thioester 68, NAD(P)H and PLP before being incubated 
overnight at 30 °C (see experimental). Debris were centrifuged down and the supernatant 
analysed by LC-MS (Figure 4.53). 
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Figure 4.53: Extracted ion chromatograms (154.16+288.16) from the overnight mixtures a) S39006 
ΔpigE extracts; b) S39006 ΔpigE pPigE extracts, c) BL21 extract, d) BL21 pPigE extract; Retention times 
corresponding to 19a and 68 are shown 
The extracted chromatograms at 288.16 (68+H+) and 154.16 (19a+H+) all looked the same for 
S39006 extracts (see appendix): only a small peak at 2.50 min was observed. Analysis of the ion's 
mass as well as comparison with synthetic 68 chromatogram (Figure 4.54) showed it was the 
unreacted thioester. 
 
Figure 4.54: Extracted ion chromatogram from LC-MS analysis of synthetic a) 68 (at m/z= 288.16, 
68+H+); b) 19a (at 154.16 19a+H+) 
As expected, extracts from BL21 also only showed the peak corresponding to 68. However, 
H2MAP was observed in the mixture with BL21 pPigE extracts. Interestingly, the presence of 
added cofactors to the mixture did not seem to impact the formation of H2MAP. This was 
probably due to the presence of NAD(P)H in the extracts themselves. It indicates that the 
protein was active, but it did not allow to discriminate between the two potential cofactors. 
The protein purification method described previously was adapted to isolate PigE from the 
soluble fraction and the membrane fraction of BL21 pPigE. After lysing the cells, the debris were 
submitted to ultracentrifugation where three layers were visible: the soluble fraction was 
collected and further purified by Ni-NTA affinity chromatography whereas the membrane 
fraction was resuspended in phosphate buffer and used directly. The rest of the cell debris was 
discarded. SDS-PAGE showed that the membrane fraction (MF) contained one main band at 180 
kDa, which was too high for PigE. This was unexpected as the insoluble fraction of the cell lysate 
did seem to contain PigE (Figure 4.55). 
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Figure 4.55: SDS-PAGE gel of samples of interest in PigE purification MF: membrane fraction, IS: 
insoluble fraction, S: soluble fraction 
Like for the cell extracts assay, protein (S or MF) were mixed with 68, ornithine and NAD(P)H 
in a phosphate buffer for 16 h at 30 °C before analysing the sample by LC-MS. 
 
Figure 4.56: Extracted chromatograms (at m/z= 154.16+288.16) from the LC-MS analysis of  the 
reaction mixtures after a 16 h incubation at 30 °C with purified PigE a) MF, NADH; b) MF, NADPH, 
NAH; c) S, NADH d) S, NADPH 
As illustrated in Figure 4.56, no peaks corresponding to H2MAP was observed. The experiment 
was then repeated but instead of resuspending PigE and the other reagents in the phosphate 
buffer, they were resuspended in the flow-through obtained when the soluble fraction was 
loaded on the Ni-NTA column (Figure 4.57). H2MAP was observed with the soluble protein but 
not with the MF. This meant that nothing in the buffer was able to catalyse both the reduction 
of 68 and the subsequent transamination. In addition, E. coli is a heterologous host and does 
not seem to have close homologues of either domain of PigE. Thus, this experiment showed that 
the soluble fraction of PigE was active, but that it required more than just NAD(P)H and 
ornithine to carry out the transformation. A screening of conditions with metal ions, different 
amino acids and possibly other hydride generators than NAD(P)H would be the next steps in 
the study of PigE.  
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Figure 4.57: Extracted chromatograms (at m/z= 154.16+288.16) from LC-Ms analysis of the reaction 
mixtures after a 16 h incubation at 30 °C in presence of cell extracts a) S, b) MF 
6. Conclusions and perspective 
Complementation assays have been designed and support our hypothesis that PigE is a 
bifunctional enzyme. This was the first time that the thioester reductase activity had been 
demonstrated through complementation assays.  
It was possible to purify PigE with an N-terminal His6 tag and LC-MS experiments showed that 
the enzyme could mediate the transformation of thioester 68 into H2MAP 19a .  
Screening of different conditions would be the next step, with in particular the study of the 
influence of metal ions and other reducing cofactors. LC-MS analysis seems promising for the 
screening of the conditions, but an assay needs to be developed to study the kinetics of the 
reaction. The construction of a plasmid expressing PigE with a C-terminal His6 tag could also be 
a way to improve the activity. 
It might be difficult to isolate PigE-C terminal domain as it is mainly insoluble (section 4.3). 
However, the construction of a strain only expressing PigE-N terminal domain would be 
interesting so as to determine the activity of each domain individually. 
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Chapter 5. Toward an in vivo characterisation 
of PigD 
 
1. Overview and aim of the project 
PigD is the first enzyme involved in MAP biosynthesis. This thiamine diphosphate (TDP) 
dependent enzyme catalyses the transfer of an acetyl group from a pyruvate to an octenoyl 
thioester through a Stetter-type reaction (Figure 5.1). 
 
Figure 5.1:Mechanism of TDP dependent 1,4-addition of an acetyl group on an , -unsaturated 
carbonyl compound 
Whilst looking for an enantioselective catalyst for Stetter reactions, Dresen et al. purified PigD 
and characterised its regioselectivity and enantiselectivity.36 The Stetter reaction uses an 
umpolung mechanism, converting the carbon atom of a carbonyl group from an electrophile to 
a nucleophile. In most cases, this requires the addition of cyanide or a thiazolium ylid to form 
the Breslow intermediate, which can then carry out a nucleophilic attack. As illustrated in 
Figure 5.1, TDP dependent acylations follow a similar mechanism, but the enzyme scaffold 
imparts higher enantioselectivity. 
Dresen et al. first used PigD on ,-unsaturated aldehyde substrates, but they only obtained 1,2-
addition products – where the attack occurs on the carbonyl carbon of the aldehyde. However, 
when they moved to less reactive species such as ,-unsaturated ketones and  thioesters, they 
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only observed 1,4-addition products. Interestingly, conversion could be obtained for a wide 
range of R1 and R2 groups, including alkyl chains, aromatic groups, and heteroatoms. The worst 
yields were obtained for branched chains whereas the best one was obtained for a thioester 70, 
a mimic of octenoyl-ACP (Figure 5.2). 
 
Figure 5.2:PigD catalysed acetylation of a mimic of octenoyl-ACP 
Finally, they confirmed that the reaction was stereoselective with ee > 95% for all the tested 
substrates. The R/S configuration of the product depends on the order of priority of R2: with 70 
as starting material the reaction gives the (S) product (S)-68. 
In this project, we aimed to probe PigD substrate specificity in vivo. Because PigD is the first 
enzyme in the biosynthetic pathway, a chemical complementation approach as in Chapter 2 and 
Chapter 4 could not be followed. It was hence decided to feed S39006 with deuterium labelled 
compounds 86 and 87 and analyse the pigment produced by MS, where the deuterium labels 
should induce a shift of two mass units (Figure 5.3). 
 
Figure 5.3: Deuterated potential substrates for PigD 
2. Bioinformatics analyses 
PigD amino acid sequence was submitted to BLAST176 and PHYRE147. BLAST showed that 
residues 373-803 were consistent with a TDP dependent enzyme and predicted that Met681, 
Gly704, Asp705, Gly706, Ala707, Asn740 and Gly742 (orange in Figure 5.4) are involved in the 
PLP binding site. Interestingly, the N-terminal region of the protein did not seem to belong to 
any family (see appendix). 
Similarly, none of the sequences aligned with PigD in PHYRE covered the first 240 amino acids. 
The best hit was an acetolactate synthase, another TPP dependent enzyme which reacts two 
pyruvate molecules together at the beginning of the biosynthesis of valine, leucine and 
isoleucine. Despite the lack of a homologue for the N-terminal region, the software was able to 
model the entire structure, with 90% of confidence for 71% of the residues (in Green in Figure 
5.4).  
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Figure 5.4: Model of PigD as predicted by PHYRE.Green: structure modelled at > 90 % confidence, 
Orange: residue involved in the TPP binding site 
The structure was submitted to 3Dligand, which predicted a unique binding site containing TPP 
but also Mg2+ and Ca2+. In addition, Dresen et al.36 used buffers containing MgSO4 when they 
assessed the activity of PigD activity, which is consistent with a metal  ion binding site. The 
residues involved in the binding site were consistent with the BLAST prediction, with the 
addition of Leu680, Ser744, Val745 and Ile 746. 
3. The PigD product is not secreted 
Cross feeding assays were used extensively to determine the prodigiosin biosynthetic 
pathway.15,26 Strains with one of the enzymes in the pathway inactivated usually accumulate the 
intermediate that was supposed to be transformed by the said enzyme. Through secretion or 
diffusion, if the molecule is small and non-polar enough, the intermediate may escape into the 
culture medium and be taken up by another strain blocked earlier in the biosynthetic pathway. 
Hence if two white strains are grown together, one with an inactive enzyme further on in the 
biosynthetic pathway than the other, then pigmentation can be recovered. However, this only 
works if the intermediate can get out of the cells. Cross-feeding experiments were conducted 
with S39006 ΔpigD, S39006 ΔpigE and S39006 ΔpigB in pairwise co-culture in LB supplemented 
with sorbitol. Pigment was extracted and quantified, leading to Figure 5.5. 
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Figure 5.5: Pigment production in cross feeding assays. 
It appeared that, unlike the products of PigE and PigB (H2MAP and MAP respectively), the 
product of PigD either cannot get out of the cell or cannot be incorporated again. It is hence 
unlikely that it is a small non-polar molecule such as aldehyde 20. It is already known from 
feeding experiments that S39006 ΔpigD can take up aldehyde 20 from solution and use it to 
complete the biosynthesis of prodigiosin (see Chapter 4). This strongly supports the product of 
PigD being a CoA or ACP thioester not an aldehyde. CoA thioesters, although small molecules, 
are sufficiently polar that they cannot diffuse through membranes. 
4. Synthesis of the unlabelled potential substrate  
Before trying a synthesis involving deuterated material, a synthesis of  70 and the non-
deuterated 2-octenal 17 was attempted. Hexanal 88 was chosen as the precursor as the 
enol/aldehyde equilibrium offered a way to replace the −hydrogen atoms with deuterium 
atoms (see section 5). 
4.1. Knoevenagel condensation 
 
 
Figure 5.6: conversion of 182 into -unsaturated acid 183 using a Knoevenagel condensation. 
As illustrated in Figure 5.6, hexanal was mixed with malonic acid in the presence of base to 
trigger the malonic addition. The mixture was then acidified, leading to the dehydration and the 
decarboxylation. However, after purification, no 2-octenoic acid 89 was obtained, but 3-octenoic 
acid 89b (Figure 5.8a) was isolated instead. The experiment was repeated, and the acidification 
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was performed at 0 °C dropwise, but it did not alter the regioselectivity of the reaction. Another 
route was hence investigated. 
4.2. Wittig reaction 
 
Figure 5.7: conversion of 88 to 89 via a Wittig reaction 
A small-scale test reaction showed that (E)-90 could be obtained by reacting 88 with the 
commercial stabilised ylid 91 in water, at r.t. for one hour. However, the yield was low, probably 
because of partial oxidation of the starting ylid. Consequently, the ratio of ylid was doubled for 
the scale up, leading to a significant increase in the conversion yield but also to the formation of 
(Z)-90. The two stereoisomers could then be separated by column chromatography. 
Ester 90 being very insoluble in water, it was necessary to conduct the hydrolysis in a mixture 
of solvents. However, when the reaction was carried in a mixture containing methanol, a Michael 
addition of the alcohol on 90 happened, leading to the formation of 89c (Figure 5.8b). An 
attempt to perform the hydrolysis in a mixture H2O/THF only gave the starting ester back and 
decreasing the amount of base was not enough to prevent the formation of 89c. More sterically 
hindered alcohols were tried: with iPrOH, traces of a Michael addition product were still 
detected, whereas tBuOH gave the desired carboxylic acid as the only product, but at a slower 
rate. 
 
Figure 5.8: Formation of undesired products in the synthesis of 70 a) formation of 89b, b) formation 
of 89c 
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Conversion to the desired thioester 70 was then performed using the same coupling conditions 
as for 68. 
4.3. Formation of the aldehyde 17  
 
Figure 5.9: Route toward 17 
To prevent polymerisation, chloroacetaldehyde 92 is sold in solution at 50% in water. But the 
first step of the preparation of the ylid was done in chloroform, so 92 was diluted in chloroform 
and the water removed by distillation of the azeotrope. Triphenylphosphine was then added and 
the mixture refluxed for 16 h. The phosphonium salts were recovered by filtration and the ylid 
93 was obtained after treatment with NaOH. 
Unfortunately, performing the Wittig reaction under the same conditions as above did not lead 
to the formation of any 17 and only the starting materials were recovered. Before investigating 
other conditions for this reaction, conditions for the deuterium labelling were explored (Section 
5). 
5. Deuterium labelling 
 
Figure 5.10: Principle of deuterium labelling of hexanal 
As illustrated in Figure 5.10, the deuterium labelling of hexanal relied on the enol/aldehyde 
equilibrium and the exchange of protons with the solvent.  
In a first attempt, hexanal was diluted in MeOD and spectra were recorded two hours and a day 
after the dissolution (Figure 5.11).  
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Figure 5.11: Hexanal in MeOH Blue: t=0, Red: t=2h, Green: t=48h 
The peak corresponding to the protons  to the carbonyl group (2.4 ppm), showed a large 
decrease in the first two hours and then remained constant. Interestingly, the proton on the 
carbonyl carbon atom (9.7 ppm) followed a similar evolution. In addition, the total number of 
protons in those spectra remained constant, and a triplet at 4.47 ppm appeared after two hours. 
This suggested that the evolution of the spectra was due to the formation of the hemiacetal 94 
(Figure 5.12) and the labelling was too slow to be observed in those conditions. 
 
Figure 5.12: Hemiacetal 94 
To increase the rate of the labelling, Et3N was added to the mixture. Despite the formation of 
the hemiacetal, a decrease of the integral of the peaks corresponding to the proton  to the 
hemiacetal (1.6 ppm) could be observed after one week at r.t. or 16 hr at 60°C (Figure 5.13).  
Unfortunately, after removing MeOD under reduced pressure, the NMR spectrum taken in 
chloroform was consistent with 94. An attempt to hydrolyse the hemiacetal by treating with 1M 
HCl  only led to degradation. 
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Figure 5.13: Evolution of hexanal NMR spectrum in MeOD in presence of Et3N a) r.t., Blue t=0, Red= 
t=1 d, Green t=2 d, Purple, t= 3 d, Yellow t)5d; b) After 16h at 60°C  
KOH was tried as an alternative base: it seemed that the signal for the protons in  to the 
carbonyl disappeared before the recording of the first spectrum. However, the intensity of 
several signals in the 13C NMR spectrum were also affected which suggest other reaction(s) might 
be involved.  
Finally, the reaction was tried in D2O, but led to the formation of the hydrate. 
These methods gave promising results but still need optimisation: the recovery of hexanal still 
has to be optimised. Acid catalysis could also be explored. The formation of labelled hexanal will 
also have to be confirmed by MS as well as NMR. Unfortunately, none of the equipment available 
at that stage could record a mass spectrum for a compound with a molecular weight of 102. 
In conclusion, this work showed that the synthesis of a thioester substrate of PigD from hexanal 
was possible and explored a route for deuterium labelling of 88. The proton exchange with the 
solvent was observed but it was coupled with the formation of acetal and hexanal could not be 
recovered. Out of the three enzymes involved in MAP synthesis, PigD has been characterised 
the best. It was hence decided to focus our efforts on PigB and PigE. 
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Chapter 6. Conclusions and future work 
 
As mentioned above (see Chapter 1), prodigiosin results from the condensation of the 
monopyrrol MAP and a bipyrrole  MBC.  In the course of this project, the three enzymes involved 
in the formation of MAP - PigD, PigE and PigB - have been studied. 
PigD being the first enzyme of the pathway, a synthesis of deuterated substrates to monitor its 
activity in cell (see Chapter 5) was attempted. It was shown that the synthesis of the wanted 
substrates from hexanal was possible. Unfortunately, the deuteration of hexanal still requires 
optimisation.  
Four new analogues with variations in the C2 substituents (see Figure 6.1) of PigB 
substrate (H2MAP) were synthesised.  The capacity of PigB’s homologue HapB to 
use these compounds as substrates was established in vitro. In addition, a ΔpigD 
mutant of S39006 was fed with these analogues as well as compounds with 
variations on the C3 position of H2MAP (see Chapter 2). It appeared that the 
quantity of prodiginine hence obtained correlated well with the in vitro results, 
showing that PigB and HapB share similar flexibility and that substrates tolerated by PigB were 
also accepted by the condensing enzyme PigC. It appeared that both longer and shorter chains 
could be tolerated on the C3 position, whereas alkyl chains of more than 3 carbons were not 
accepted on the C2 position. 
Eight analogues of prodigiosin were obtained when S39006 ΔpigD was fed with analogues of 
H2MAP. Activity both against Gram-positive and Gram-negative bacteria was assessed, and in 
both cases all the prodiginines displayed some antibiotic activity in the disc diffusion assay. IG50 
experiments indicated that some of these compounds could inhibit the growth of E. coli and S. 
aureus in the low micromolar range. In addition, a preliminary experiment with HeLa cells 
showed that some of the new prodiginines could be more potent than prodigiosin against cancer 
cells (see Chapter 3). 
However, a more detailed analysis of antibiotic and anticancer activity of the derivatives would 
be useful. In particular, the GI50 experiment needs to be repeated with all the analogues of 
prodigiosin rather than just two. For the anticancer activity, more analogues need to be tested 
and the proper concentration range to measure the activity is still to be determined.   In addition, 
the prodiginines tested here were all issued form analogues of H2MAP with variation on the C2 
Figure 6.1: 
H2MAP 
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or C3 position. It would be interested to test other analogues of H2MAP, which would require 
the optimisation of some of the potential synthetic route explored in Chapter 2. 
Finally, using feeding experiments, we demonstrated that 
thioester 68 (Figure 6.2) could be accepted as a substrate in the 
prodigiosin biosynthetic pathway (see Chapter 4). This proved 
the existence of a thioester intermediate, probably either 3- 
acetyloctanoyl-CoA 66 or, more likely, a 3-acetyloctanoyl-ACP 
67. LC-MS experiments with lysates of E. coli expressing PigE 
showed that PigE could catalyse the transformation of 68 into H2MAP proving that PigE plays 
the role of thioester reductase for the thioester substrate.  However, a number of unknowns 
about this reaction remain: what are the cofactors? Can PigE perform substrate channelling 
between the thioester reductase the aminotransferase active sites? What are the kinetic 
parameters of the thioester reduction and of the transamination? The first question can probably 
be answered by screening conditions to see in which cases H2MAP can be detected by LC-MS 
when purified PigE is incubated with 68 and various cofactors.  It will only be possible to design 
experiments to answer the other questions once all the reagents involved in the transformations 
catalysed by PigE are known.
Figure 6.2: Mimic of potential 
natural thioester substrate of 
PigE 
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Chapter 7 Materials and methods 
 
1. Biological chemistry 
1.1. General considerations 
Chemicals and media were purchased from Sigma Aldrich, Insight Biotechnology LDT, Fluka, 
Formedium, Fisher Scientific, Tetanal, Difco, and Biorad. Commercial enzymes and kits were 
purchased from New England Biolab (NEB), Sigma, Thermo Fisher, and Gibco. Sequencing was 
performed by Eurofins Genomics (formerly GATC). 
All media were prepared in deionised water and sterilised at 121 °C for 20 min. Glassware used 
for bacterial culture was sterilised at 121 °C. 
HPLC purification and analysis were performed on an Agilent 1100 Series system fitted with a 
autosampler and a UV/Vis detector. Eluents were supplemented with 0.1% formic acid. 
1.2. Media and buffers 
1.2.1. Culture media 
Media  Component Quantity (g/L) 
Luria-Bertani medium (LB) Tryptone 10 
 Yeast extract 5 
 NaCl 10 
   
LB agar (LBA) LB As above 
 Agar  15 
   
LB+ sorbitol 0.25M (LBS) LB As above 
 sorbitol 45.5 
   
Marine broth Difco™ Marine Broth 2216 37.4 
   
Marine agar Marine broth As above 
 Agar 18 
   
Peptone Glycerol Media (PGM) Peptone 5 
 Glycerol 10 ml 
 Agar 15 
   
Mueller Hinton (MH) Infusion from dehydrated beef  300.0  
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 Casein hydrolysate  17.5  
 Starch  1.5  
 
1.2.2. Buffers for protein purification (pH = 8) 
 
When relevant the buffers were supplemented by 1 mM of PLP 
1.2.3. Buffer for SDS-PAGE and Western blot 
Running gel buffer Tris 50.86 
 HCl (1 M)  To pH 8.3 
   
Stacking gel buffer Tris 30.3 
 HCl (1 M)  To pH 6.8 
   
Electrode buffer (stock x 10) Glycine 150 
 Tris 30 
   
Transfer buffer Glycine 14.4 
 Tris (base) 3.03 
 MeOH 150 ml 
Wash buffer PBS  
 Tween 20 20 
 
Lysis NaH2PO4, (H2O)2 7.8 
 Imidazole 0.68 
 NaCl 17.54 
   
Wash NaH2PO4, (H2O)2 7.8 
 Imidazole 1.36 
 NaCl 17.54 
   
Elution NaH2PO4, (H2O)2 7.8 
 Imidazole 17 
 NaCl 17.54 
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1.2.4. Selection 
Supplement Concentration  
Ampicilin (Amp) 0.1 mg/ml 
Erythromycin (Erm) 0.2 mg/ml 
Kanamycin (Kn) 50 µg/ml 
Spectinomycin (Sp) 50 µg/ml 
DAPA 0.3 mM 
1.2.5. Buffer for heat shock competent cells preparation 
Solution A 1 M MnCl2 9.9 ml 
 1 M CaCl2 49.5 ml 
 50 mM MES 198 ml 
 dH2O 742.6 ml 
   
Solution A + glycerol Solution A  350 ml 
 Glycerol 150 ml 
1.2.6. Miscellaneous  
Buffer Component Quantity  
TAE 1X Tris base 40 mM 
 Acetic acid 20 mM 
 EDTA (sodium salt dihydrate) 1 mM 
   
Sodium fluoride NaF 4.1 g/L 
 NaH2PO4 7.8 g/L 
 NaOH To pH 8 
   
Phosphate (Kpi) KH2PO4 6.8 g/L 
 KOH To pH 7 
   
Tris  Tris HCl 10 mM 
   
HEPES  50 mM 
Citric acid  0.1 M 
pH in Tris, HEPES and citric acid buffer was adjusted to 7.5 
Chapter 7: Materials and Methods 
117 
 
1.3. PCR 
Polymerase Chain Reaction (PCR) was performed using a Veriti® 96-Well Thermal Cycler. For 
25 µl standard PCR reactions the following mixture was used. 
 Compound Quantity (µl) 
Standard PCR gDNA template 1 
 Oligonucleotide 1 (10 µM) 2.5 
 Oligonucleotide 2 (10 µM) 2.5 
 DMSO 0.75 
 dNTP (10 µM) 2 
 5x HF Buffer 5 
 Phusion® Hi-Fidelity DNA 
polymerase 
0.2 
 SD-H2O Up to 25 µl 
   
Colony PCR DNA template*  1 
 Oligonucleotide 1 (10 µM) 2.5 
 Oligonucleotide 2 (10 µM) 2.5 
 dNTP (10 µM) 0.5 
 DMSO 0.75 
 5x GC Buffer 5 
 Phusion® Hi-Fidelity DNA 
polymerase 
0.25 
 SD-H2O Up to 25 µl 
*1 colony resuspended in 100 µl of H2O 
PCR cycling parameters included 6 minutes of initial denaturation at 98°C, following 35 cycles 
of denaturation (10 seconds at 98 °C), annealing (15 second at 55 °C) and extension (5 to 7 
minutes at 72 °C), and a final extension for 10 minutes at 72 °C. The amplified PCR products 
were analysed by agarose gel electrophoresis. 1% (w/v) agarose gel containing ethidium bromide 
was run at 90 V in 1×TAE buffer (section 1.2.6). 
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Name Sequence 5’-3’ 
Restriction 
enzyme 
Usage 
oQE-F CCCGAAAAGTGCCACCTG 
 
pQE80-L and pQE80-L:oriT 
sequencing - forward 
oQE-R GTTCTGAGGTCATTACTGG 
 
pQE80-L and pQE80-L:oriT 
sequencing - reverse 
oBS-F GTAAAACGACGGCCAGT   
pBlueScript Sequencing -
Forward 
oBS-R AGCGGATAACAATTTCACACAGGA   
pBlueScript Sequencing -
Reverse 
MC01 GGCTGCAGTTACTCTAAAAATGTTGATAGC PstI pigE amplification -reverse 
MC02 
GAGAAGAGCTCATGATGGTGGAATTTCTCAA
ACTG SacI 
pigE C-terminal domain 
amplification - forward 
MC03 
GAGAAGAGCTCATGAAGTTTGGATTTATCGC
TC SacI 
pigE amplification- forward 
MC04 AATGCGGCCATCTGTTTA  pigE + 250 F 
MC05 TTGGCGGCATCAATACC  pigE + 250 R 
1.4. Cloning  
1.4.1. Plasmid construction 
Genes of interest were amplified using the conditions described above and the appropriates 
primers (see above). Amplicons were extracted from the agarose gel and digested for 1 hr at 37 
°C following the conditions described below by the appropriate restriction enzymes. In parallel 
the vector was digested with the same restriction enzymes and 0.5 µl of CIP were added 15 min 
before the end of the incubation. The digestion products were analysed by agarose gel 
electrophoresis and the digested products were purified using a PCR purification kit. Instead of 
a PCR amplicon, a plasmid with the insert could be digested with the appropriate restriction 
enzymes and the digested insert was then extracted from the agarose gel. Ligation mixtures were 
prepared following the conditions described below and the mixtures were incubated at 22°C. 
After 30 min, 5 µl of the mixtures were used to transform competent cells. The remaining 
mixture was incubated a further 16 h at 22°C and then used for transformation. 
 Compound Quantity (µl) 
Digestion Restriction enzyme 1 1 
 Restriction enzyme 2 1 
 CutSmart® Buffer 2 
 Plasmid/ PCR amplicon 5 /16 
 SD-H2O Up to 20 µl 
   
Ligation Linear vector 5 
 Insert 5 or 12.8 
Chapter 7: Materials and Methods 
119 
 
 10x T4DNA ligase buffer 2 
 Thermo Scientific T4 DNA 
Ligase 
0.2 
 SD-H2O Up to 20 µl 
 
1.4.2. Preparation of heat shock competent cells and transformation 
25 ml LB in 250 ml conical flask containing 375 μl 1 M MgCl2 (final conc. 15 mM) were inoculated 
with 500 μl of an overnight culture (OD600~3). The cells were grown at 37°C, 300 rpm until 
OD600=0.4-0.6. The cultures were transferred to a pre-chilled universal flask and kept on ice for 
1 h. The cells were pelleted by centrifugation, the supernatant was discarded and the cells 
resuspended in 10 ml of cold solution A. After 20 min on ice the cells were pelleted (4500 rpm, 
10 min, 4°C), the supernatant discarded and the cells resuspended in 2 ml of cold solution A + 
glycerol. 5 µl of DNA were added to 50 µl of cell and the mixture was incubated on ice for 1 h. 
the mixture was put at 42°C for 2 min, resuspended in LB and allowed to recover for 45 min at 
37 °C. The cells were then plated on LBA with the appropriate selection. 
1.5. Conjugation 
Overnight cultures of the donor strain (DS) and recipient strain (RS) were prepared. OD600 were 
recorded and cells were pelleted and resuspended at the same concentration. The cells were 
mixed in a 1:3 ratio (DS/RS) and 20 µl were spotted on LBA appropriately supplemented. The 
plate was incubated overnight (at 30 °C for S39006 and related strains) and the spot was 
resuspended in 1 ml of LB. The mixture was diluted  100-fold and 1000 fold and the two resulting 
suspensions were plated on LBA with appropriate selection. 
1.6. Transduction 
1.6.1. Preparation of the phage lysate 
A 10-fold serial dilution of a  lysate was prepared (10-1 - 10-4). 10 µl of each dilution was 
added to 4 ml of top agar (0.35%) inoculated with 200 µl of an overnight culture of the DS. The 
top lawn was then pured on LBA, and after solidification, the plates were incubated overnight 
(at 30 °C for Serratia). The top lawn from plate with congruent plaques were then resuspended 
in 3 ml of LB and 0.5 ml of CHCl3 saturated with NaHCO3, vortexed for 30 s and incubated at r.t. 
for 30 min. The mixture was then centrifugated and the supernatant was used as phage lysate. 
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1.6.2. Testing the phage lysate 
10 fold serial dilutions from 10-3 to 10-10 of the phage lysates were 
prepared. 10 µl of each dilution were then spotted on a top lawn 
infected with a strain susceptible to the phage (Figure 7.1). After an 
growing the cell overnight at an appropriate temperature, the 
p.f.u./ml was estimated. 
1.6.3. Transduction  
2 ml of an overnight culture of RS were inoculated with 50 µl of 
lysate, vortexed and incubated for 1 h at r.t. The cells were then pelleted and resuspended in 0.3 
ml of LB three times to remove the phage. 150 µl were then plated on LBA with the appropriate 
selection. 
1.7. Protein expression and purification 
1.7.1. Preparation of cell lysates  
Cells expressing the desired protein were grown at an appropriate temperature (37 °C for E. coli, 
30 °C for S39006) on a shaker at 250 rpm to obtain an OD600 of approximately 0.6. Cultures 
were then induced with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) at 16 °C for 14-16 h. 
This step was skipped for strains expressing the protein from their genomic DNA.  Aliquots were 
collected before and after the induction by IPTG to monitor the expression of protein and 
analysed by Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE). Cells 
were harvested by centrifugation at 4500 rpm for 20 min at 4 °C. The cells were incubated 15 
min on ice and resuspended in 20 ml of lysis buffer including lysosyme (20 mg/g of cell) (Method 
A) or phosphate buffer (Method B). After a further 30 min on ice, the cells suspensions were 
sonicated (6 x 20 s with 30 s breaks). The lysate could then be used directly for assay, or the 
soluble and insoluble fractions could be separated by centrifugation (see below) 
1.7.2. Protein purification from soluble fraction 
The above lysate was centrifuged at 4500 rpm at 4 °C for 1 h. The clarified lysate was loaded onto 
a Ni- NTA (Ni2+-nitrilotriacetate) column (Qiagen) for affinity purification and the flow through 
was collected for SDS-PAGE analysis. The column was washed twice with wash buffer and the 
bound protein was eluted: 6 fractions of 2 ml with a gradient of elution buffer (0 to 100%, 
increase of 20% at each fraction) in wash buffer were collected. The fractions containing purified 
protein were pooled and dialyzed against storage buffer. 
Figure 7.1: Phage lysate 
assessment 
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1.7.3. For protein isolation as membrane fraction 
Cell lysates were prepared as described in Section 1.7.2. The lysates were submitted to ultra-
centrifugation (4 °C, 1 h, 25000 rpm, SW32 Ti rotor, Beckman Coulter OPTIMA L-100XP 
ultracentrifuge). The soluble fraction was discarded, and the membrane fraction was separated 
from the cells debris and resuspended in phosphate buffer. 
1.8. SDS- PAGE and Western blot 
Once the running gel has polymerised, the stacking gel is poured on top of it with a comb. After 
polymerisation the gel was transferred to the running buffer, the protein loaded and 
approximately 90 V are applied for 2 h. 
Running gel  Running gel buffer 5 ml 
 Acrylamide 30% 5 ml 
 APS (80 mg/ml) 100 µl 
 SDS 20% 50 µl 
 TEMED 5 µl 
   
Stacking gel Stacking gel buffer 1 ml 
 Acrylamide 30% 2 ml 
 APS (80 mg/ml) 100 µl 
 SDS 20% 50 µl 
 TEMED 5 µl 
 H2O  7 ml 
   
Coomassie stain MeOH 10 ml 
 Acetic acid 20 ml 
 H2O 70 ml 
 Coomassie  A few mg 
The gel was removed and either stained with Coomassie or equilibrated in transfer buffer for the 
Western Blot. The transfer unit was then prepared, with, in that order, the negative base, a 
sponge, wet filter paper, the gel, activated PVDF membrane, filter paper, another sponge and 
the positive base. 250 mA are then applied for 90 min at 0 °C. The membrane was blocked with 
milk and incubated with the primary antibody for 1 h. After washing, the secondary antibody 
was added for 1 h. the membrane was then developed using a Millipore kit and X-Ray film. 
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1.9. Complementation assay on agar plates 
Two colonies of the strain of interest were picked and plated as two parallel streaks on a PGM 
agar plate. The plate was incubated for two days at 30 °C and 5 µl of the potential substrate in 
DMSO were spotted next to the streaks. The plate was incubated for a further 16 hr at 30 °C. 
1.10. Prodigiosin production, extraction and quantification 
1.10.1. Strains producing pigment. 
A solution of LBS was inoculated with an overnight culture of the strain (5 ml of overnight 
culture for 20 ml of LBs, the final concentration of sorbitol is 0.25M). The culture was incubated 
at 30 °C, 250 rpm for 16 h. 25 ml of cells were then pelleted (2219 g, 20 min, 4 °C) and the 
supernatant was discarded. The pellets were vortexed for 1 min in acidified EtOH (4% 1 M HCl). 
After centrifugation the supernatant gave the desired prodiginine extract. 
1.10.2. Strain not producing prodigiosin.  
The strain of interest was grown in LBS at 30 °C, 250 rpm until OD600 reached 4. A potential 
substrate was added (10 µM for H2MAP and its analogues, 1 mM for PigE putative substrates) 
was then added and the cells were grown for a further 16 h. Cells were then pelleted and 
prodiginine extracted as described above. 
1.10.3. Prodigiosin quantification  
A spectrum of the extract described above was recorded on a Cary 300-Bio UV-visible 
spectrophotometer. If the A535>2, the sample was diluted 10 times in EtOH (4% 1 M HCl), and 
the recorded absorbance was subsequently multiplied by 10. Prodigiosin’s maximum absorbance 
is at 535 nm, but to correct for the absorption of other extracted compounds, A535 was corrected 
using the formula  
𝐴535
𝑐𝑜𝑟𝑟  =  𝐴535 −  
85 ×  𝐴570  +  35 ×  𝐴450
120
 
1.11. High Pressure Liquid Chromatography (HPLC) 
1.11.1. Achiral analytical 
1.11.1.1. Analysis of prodiginines 
Samples obtained following the procedures described in Section 1.9 were concentrated to 
dryness and resuspended in ACN/ H2O 1:1 (15 ml for strain producing prodigiosin, 1 ml 
otherwise). They were then run on the HPLC equipped with Phenomenex Jupiter 5 C18 300A 
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with an acetonitrile gradient (5 to 100% in 30.5 min, then back to 5% in 30 s and constant 5% 
for 9 minutes). The absorbances at 500 and 535 nm were monitored. 
1.11.1.2. Analysis of 60 
 Amide 60 was diluted in ACN/H2O at 0.1 mg/ml. The sample was then run of the HPLC 
equipped as above with an acetonitrile gradient (50 to 90% in 12 min). The absorbance was 
monitored at 260 nm. 
1.11.2. Chiral analytical 
H2MAP was diluted in hexane (50 mg/ml). 20 µl were injected in the HPLC equipped with 
Supleco Analytical Astec cellulose DMP column and submitted to a gradient of iPrOH in hexane 
(15 to 50% in 30 min). The absorbance was monitored at 210 nm and 280 nm. 
1.11.3. Semi preparative column-prodiginine purification 
S39006 ΔpigD in 1 L of LBS were supplemented with 19a, 19e, 19g or 19h (10 µM) at OD600 
around 4. The cultures were grown a further 16 hr and the cells were pelleted by centrifugation 
(25 min, 4500 rpm, 4 °C). Prodigiosin was extracted in 150 ml of acidified EtOH (4% 1 M HCl). 
After removing the cells by centrifugation, the extract was sterile-filtered (22 µm pores) and 
concentrated to dryness under reduced pressure. The solid deposit was then resuspended in 1 
ml of ACN/H2O with a few drops of MeOH. After filtration of solid residues, the mixture was 
purified on the HPLC equipped with an Agilent Zorbax SB-C18 column with a gradient of ACN 
in H2O (5 min at 5% then 5 to 100% in 30.5 min, then back to 5% in 30 s and constant 5% for 9 
min). The absorbance was monitored at 500 and 535 nm. 
1.12. Mass spectrometry 
1.12.1. Sample preparation for MS  
1.12.1.1. H2MAP from S39006 ΔpigB 
200 ml of LBS in a 2 L flask were inoculated with a 5 ml of an overnight culture of S39006 ΔpigB 
(or ΔpigD for negative control). The cells were cultured at 30 °C for 16 h. The cultures were 
centrifuged, and the cell pellets extracted with 100 ml of acetone/Et2O 4:1. The extracts were 
concentrated to 5 ml under reduced pressure. 300 µl were taken and diluted to 1 ml in 
CH3CN/H2O 1:1 
1.12.1.2. Analysis of PigE effect on 68 
Eppendorf tubes were charged with 1 mM of 68, 1.25 mM of ornithine and PLP, and 1.25 mM of 
NAD(P)H. For negative control, no NAD(P)H was added. The solution contained PigE (cell 
lysates or purified protein) or the corresponding control was added. The resulting 0.5 ml were 
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gently shaken overnight at 30 °C. The insoluble fraction was eliminated by centrifugation and 
the soluble fraction analysed directly. 
1.12.1.3. Prodigiosin  
20 ml of LBS were inoculated with 5 ml of an overnight culture of S39006, ΔpigB (pHDB4) or 
ΔpigB (pHDB1). In the case of ΔpigB (pHDB1) and ΔpigB (pHDB4), ampicillin (0.1 mg.ml-1) was 
added. After growing the cells overnight at 30 °C at 250 rpm, pigment was extracted following 
the method described above. The solvent was then removed under reduced pressure in a pre-
weighed flask. The extracts were redissolved in CH3CN/H2O 1:1 at 10 mg/ml. When some solid 
was still visible after vortexing, the sample was filtered through cotton wool.  
1.12.2. MS method  
H2MAP samples were run on a Waters Xevo G2-S. Eluent A: H2O+ 0.1% formic acid, eluent B: 
95% ACN/ H2O+0.1% formic acid. Gradient: 0-0.38 min, 95% A, 5% B; 0.38-3 min, 95-5% A, 5-
95% B; 3-4 min, 5% A, 95% B. The chromatograms at 154.16 (H2MAP+H+) are then extracted. 
Prodigiosin samples were run on a Waters LCT Premier. Eluent A H2O+0.05% formic acid, 
eluent B ACN. Flow: 50% A, 50% B for 3 min 
1.13. Antimicrobial assays  
1.13.1. Carbapenem assay 
8 ml of top lawn agar (LB+0.7% agar) were inoculated with 400 µl of an overnight culture of E. 
coli Super Sensitive (ESS) and poured on an LBA plate (square, 125 x 125 mm). Once the lawn 
had set, 5-10 µl of an overnight culture of the strain of interest were spotted on the plate. When 
the carbapenem productions of different strain were assessed on the same plate, the OD600 of 
the overnight cultures were normalized by dilution in LB. The plate was then cultured at 37 °C 
overnight and the size of the halo around the spot assessed.  
1.13.2. Disc assays 
Prodiginine extracts were prepared from 400 ml of Serratia ΔpigD complemented with H2MAP 
or one of its analogues using the method described above. The extracts were then concentrated 
under reduced pressure and resuspended in 0.5 ml of acidified EtOH. Paper-filter discs 
(diameter: 5 mm) were sterilized and 50 µl of the concentrated extract or 40 µl of 10 mM of 19b 
in EtOH were spotted on it. Ampicillin discs (10 µg) were bought from Abtek Biological Ltd. The 
discs were placed on a top lawn (LB + 0.35% agar) inoculated with ESS or S. aureus. The plate 
was incubated overnight at 37°C and the size of the halo around the discs assessed. 
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1.13.3. Half growth inhibition (IG50) 
Prodiginine samples were purified as described in Section 1.10.1.1. Fractions containing 
prodiginines were then concentrated under reduced pressure and resuspended in 200 µl of 
acidified EtOH. The presence of prodiginines was checked by MS and UV/Vis spectra were 
recorded. The samples were diluted to 140 µM and a 2-fold serial dilution in water was prepared. 
A 96 well plate was then charged with MH broth (100 µl), bacterial culture at OD600 0.063 (10 
µl, ESS or S. aureus), and antibiotic (20 µl). A serial dilution of ampicillin (from 10 µg/ml) was 
used as a positive control. Wells not inoculated with bacteria nor antibiotic were included to 
check the sterility of the media and wells with media, bacteria and solvent were included as the 
negative controls. Two wells were used for each concentration of antibiotic. The plates were 
gently shaken overnight at 37 °C and the OD600 with Biochrom EZ Read 400 Microplate Reader. 
When no growth was visible in the well with the highest concentration of prodigiosin, the OD600 
was corrected following the formula: OD600cor=OD600-(OD600(highest concentration 
prodigiosin)-average (OD600 (no bacteria))/2^n where n is the number of time the most 
concentrated solution of prodigiosin  solution of prodiginine have been diluted by 2. The 
percentage of growth was then calculated by dividing by the average OD600 of wells without 
antibiotic.  
1.14. Anticancer activity 
The prodiginine samples were prepared as described in Section 1.11.3. The solvent was removed 
under reduced pressure and the pigments resuspended in DMSO at 100 µM. HeLa (HeLa ATCC® 
CCL-2™) cells were grown in a humidified incubator at 37 °C under 5% CO2 with 90% humidity 
and passaged at approximately 80% confluence using Trypsin-EDTA solution 0.25%. Cells were 
grown in DMEM supplemented with 10% heat-inactivated FBS, 100 units/mL penicillin and 100 
μg/mL streptomycin, 2 mM GlutaMax™. When the cell density reached 3.2.105 cells/ml, the 
media was removed, and the cells resuspended in DMEM supplemented with 2 mM GlutaMax™ 
and diluted 4 fold. A serial dilution of the prodiginine in the buffer was prepared. The quantity 
of DMSO was equalised at all dilutions and controls with just DMSO in the buffer were prepared. 
In a 96 well plate, wells were charged with 180 µl of the cell culture (15000 cells/well) and 20 µl 
of prodiginine solution or the control 2 h later. After 48 h the media was removed, and the cells 
were resuspended in Cell Titer Blue (Promega). After 2 h, the fluorescence at 560Ex/590Em was 
recorded. Results were normalised to the viability measured for the control.  
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1.15. Thermal shift assay 
A RT-PCR 96 well plate was charged as described below with the following potential ligands: 68, 
NADH, Ala, Asn, Cys, Glu, Gln, Gly, Ser, Tyr, His, Orn, Ile, Lys, Phe, Thr, Val and NADPH. It was 
loaded in the RT-PCR machine and a temperature gradient (25°C to 80°C, 0.5 °C every 30 s) was 
applied and the fluorescence was recorded. 
Component Volume (µl) 
NaF buffer 22.025 
Sypro orange (5 M) 0.025 
Protein (147 µM) 1.7 
Ligand (100 mM) 1.25 
1.16. CD spectra 
The spectra were recorded on an Aviv Model 410. The apparatus was flushed with N2 before 
turning on the lamps, followed by the rest of the device. After running a blank in sodium fluoride 
buffer, the spectra with PigE in solution in this buffer (0.07 mg/ml) was recorded. 
1.17. NAD(P)H assay 
Cell lysates were prepared as described in section1 1.7.1. UV transparent 96 well plates were 
charged as described below. A340 was then monitored at 30°C with a FLUOstar Omega for a few 
hr. 
 Compound Final concentration (mM) 
Purified protein 68  0.2 
 Ornithine  0.2 
 NAD(P)H  0.2 
 Metal ions cocktail 0.2 
 Enzyme  1 or 10 µM 
 Buffer To 100 µl 
   
Cell extracts 68 0.2 
Method A Ornithine  0.2 
 NAD(P)H  0.2 
 Metal ions cocktail* 0.2 
 Extract 1 or 10   
 Buffer To 100 µl 
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Cell extracts 68  1 
Method B Ornithine  0.125 
 NAD(P)H  1.25 
 PLP 0.125 
 Extract in phosphate buffer To 100 µl  
The metal ions cocktail contained MgCl2, MnCl2, KCl and NiCl2; at the same concentration. 
For the experiment with purified protein and method A, Phosphate buffer, TRIS buffer, citric 
acid and HEPES buffer were tried. 
1.18. Ninhydrin assay 
Cell lysates were prepared as described in Section 1.7.1. The mixture described below was 
incubated 15 min at 30 °C. 0.3 ml of perchloric acid (3 M) was added, followed by 0.3 ml of 
ninhydrin. The UV spectrum was recorded after a 10-fold dilution to avoid saturating the 
detector. 
Component Concentration (mM) 
129 5 
Ornithine 35 
PLP 50 
Cell lysate 20 µl 
TRIS buffer To 1 mL 
 
1.19. Ehrlich’s assay 
Solution A (MES pH 6.0 10 mM, HapB 29 µg.ml-1 or cell lysate) and B (MES pH 6.0 10 mM, 
H2MAP 0.1 to 1.4 mM, DMSO 8%) were prepared and incubated separately for 10 and 5 min 
respectively. The reaction was then initiated by mixing 25 l of each per well in a 96-well plate. 
The reaction was stopped by addition of 50 µl of stop reagent (HgCl2 100 mM, TCA 10% in H2O) 
followed by 100 µl of Ehrlich’s reagent (2% p-dimethylaminobenzaldehyde in acetic acid with 
16% perchloric acid). The plate was incubated for a further 20 min at r.t. and an absorbance 
spectrum was recorded. The baseline was subtracted using the formula A555corr = A555 - 
(A460+A650)/2   
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1.20 Bacterial strains and plasmid 
Strain Genotype/phenotype Source  
Serratia   
ATCC 39006 Wild type (Car+, Pig+) Bycroft et al.198 
NW14 (noted ΔpigB) In-frame pigBΔ (3270–4773, 501 aa Δ) Williamson et al.26 
NW13 (noted ΔpigD) In-frame pigDΔ (7895–9446, 517 aa Δ) Williamson et al. 
NW6 (noted ΔpigE) In-frame pigEΔ (10321–12865, 848 aa D) Williamson et al. 
ROP2 pstS::miniTn5Sm/Sp, SpR Slater et al.150 
MCA54 carA::miniTn5lacZ1, KmR Thomson et al.23 
ΔpigD carA- 
In-frame pigDΔ (7895–9446, 517 aa Δ), 
carA::miniTn5lacZ1, KmR 
This study 
ΔpigD rop2 
In-frame pigDΔ (7895–9446, 517 aa Δ), 
pstS::miniTn5Sm/Sp, SpR 
This study 
E. coli   
DH5 
supE44, hsdR17(rK - mK -), thi-1, recA1, gyrA96 
(NalR), relA1, Δlac (lacIZYA-argF) U169 deoR 
(80 lacZ∆M15) 
Grant et al.199 
BL21 (DE3) 
B F– ompT gal dcm lon hsdSB(rB–mB–) λ(DE3 
[lacI lacUV5-T7p07 ind1 sam7 nin5]) [malB+]K-
12(λS) 
Studier et al.200 
C43 F– ompT gal dcm hsdSB(rB- mB-)(DE3) NEB 
ESS -Lactam super-sensitive indicator strain Bainton et al.155 
2163 F–RP4-2-Tc::Mu DdapA::(erm-pir), KmREmR Ramsay et al.201 
S. aureus H WT Takebe et al.202 
Plasmid   
pQE80-L 6xHis fusion expression vector, AmpR Qiagen 
pQE80-L::oriT 
6xHis fusion expression vector containing 
oriT gene for bacterial conjugation, AmpR 
Monson et al.188 
pBlueScript-II KS+ ColE1 replicon, AmpR Stratagene 
pHDB1 
1698 bp BamHI/SphI containing N-His6-hapB 
ligated into pQE80L 
Couturier et al.37 
pHDB2 
1639 bp BamHI/PstI containing N-His6-pigB 
ligated into pQE80-L (truncated) 
Couturier et al. 
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pHDB3 
2013 bp BamHI/PstI containing N-His6-pigB 
ligated into pQE80-L::oriT 
Couturier et al. 
pHDB4 
2013 bp EcoRI/PstI containing C-His6-pigB 
ligated into pQE80-L::oriT 
Couturier et al. 
pBS-pigEC 
1359 bp PstI/SacI containing pigE  C-
terminal domain ligated into pBlueScript 
This study 
pPigEC 
1359 bp PstI/SacI containing N-His6 tag pigE 
C-terminal domain ligated into pBlueScript 
This study 
pBS-pigE 
2562 bp PstI/SacI containing pigE ligated 
into pBlueScript 
This study 
pPigE 
2562 bp PstI/SacI containing N-His6 tag pigE 
ligated into pQE80-L::oritT 
This study 
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2. Synthesis  
2.1. General considerations 
Standard solution-phase chemistry was used for the synthesis of the various biosynthetic 
intermediates and their analogues. All reactions were carried out under N2 in pre-dried 
glassware and all organic solvents used were freshly distilled. Solvents and reagents for 
anhydrous reactions were dried by conventional methods prior to use. Milli-Q deionised water 
was used in all chemical reactions and biochemical work. High temperature reactions were 
carried out using a silicone oil bath. Yields refer to chromatographically and spectroscopically 
pure compounds. Microanalyses were performed by the University of Cambridge 
Microanalytical Laboratory in the Department of Chemistry, and are quoted to the nearest 0.1% 
for all elements except for hydrogen, which is quoted to the nearest 0.05%. Reported atomic 
percentages are within the error limits of ± 0.3%.  
2.1.1.  Nuclear Magnetic Resonance spectroscopy 
NMR Spectra were recorded in deuterated solvents (as specified) using a Bruker AM/DPX-400 
(1H NMR at 400 MHz, 13C NMR at 100 MHz). Chemical Shifts (δ) are quoted in parts per million 
(ppm) and referenced to solvent peaks. Coupling constants (J) are reported in Hz. The 
multiplicities and general assignments of the spectroscopic data are denoted as: singlet (s), 
doublet (d), triplet (t), quartet (q), quintet (quin), double doublet (dd), double double doublet 
(ddd), double doublet triplet (ddt), double triplet (dt), triple triplet (tt), double quartet (dq), 
unresolved multiplet (m), and broad (br).  
2.1.2. LC-MS 
LC-MS analyses were performed with an Waters H-Class UPLC on a Waters Acquity UPLC BEH 
C18, 1.7µm column eluted with a gradient of 10 mM aqueous ammonium acetate containing 0.1% 
formic acid to 95% acetonitrile over 3 min, coupled to a Waters SQD2 and/or with a Alliance 
HT Waters 2795 Separations Module on a Waters Atlantis dC18 4.6 x 30 mm, 3 μm column 
eluted with a gradient of 10 nM aqueous ammonium acetate containing 0.1% formic acid to 95% 
acetonitrile over 8 min, coupled to a Waters Micromass ZQ Quadrupole Mass Analyser (using 
electrospray ionisation (ESI)) with accuracy no greater than 0.4 Da. 
2.1.3. High Resolution Mass Spectrometry  
Accurate masses were obtained with a Waters LCT Premier high-resolution mass spectrometer 
and/or a Waters Xevo G2-S. 
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2.1.4. Infra-Red (IR) Spectroscopy  
IR spectra were recorded neat on a diamond/ZeSe plate using a Perkin-Elmer Spectrum One FT-
IR Universal Attenuated Transmittance Reflectance (ATR) sampling accessory spectrometer 
with internal referencing. Characteristic absorption maxima (λmax) are reported in wavenumbers 
(cm−1) and the following abbreviations are used: w, weak; m, medium; s, strong; br, broad. 
2.1.5. Silica Gel Chromatography 
Unless otherwise stated, flash column chromatography was performed using 230-400 mesh 
Kieselgel 60 silica. Analytical thin layer chromatography (TLC) was performed on commercial 
silica gel plates (Merck glass- or aluminium-backed plates coated with a 0.20 mm layer of silica 
gel 60 with fluorescent indicator UV254). These plates were visualised using either ultraviolet 
light (254 or 365 nm), or by staining the plates with potassium permanganate or vanillin 
solutions or with Ehrlich's reagent. 
2.1.6. Ultraviolet-Visible (UV-Vis) spectrophotometry  
All the UV-Vis spectra for the various compounds were taken on a Helios Zeta UV-Vis with a 6 
multicell holder using 1 cm path length using either 1 ml quartz cuvettes or polystyrene 
disposable cuvettes. 
2.2. Synthesis of H2MAP analogues 
 
3-Pentyl-1-vinylpyrrolidin-2-one 40a 
A solution of N-vinylpyrrolidin-2-one 39 (5 ml, 50 mmol, 1 eq.) in dry 
THF (20 ml) was added dropwise to a stirred solution of NaHDMS (2 M 
in THF, 26 ml, 52 mmol, 1.04 eq.) at -78 °C under N2. After 1 h a solution 
of 1-iodopentane (7.15 ml, 55 mmol, 1.1 eq.) in dry THF (20 ml) was added 
dropwise. The mixture was allowed to warm to r.t. (RT), stirred for 16 h, 
diluted with diethyl ether (20 ml), filtered and evaporated under reduced pressure. Purification 
by column chromatography (petroleum ether/EtOAc, 85:15) gave 40a (5.6 g, 30 mmol, 60%) as 
a colourless oil. 1H NMR (400 MHz, CDCl3):  0.89 (3H, t, J 7.0 Hz, H13), 1.20-1.40 (7H, m, H10, 
H11, H12, H9a), 1.74 (1H, m, H4a), 1.87 (1H, m, H9b), 2.28 (1H, m, H4b), 2.50 (1H, m, H3), 3.38 (1H, m, 
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H5a), 3.49 (1H, td, J  10.0 & 4.0 Hz, H5b), 4.38 (1H,d, J 16.0 Hz, H8a), 4.42 (1H,d, J 9.0 Hz, H8b), 
7.10(1H, dd, J 16.0 & 9.0 Hz, H7); 13C NMR (100 MHz, CDCl3):  14.02 (C13), 22.52 (C12), 24.41 (C4), 
26.83 (C10), 31.11 (C9), 31.71 (C11), 42.44 (C3), 42.88 (C5), 93.97 (C8), 129.63 (C7), 175.32 (C2); IR 
(neat): max 2954m, 2928m, 2858m, 1704s (C=O) cm-1; HRMS: m/z calcd for C11H19NO+H+: 
182.1545; found: 182.1551. 
3,3-Dipentyl-1-vinylpyrrolidin-2-one 41 
This compound was sometimes formed along 40a. 1H NMR (400 MHz, CDCl3) 
 0.87 (6H, t, J 7.0 Hz, H13), 1.1-1.40 (12H, m, H10, H11 and H12), 1.51 (4H, m, H9), 
1.97 (2H, t, J 7.0 Hz, H4), 3.39 (2H,  t, J 7.0 Hz, H5), 4.37 (1H, d, J 16.0 Hz, H8a), 
4.42 (1H, d, J, 9.0 Hz, H8b), 7.10 (1H,dd, J 9.0 & 16.0 Hz, H7) 
 
 
3-Ethyl-1-vinylpyrrolidin-2-one 40b 
Product 40b (17 mmol, 70%) was obtained by a similar procedure as for 40a. 
1H NMR H (400 MHz, CDCl3): 0.97 (3H, t, J 8.0 Hz, H10), 1.45 (1H, m, H9a), 
1.75 (1H, m, H4a), 1.90 (1H, m, H9b), 2.28 (1H, m, H4b), 2.46 (1H, m, H3), 3.39 
(1H, m, H5a), 3.49 (1H, td, J 10.0 & 3.0 Hz, H5b), 4.38 (1H, d, J 16.0 Hz, H8a), 
4.42 (1H,d, J 9.0 Hz, H8b), 7.10 (1H, dd, J 16.0 & 9.0 Hz, H7); 13C NMR (100 MHz, CDCl3): 11.40 
(C10), 23.80 (C4), 24.14 (C9), 42.88 (C3), 43.78 (C5), 94.02 (C8), 129.60 (C7), 175.13 (C2); IR  (neat): 
max 2954m, 2928m, 2858m, 1704s (C=O) cm-1; HRMS: m/z calcd for C8H13NO+H+: 140.1070; 
found 140.1068. 
3-Propyl-1-vinylpyrrolidin-2-one 40c 
Product 40c (15 mmol, 60%) was obtained by a similar procedure as for 
40a. 1H NMR (400 MHz, CDCl3): 0.94 (3H, t, 7.0 Hz, H11), 1.33-1.46 (3H, m, 
H10, H9a), 1.74 (1H, m, H4a), 1.86 (1H, m, H9b), 2.28 (1H, m, H4b), 2.51 (1H, m, 
H3), 3.37 (1H, m, H5a), 3.49 (1H, td, J 10.0 & 4.0 Hz, H5b), 4.38 (1H, d, J 16.0 
Hz, H8a), 4.42 (1H, d, J 9.0 Hz, H8b), 7.10(1H, dd, J 16.0 & 9.0 Hz, H7); 13C NMR (100 MHz, CDCl3): 
13.95 (C11), 20.36 (C10), 24.40 (C4), 33.28 (C9), 42.21 (C3), 42.88 (C5), 93.97 (C8), 129.62 (C7), 175.32 
(C2); IR (neat): max 2956m, 2928m, 2860m, 1702s (C=O) cm-1; HRMS: m/z calcd for 
C9H15NO+H+: 154.1226; found: 154.1227. 
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3-Allyl-1-vinylpyrrolidin-2-one 40d 
Product 40d (16 mmol, 64%) was obtained by reacting 39 with allylbromide 
in the same conditions as for  40a. 1H NMR (400 MHz, CDCl3):  1.80 (1H, 
m, H4a), 2.23 (2H, m, H4b and H9a), 2.61 (2H, m, H3 and H9b), 3.39 (1H, m, 
H5a), 3.49 (1H, td, J 10.0 & 4.0 Hz, H5b), 4.38 (1H, d, J 16.0 Hz, H8a), 4.42 
(1H,d, J 9.0 Hz, H8b), 5.10 (2H, m, H11), 5.78 (1H, m, H10) 7.10 (1H, dd, J 16.0 & 9.0 Hz, H7); 13C 
NMR (100 MHz, CDCl3): 23.52 (C4), 35.27 (C9), 41.90 (C3), 42.86 (C5), 94.30 (C8), 117.20 (C11), 
129.54 (C7), 135.50 (C10); IR (neat): max 2954m, 2928m, 2859m, 1700s (C=O) cm-1; HRMS: m/z 
calcd for C9H13NO+H+: 152.1070; found: 152.1068. 
3-Hexyl-1-vinylpyrrolidin-2-one 40e 
Product 40e (18 mmol, 70%) was obtained by a similar procedure as 
for 40a. 1H NMR (400 MHz, CDCl3):  0.87 (3H, t, J 6.0 Hz, H14), 1.26-
1.42 (9H, m, H10, H11, H12, H13, H9a), 1.73 (1H, m, H4a), 1.88 (1H, m, H9b), 
2.28 (1H, m, H4b), 2.49 (1H, m, H3), 3.37 (1H, m, H5a), 3.49 (1H, td, J  
10.0 & 3.0 Hz, H5b), 4.38 (1H, d, J 16.0 Hz, H8a), 4.42 (1H, d, J 9.0 Hz, 
H8b), 7.10 (1H, dd, J 16.0 & 9.0 Hz, H7); 13C NMR (100 MHz, CDCl3):  14.07 (C14), 22.60 (C13), 
24.40 (C4), 27.12 (C10), 29.18 (C11), 31.16 (C9), 31.70 (C12), 42.44 (C3), 42.88, 93.98 (C8), 129.62 (C7), 
175.32 (C2); IR (neat) max 2956m, 2928m, 2860m, 1703s (C=O) cm-1; HRMS, m/z calcd for 
C12H21NO+H+: 196.1696; found 196.1694. 
3-Heptyl-1-vinylpyrrolidin-2-one 40f 
Product 40f (19 mmol, 73%) was obtained by a similar procedure as 
for 40a. 1H NMR (400 MHz, CDCl3): 0.88 (3H, t, J 7.0 Hz, H15), 1.20-
1.40 (11H, m, H10, H11, H12, H13, H14, H9a), 1.74 (1H, m, H4a), 1.87 (1H, m, 
H9b), 2.28 (1H, m, H4b), 2.49 (1H, m, H3), 3.38 (1H, m, H5a), 3.49 (1H, 
td, J 9.7 & 3.2 Hz, H5b), 4.38 (1H,d, J 16.0 Hz, H8a), 4.42 (1H, d, J 9.0 
Hz, H8b), 7.10 (1H, dd, J 16.0 & 9.0 Hz, H7); 13C NMR (100 MHz, CDCl3): 
 14.07 (C15), 22.64 (C14), 24.40 (C4), 27.17(C10), 29.17(C12), 29.49 (C11), 31.16 (C9), 31.81 (C13), 42.44 
(C3), 42.88 (C5), 93.97 (C8), 129.62 (C7), 175.32 (C2); IR (neat): max 2954m, 2930m, 2858m, 1705s 
(C=O) cm-1; HRMS: m/z calcd for C13H23NO+H+: 210.1852; found: 210.1853. 
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3-Isopropyl-1-vinylpyrrolidin-2-one 40g 
Product 40g (3.8 mmol, 60%) was obtained by a similar procedure as for 40a. 
1H NMR (400 MHz, CDCl3):  0.87 (3H, d, J 7.0 Hz, H11), 1.01 (3H, d, J 7.0, H10), 
1.87 (1H, m, H4a), 2.10 ( 1H, m, H4b), 2.23 (1H, m, H9), 2.50 (1H, m, H3), 3.38 (1H, 
m, H5a), 3.46 (1H, td, J  10.0 & 4.0 Hz, H5b), 4.37 (1H, d, J 16.0 Hz, H8a), 4.42 (1H, 
d, J  9.0 Hz, H8b), 7.11 (1H, dd, J 16.0 & 9.0 Hz, H7); 13C NMR (100 MHz, CDCl3):  17.71 (C11), 19.32 
(C4), 20.52 (C10), 28.46 (C9), 43.04 (C5), 48.20 (C3), 93.99 (C8), 129.55 (C7), 174.65 (C2); IR (neat): 
max 2954m, 2930m, 2858m, 1704s (C=O) cm-1; HRMS: m/z calcd for C9H15NO+H+: 154.1226; 
found: 154.1225. 
3-(Pyridin-2-yl)-1-vinyl-4,5-dihydro-1H-pyrrol-2-ol 40h 
Product 40h (1.817 g, 20%) was obtained by reacting 39 with 
bromopyridine in the same conditions as for 40a. 1H NMR (400 MHz, 
CDCl3):  2.50 (1H, m, H4a), 2.68 (1H, m, H4b), 3.74 (2H, m, H5), 4.64 (2H, 
m, H8), 7.14 (1H, dd, J 9.0 & 16.0 Hz, H7), 7.26 (1H, m, H12), 7.45 (1H, d, J 8.0 
Hz, H10), 7.74 (1H, t, J 8.0 Hz, H12), 8.57 (1H, d, J 5.0 Hz); 13C NMR (100 
MHz, CDCl3):  34.0 (C4), 41.9 (C5), 79.3 (C3) 96.2 (C8), 119.5 (C10), 123.1 (C12), 129.8 (C7), 137.2 
(C11), 148.4 (C13), 172.8 (C2) ; IR (neat): max   3326br (O-H), 3000w, 2957w, 2893w, 1681s (C=N), 
1635s (C=O)cm-1 ; HRMS: m/z calcd for C11H12N2O+H+: 189.1022 found 189.1024 
5-Methyl-4-pentyl-3,4-dihydro-2H-pyrrole (H2MAP) 19a 
A solution of 3-pentyl-1-vinylpyrrolidin-2-one 40a (1 g, 5.5 mmol, 1 eq) 
in Et2O (2 ml) was added dropwise to a stirred solution of MeLi (1.6 M 
in Et2O, 4.5 ml, 7.2 mmol, 1.3 eq.) at -10 °C. The mixture was stirred at -
10°C for 1 h and at r.t. for 1 h. It was then cooled to 0 °C and hydrochloric acid (1 M) was added 
slowly to pH 2. The mixture was stirred at r.t. for 40 min. The two phases were separated, and 
the organic phase was extracted with hydrochloric acid (1 M). The combined aqueous phases 
were washed with DCM. Aq. NaOH (1 M) was added to pH 11 and the mixture was extracted with 
DCM. The organic layer was dried (MgSO4) and evaporated. Purification by column 
chromatography (DCM/MeOH, 9:1) gave 19a (658 mg, 78%) as an oil. 1H NMR (400 MHz, 
CDCl3)  0.87 (3H, t, J 7.0, H11), 1.28 (7H, m, H7a, H8, H9 and H10), 1.50 (1H, m, H4a), 1.65 (1H, m, 
H7b), 1.94 (3H, s, H6), 1.98-2.08 (1H, m, H4b), 2.51-2.65 (1H, m, H3), 3.54-3.66 (1H, m, H5a), 3.67-
3.82 (1H, m, H5b); 13C NMR (125 MHz, CDCl3, APT used for assignments):  13.9 (C11), 18.1 (C6), 
22.6 (C10), 27.3 (C4), 29.1, 31.8 and 31.9 (C7, C8 and C9), 50.7 (C3), 58.8 (C5), 177.6 (C2); IR (neat): 
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max 2955m, 2928s, 2860m, 1649s (C=N) cm-1; HRMS: m/z calcd for C10H19N+H+: 154.1596; found: 
154.1595. 
5-Methyl-4-ethyl-3,4-dihydro-2H-pyrrole 19b 
Product 19b (5.3 mmol, 75%) was obtained by a similar procedure as for 19a. 
Purification by column chromatography was not necessary. 1H NMR (400 MHz, 
CDCl3):  0.91 (3H, t, J 7.2 Hz, H8), 1.28 (1H, m, H7a), 1.52 (1H, m, H4a), 1.73 (1H, 
H7b), 1.97 (3H, s, H6), 2.05 (1H, m, H4b), 2.59 (1H, m, H3), 3.64 (1H, m, H5a), 3.74 (1H, m, H5b); 13C 
NMR (100 MHz, CDCl3):  11.73 (C8), 17.96 (C6), 24.63 (C7), 28.52 (C4), 52.20 (C3), 58.90 (C5), 
177.94 (C2); IR (neat): max 2957m, 2929s, 2860m, 1649s (C=N) cm-1; HRMS: m/z calcd for 
C7H13N+H+: 112.1121; found: 112.1121. 
5-Methyl-4-propyl-3,4-dihydro-2H-pyrrole 19c 
Product 19c (4.6 mmol, 71%) was obtained by a similar procedure as for 19a. 
Purification by column chromatography was not necessary. 1H NMR (400 
MHz, CDCl3):  0.87 (3H, t, J 8.0 Hz, H9), 1.14-1.42 (3H, m, H8, H7a), 1.50 (1H, 
m, H4a), 1.65 (1H, m, H7b), 1.97 (3H, s, H6), 2.05 (1H, m, H4b), 2.62 (1H, m, H3), 
3.62 (1H, m, H5a), 3.74 (1H, m, H5b); 13C NMR (100 MHz, CDCl3):  14.10 (C9), 17.97 (C6), 20.94 
(C8), 29.12 (C4), 34.05 (C7), 50.63 (C3), 58.78 (C5), 178.04 (C2); IR (neat): max 2955m, 2929s, 
2862m, 1650s (C=N) cm-1; HRMS: m/z calcd for C8H15N+H+: 126.1217; found: 126.1215. 
5-Methyl-4-allyl-3,4-dihydro-2H-pyrrole 19d 
Product 19d (4.5 mmol, 70%) was obtained by a similar procedure as for 19a. 
Purification by column chromatography was not necessary. 1H NMR (400 
MHz, CDCl3):  1.58 (1H, m, H4a), 2.0 (3H, s, H6), 2.05 (2H, m, H4b, H7a), 2.42 
(1H, m, H7b), 2.74 (1H, m, H3), 3.70 (2H, m, H5), 5.06 (2H, m, H9), 5.72 (1H, m, H8); 13C NMR (100 
MHz, CDCl3):  18.07 (C6), 28.67 (C4), 36.05 (C7), 50.09 (C3), 58.91 (C5), 116.71 (C9), 135.74 (C8), 
176.88 (C2); IR (neat): max 2955m, 2927s, 2859m, 1649s (C=N) cm-1; HRMS: m/z calcd for 
C8H13N+H+: 124.1121; found: 124.1123. 
5-Methyl-4-hexyl-3,4-dihydro-2H-pyrrole 19e 
Product 19e (3.4 mmol, 68%) was obtained by a similar procedure as 
for 19a. 1H NMR (400 MHz, CDCl3):  0.89 (3H, t, J  7.0  Hz, H12), 1.20-
1.34 (9H, m, H11, H10, H9, H8, H7a), 1.50 (1H, m, H4a), 1.67 (1H, m, H7b), 
1.97 (3H, s, H6), 2.05 (1H, m, H4b), 2.62 (1H, m, H3), 3.63 (1H, m, H5a), 
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3.76 (1H, m, H5b); 13C NMR (100 MHz, CDCl3):  14.07 (C12), 18.01 (C6), 22.62 (C11), 27.71 (C8 or 
C9), 29.17 (C4), 29.35 (C8 or C9), 31.77 (C7), 31.86 (C10), 50.83 (C3), 58.89 (C5), 177.88 (C2); IR 
(neat): max 2957m, 2930m, 2861 M, 1649s (C=N) cm-1; HRMS: m/z calculated for C12H21NO+H+: 
196.1696; found: 196.1694. 
5-Methyl-4-heptyl-3,4-dihydro-2H-pyrrole 19f 
Product 19f (3.1 mmol, 65%) was obtained by a similar procedure 
as for 19a. Purification by column chromatography was not 
necessary. 1H NMR (400 MHz, CDCl3):  0.88 (3H, t, J  7.0 Hz, H13), 
1.20-1.34 (11H, m, H12, H11, H10, H9, H8, H7a), 1.50 (1H, m, H4a), 1.65 
(1H, m, H7b), 1.97 (3H, s, H6), 2.05 (1H, m, H4b), 2.61 (1H, m, H3), 3.63 (1H, m, H5a), 3.75 (1H, m, 
H5b); 13C NMR (100 MHz, CDCl3):  14.08 (C13), 17.99 (C6), 22.64 (C12), 27.7 (C8), 29.14 (C4), 29.22 
(C10), 29.64 (C9), 31.83 & 31.84 (C7 and C11), 50.82 (C3), 58.84 (C5), 177.96 (C2); IR (neat): max 
2955m, 2928s, 2860m, 1650s (C=N) cm-1; HRMS: m/z calcd for C12H23N+H+: 182.1903; found: 
182.1906. 
5-Methyl-4-isopropyl-3,4-dihydro-2H-pyrrole 19g 
Product 19g (3.9 mmol, 60%) was obtained by a similar procedure as for 19a. 1H 
NMR (400 MHz, CDCl3):  0.71 (3H, d, J  6.0 Hz, H8), 0.96 (3H, d, J  7.0 Hz, H9), 
1.66 (H, m, H4a), 1.84 (1H, m, H4b), 1.97 (3H, s, H6), 2.10 (1H, m, H7), 2.69 (1H, m, 
H3), 3.69 (2H, m, H5); 13C NMR (100 MHz, CDCl3):  16.3 (C8), 18.2 (C6), 21.7 (C9), 22.9 (C4), 28.0 
(C7), 57.2 (C3), 59.54 (C5); IR (neat): max 2956m, 2928s, 2860m, 1650s (C=N) cm-1; HRMS: m/z 
calcd for C8H15N+H+: 126.1217; found: 126.1216. 
5-Ethyl-4-pentyl-3,4-dihydro-2H-pyrrole 19h 
Product 19h (0.17 mmol, 17%) was obtained by a similar procedure as for 
19a. 1H NMR (400 MHz, CDCl3):  0.87 (3H, t, J 7.0, H12), 1.13 (3H, t, J 8.0, 
H7), 1.17-1.36 (7H, m, H8a, H9, H10 and H11), 1.50 (1H, m, H8b), 1.64 (1H, m, 
H6a), 2.04 (1H, m, H6b), 2.23 (1H, m, H4a), 2.34 (1H, m, H4b), 2.66 (1H, m, 
H3), 3.65 (1H, m, H5a), 3.76 (1H, m, H5b); 13C NMR (100 MHz, CDCl3):  10.7 (C7) 14.2 (C12), 22.8 
(C11), 25.0 (C6), 27.7 (C4), 29.3, 32.0, 32.1 (C8, C9 and C10), 49.9 (C3), 58.9 (C5), 182.4 (C2); LC/MS: 
m/z for C11H21N+H+:168.17 ; found.168.3  
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5-Propyl-4-pentyl-3,4-dihydro-2H-pyrrole 19i 
To a stirred solution of iodopropane (52 l, 0.55 mmol, 1 eq.) dry n-
pentane-Et2O (3:2, 5 ml) under N2 at -78 °C was added dropwise tBuLi 
(1.7 M in hexane, 0.7 ml 1.21 mmol, 2.2 eq). The mixture was stirred at -
78 °C for 5 min and at r.t. for 1 h, then cooled again to -78 °C. A solution 
of 40a (200 mg, 1.1 mmol, 2 eq.) in dry Et2O (0.4 ml) was added dropwise. The mixture was 
stirred for 1 h at -10 °C and then 1.5 h at r.t. Hydrochloric acid (1 M) was then added dropwise to 
pH 2. After being stirred for 20 min, the organic layer was separated and extracted with 
hydrochloric acid (0.1 M). The combined aqueous layers were washed with Et2O. Aq. NaOH (1 
M) was then added to pH 10 and mixture was extracted with DCM. The combined extracts were 
dried (MgSO4) and evaporated. Purification by column chromatography (DCM/MeOH, 98:2) 
gave 19i (10 mg, 55 µmol, 10%). 1H NMR (400 MHz, CDCl3):  0.87 (3H, m, H13), 0.93 (3H, t, J 
7.0 , H8), 1.26-1.39 (11H, m, H6, H7 H9a, H10, H11 and H12), 2.13-2.34 (3H, m, H4 and H9b), 2.63 (1H, 
m, H3), 3.57-3.69 (1H, m, H5a), 3.69-3.81 (1H, m, H5b); 13C NMR (125 MHz, CDCl3):  14.1 (C8) 14.1 
(C13), 21.1 (C4), 22.5 (C12), 22.6 (C7), 27.5 ,30.8, 31.7, 31.9 (C6, C9, C10 and C11), 40.2 (C3), 60.2 (C5), 
171.1 (C2); LC/MS: m/z  calcd for C12H23N+H+:182.19 ; found 182.3.  
5-Butyl-4-pentyl-3,4-dihydro-2H-pyrrole 19j 
Product 19j (66 mmol, 33%) was obtained by a similar procedure as for 
19a. 1H NMR (400 MHz, CDCl3):  0.90 (6H, m, H9 and H14), 1.13-1.42 (9H, 
m, H6, H8, H10a, H11, H12 and H13), 1.13-1.73 (4 H, m, H6 and H7), 2.02 (1H, 
m, H10b), 2.19 (1H, m, H4a), 2.28 (1H, m, H4b), 2.62 (1H, m, H3), 3.64 (1H, m, 
H5a), 3.75 (1H, m, H5b); 13C NMR (100 MHz, CDCl3):  13.9 (C14), 14.1 (C9), 
22.6 (C13), 22.7 (C8), 27.5 (C4), 28.4, 29.0, 31.4, 31.8 and 31.9 (C6, C7, C10, C11, and C12), 49.8 (C3), 
58.8 (C5), 181.0 (C2); LC/MS: m/z calcd for C13H25N+H+:196.21 ; found 196.3. 
 
5-Phenyl-4-pentyl-3,4-dihydro-2H-pyrrole 19k 
Product 19k (1.5 mmol, 75%) was obtained by a similar procedure as 
for 19a. 1H NMR (400 MHz, CDCl3):  0.84 (3H, t, J 7.0, H16), 1.19–1.34 
(6H, m, H13, H14 and H15), 1.64 (2H, m, H12),1.82 (1H, m, H4a), 2.14 (1H, 
m, H4b), 3.33 (1H, m, H3), 3.92 (1H, m, H5a), 4.03 (1H, m, H5b), 7.39 (3H, 
m, H8, H9 and H10), 7.77 (2H, m, H7 and H11); 13C NMR (100 MHz, 
CDCl3):  14.0 (C16), 22.6 (C15), 27.5 (C4), 29.1, 31.8, 32.0 (C12, C13 and C14), 47.3 (C3), 58.8 (C5), 
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127.8 (2C, C7 and C11), 128.4 (2C, C8 and C10), 130.0 (C9) 176.7 (C2); LC/MS: m/z calcd for 
C15H21N+H+:216.17 ; found 216.3.  
2.3. Synthetic route toward other analogues of H2MAP 
1,5-Dihydro-2H-pyrrol-2-one 45 
To a solution of NH4Cl (6.2g 115 mmol, 5 eq.) in H2O (18 ml), 2,5-dimethoxy-3,4-
dihydrofuran (3 g, 23 mmol, 1 eq.) was added. The mixture was stirred at r.t. for 1 
h. NaHCO3 was added until pH = 7. EtOAc (20 ml) was added and the mixture 
was filtered. The aqueous layer was extracted with EtOAc (2 x 20 mL). The extracts were 
concentrated under reduced pressure to give 1,4 g of a brown liquid. Column chromatography 
was performed (EtOAc then EtOAc/ MeOH 9:1) to give 45 (0.7 mmol, 3%). 1H NMR (400 MHz, 
CDCl3)  4.02 (2H, m, H5), 6.13 (1 H, m, H3), 7.14 (1H, m, H4); LC/MS: m/z calcd for C4H5NO: 
83.04; found 83.1. 
tert-Butyl 2-oxo-2,5-dihydro-1H-pyrrole-1-carboxylate 46 
To a solution of 45 (40 mg, 0.48 mmol, 1 eq.) in THF (0.69 ml), DMAP (4.3 
mg, 0.04 mmol, 0.1 eq.), dissolved in THF (0.1 mL), was added followed by 
(Boc)2O (152mg, 0.69 mmol, 1.5 eq.). The mixture was stirred for 20 min at 
r.t. It was concentrated under reduced pressure, diluted in EtOAc (2 mL), 
washed with NH4Cl sat. (2x5mL) and water (2 x 5 mL). The aqueous layers were extracted with 
EtOAc (2 x 10 mL). The organic layers were gathered, dried (MgSO4) and concentrated under 
reduced pressure to give 46 (0.32 mmol, 68%) as a black oil. 1H NMR (400 MHz, CDCl3)  1.48 
(9H, s, H11, H12 and H13), 4.28 (2H, t, J 2.0, H5), 6.09 (1 H, dt, J 3. & 2.0 Hz H4), 7.15 (1H, dt, J 3.0 
& 2.0 Hz H3); 13C (100 MHz, CDCl3),  28.0 (C11, C12 and C13), 52.0 (C5), 82.8 (C10), 128.2 (C3), 
145.4 (C4), 149.7 (C6), 169.2 (C2). 
tert-Butyl 4-ethyl-2-oxopyrrolidine-1-carboxylate 43 
CuI (62 mg, 0.33 mmol, 1 eq.) was suspended in dry THF (0.6 ml) under N2 and cooled at -78°C. 
EtLi (0.5 M in benzene, 1.3 ml, 0.65 mmol, 2 eq.) was added and the mixture was stirred for 1 h. 
46 (60 mg, 0.33 mg, 1 eq.) dissolved in dry THF (0.18 ml) was then added. The mixture was 
stirred for 1 h at -78 °C and 2 h at 0 °C. Hydrochloric acid (1 M; 0.6 ml) was added. The aqueous 
layer was extracted with hexane and the combined organic layers were washed with water, dried 
(MgSO4) and concentrated under reduced pressure. No pure product could be isolated. 
3-Bromooctan-2-one 48a 
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A RBF was charged with 2-octanone (5 g, 39 mmol) 47 and CHCl3 (40 ml). 
NH4OAc (300 mg, 0.1 eq.) was added, followed by N-bromosuccinimide (NBS) 
(7g, 39 mmol). The mixture was heated at 80 °C and stirred for 24 h. Hexane 
(40 ml) was added and the mixture was filtered. The filtrate was washed with 
sat. aq. NaHCO3 and brine. The organic layer was dried (MgSO4) and the solvent 
removed under reduced pressure. The mixture was purified by flash column 
chromatography EtOAc/hexane, 1:9 leading to a mixture 9:1 MC21/1-bromooctanone 48b. (1.285 
g, 6.2 mmol, 16%). Pure 48a was recovered from kinetic resolution. 1H NMR (400 MHz, CDCl3): 
 0.90 (3H, t, J 7.0 Hz, H8), 1.27-1.40 (5H, m, H7,H6, H5a), 1.5 (1H, m, H5b) 1.85-2.08 (2H, m, H4), 
2.37 (3H, s, H1), 4.24 (1 H, t, J 7.0 Hz, H3); 13C NMR (100 MHz, CDCl3, HMQC and HMBC used 
for assignments): 13.9 (C8), 22.4 (C7), 26.0 (C1), 26.9 (C5), 31.1 (C6), 33.5 (C4), 54.4 (C3), 202.19 
(C2) IR (neat): max 2929m, 2860m, 1716s (C=O) LC-MS: m/z calcd for C8H15BrO+H+: 209.04; 
found: 209.08 
1-bromooctanone 48b  
1H NMR (400 MHz, CDCl3)  0.88 (3H, t, J 7.0 Hz, H8), 1.27-1.36 (6H, 
m, H5, H6 and H7), 1.61 (2H, m, H4), 2.65 (2H, t, J 7.0 Hz, H3), 3.88 
(2H, s, H1)  
 
Kinetic resolution: A mixture of 48a and 48b (approximately 
9:1, 1 g, 4,8 mmol, 1 eq.) was dissolved in acetone (5 ml) along 
with K2CO3 (0.5 g, 3.6 mmol, 0.75 eq.) and dimethylmalonate 
(300 µl, 2 mmol, 0.4 eq.). The mixture was stirred at 60 °C for 
2 h. DCM (15 ml) was added and the mixture was washed with 
brine. The organic layer was dried (MgSO4), concentrated under reduced pressure and purified 
by flash column chromatography, giving pure 48a (846 mg, 4 mmol, 90% recovery). 51 was 
isolated, but it was not quantified. 1H NMR (400 MHz, CDCl3)  0.88 (3H, t, J 7.0 Hz, H8), 1.25-
1.29 (6H, m, H5, H6 and H7), 1.58 (2H, m, H4), 2.45 (2H, t, J 7.0 Hz, H3), 3.04 (2H, d, J 7.0 Hz, 
H1), 3.7 (6H, s, H13), 3.90 (1H, t, J 7.0 Hz, H10)  
3-(Triphenyl-5-phosphanylidene)octan-2-one 49a 
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To a solution of 48a (500 mg, 2.4 mmol) in toluene (5 ml) PPh3 (650 mg, 
2.4 mmol) was added under N2. The mixture was stirred at 80 °C 
overnight. After cooling to r.t. the mixture was filtered and the filtrate was 
concentrated under reduced pressure. The residue was diluted in DCM (20 
ml) and stirred vigorously with aq. NaOH (1 M; 5.2 ml) at r.t. for 1 h. The 
mixture was extracted with DCM and washed with brine. The organic layer 
was dried (MgSO4) and concentrated under reduced pressure. After purification by flash column 
chromatography (PET/EtOAc then MeOH/DCM), 49a was obtained (17 mg, 2%). 1H (400MHz, 
CDCl3)  0.73 (3H, t, J 7.0 Hz, H1), 0.94-1.10 (4H, m, H2 and H3), 1.19 (2H, tt, J 7.0 & 8.0, H4), 1.90 
(2H, ddd, J 8.0 & 10.0 & 22.0 Hz, H5), 2.13 (3H, s, H8), 7.40-7.49 (6H, m, H10), 7.50-7.62 (9H, m, 
H11 and H12); 13C (100 MHz, CDCl3)  14.05 (C1), 21.69 (C8), 22.14 (C2), 23.65 (m, C6), 28.20 (d, J 
14 Hz, C5), 31.53 (C3), 33.74 (C4), 128.60 (d, J  11.0 Hz, C10), 131.62 (C12) ,133.57 (d, J 8.0 Hz, C11), 
174 .13 (C7); 31P (160.16 MHz, CDCl3) 18.18; IR (neat): max 3061w, 2925m, 2954m, 1509s (C=O), 
1104 (P-Ph) cm-1; LC-MS m/z calcd for C26H29OP+H+ 389.2, found 389.3 
1-(Triphenyl-5-phosphanylidene)octan-2-one 49b 
A mixture of 48a and 48b was submitted to the same conditions as for 
the formation of 49a. 49b was isolated after flash column 
chromatography (23 mg, 0.06 mmol, 1%). 1H NMR (400 MHz, CDCl3),  
0.87 (3H, t, J 13.0 Hz, H1), 1.25-1.40 (6H, m, H2, H3 and H4), 1.66 (2H, tt, 
J 7.0 & 8.0 Hz, H5), 2.30 (2H, t, J  8.0 Hz, H6), 7.44 (6H, m, H11), 7.52 
(3H, t, J 7.0 Hz, H12), 7.64 (6H, dd, J 8.0 & 12.0 Hz, H10); 13C NMR (100 MHz, CDCl3) : 14.1 (C1), 
22.7 (C2), 27.2, 29.4, 31.9 (C3, C4 and C5), 41.8 (d, J 14.0 Hz, C6), 51.0 (d, J 102.0 Hz, C8), 127.4 (d, 
J 90.0 Hz, C9), 128.8 (2C, d, J 14.0 Hz, C11), 131.9 (C12), 133.1 (2C, d, J 11.0 Hz, C10), 194.3 (C7)  
tert-Butyl 3-(4-hydroxy-3-methoxyphenyl)acrylate (E+Z) 55 
 
Vanillin (100 mg, 0.67 mmol, 1 eq.) in solution in dry THF (2 ml) was added dropwise to a 
solution of tert-butyl 2-(triphenyl-5-phosphanylidene)acetate 53 (252 mg, 0.67 mmol, 1 eq.) in 
THF (2 ml) under N2. The mixture was stirred at r.t. for 16 h. Solvent was removed under reduced 
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pressure and a flash column chromatography (hexane/EtOAc) gave (E)-55 (47mg, 28%) and (Z)-
55 (40 mg, 24%). (E)-55: 1H (400MHz, CDCl3)  1.52 (9H, s, H12), 3.91 (3H, s, H1), 6.22 (1H, d, J 
16.0 Hz, H9), 6.90 (1H, d, J 8.0 Hz, H4), 7.00-7.06 (2H, m, H7 and H5), 7.51( 1H, d, J 16.0 Hz, H8); 
13C (100 MHz, CDCl3)  28.24 (C12), 55.93 (C1), 80.29 (C11), 109.23 (C7), 114.67 (C4), 117.63 (C9), 
122.89 (C5), 127.49 (C6), 143.64 (C8), 146.75 (C2), 147.70 (C3), 166.63 (C10); IR (neat): max 3379br, 
2977m, 2934m, 1692m (C=O), 1511 M, 1267s, 1204m, 1145s cm-1; HR-MS m/z calcd for C14H18O4  
273.11, found 273.11. 
(Z)-55:  1H (400 MHz,CDCl3), 1.47 (9H, s, H12), 3.90 ( 3H, s, H1), 5.75 (1H, d, J 13.0 Hz, H9), 6.71 
(1H, d J 13.0 Hz, H8), 6.87 (1H, d J 8.0 Hz, H4), 7.07 (1H, dd, J 8.0, 1.9 Hz, H5), 7.45 (1H,m, H7); 
13C (100 MHz, CDCl3)  28.11 (C12), 55.93 (C1), 80.36 (C11), 112.51 (C7), 113.82 (C4), 119.31 (C9), 124.84 
(C5), 127.26 (C6), 141.70 (C8), 145.87 (C2), 147.17 (C3), 166.09 (C10); IR (neat): max 3438br, 2977m, 
2934m, 1706m (C=O), 1514m, 1276m, 1209m, 1140s cm-1 
tert-Butyl 3-(4-hydroxy-3-methoxyphenyl)-4-nitropentanoate 56 
DBU (3 µl, 0.02 mmol, 1 eq.) was added to a solution of nitroethane 
(2 µl, 0.03 mmol, 1.5 eq.) and 55 (5mg, 0.02 mmol, 1 eq.) in ACN 
(0.2 ml). The mixture was stirred 24 h at r.t. and water (1 ml) was 
added dropwise. The mixture was acidified to pH2 with HCl (1 M) 
and extracted with DCM. The organic layer was dried (MgSO4). The crude was mainly consistent 
with 55 but proton NMR was consistent with a partial conversion (approx. 10%) to 56. Isolation 
was unsuccessful. 1H NMR (partial, 400 MHz, CDCl3),  1.47 (9H, s, H12), 3.0 (1H, m, H8), 3.5 (3H, 
m, H1), 4.1 (1H, q, J 7.0 Hz, H13) 
  
Chapter 7: Materials and Methods 
142 
 
2.4. Racemic resolution of H2MAP 
2-Methyl-3-pentylpyrrolidine 59 
H2MAP 19a (100 mg, 0.65 mmol, 1 eq.) was dissolved in MeOH/H2O 
(4:1, 15 ml) in a RBF. NaBH4 (30mg, 0.81 mmol, 1.2 eq.) were added in 
small quantity with vigorous stirring at r.t. The mixture was stirred at 
r.t. under N2 overnight. The mixture was cooled on an ice bath and 1 M HCl was added slowly to 
pH 2. The mixture was stirred 1 h at r.t. The pH was adjusted to 13 with 3M NaOH and the 
product was extracted with DCM. The organic phase was dried (MgSO4) and concentrated under 
reduced pressure to give 59 (60 mg, 59%). Main diastereomer: 1H NMR (400 MHz, CDCl3):  
0.88 (3H, t, J 7.0, H11), 1.15 (3H, d, J 6.0, H6), 1.2-1.5 (10H, m, H4a, H3, H7, H8, H9 and H10), 1.98 
(1H, m, H4b), 2.4 (1H, s, H1), 2.6 (1H, m, H2), 2.88 (1H, m, H5a) 3.01 (1H, m, H5b);  13C NMR (100 
MHz, CDCl3, HMQC used for assignment):  14.26 (C11), 20.05 (C6), 22.73, 28.35, 32.22, 33.5 (C7, 
C8, C9 and C10), 32.95 (C4), 45.29 (C5), 47.38 (C3), 60.49 (C2); Minor diastereomer 1H NMR (400 
MHz, CDCl3):  1.15 (d, J 7.0, H6), 3.23 (1H, m, H2); 13C NMR (100 MHz, CDCl3):  16.25 (C6), 
29.84, 30.74 (pentyl), 42.65 (C4), 44.70 (C5), 56.16 (C2); IR (neat): max 2934m, 2923m, 2856m, 
1634w (N-H bend), 1457m, 1376m (C-N); LC-MS m/z calcd for C10H21N+H+ 156.18; found 156.16 
(R)-3,3,3-Trifluoro-2-methoxy-2-phenylpropanoyl chloride 62 
 (R)-Mosher’s acid 61 (30 mg, 0.1 mmol, 1 eq.) and thionyl chloride (0.4 ml, 5 
mmol, 50 eq.) were mixed in CDCl3 (0.4 ml) and heated at 80 °C. The 
reaction was monitored by NMR. After 24 hr a complete conversion was 
observed, and volatile species were removed under reduced pressure. 1H 
NMR (400 MHz, CDCl3):  3.76 (3H, s, H12), 7.41-7.46 (3H, m, H2, H4 and H6), 7.56, (2H, m, H1 
and H3);  13C NMR (100 MHz, CDCl3)  56.6 (C12), 127.0 (C4 and C6), 128.8 (C1 and C4), 130.5 (C2), 
171.1 (C8); 19F NMR (376 MHz, CDCl3):  -71.8; IR (neat): max 2953w, 1788m (C=O) ,1260m, 1168s 
(C-F), 706s (C-Cl) cm-1 
(2R)-3,3,3-Trifluoro-2-methoxy-1-(2-methyl-3-pentylpyrrolidin-1-yl)-2-phenylpropan-1-one 60 
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Amine 59 (30 mg, 0.2 mmol, 1 eq.) was dissolved in DCM (2ml) 
and added.to 62 (50 mg, 0.2 mmol, 1 eq.). The mixture was stirred 
at r.t. overnight. The resulting mixture was diluted in 5 ml of 
saturated aq. NaHCO3 and then extracted with DCM. The organic 
phase was dried (MgSO4) and the solvent removed under reduced 
pressure to give 60 (70 mg, 94%).1H NMR (400 MHz, CDCl3):  
0.89 (3H, t, J 7.0, H19), 1.08 (2H, m, H20), 1.14-1.34 (9H, m, H16, H21, 
H22 and H23), 1.40 (1H, m, H14a) 1.62 (1H, m, H5), 1.88 (1H, m, H14b), 2.03 (1H, m, H12), 2.99 (2H, 
m, H15), 3.49 and 3.54 (3 H, 2 x s, H17: not a doublet but one peak for each enantiomer), 7.32, 
7.46, 7.66 (H1, H2, H3, H4 and H6); 13C NMR (100 MHz, CDCl3, ATP used for assignment):  14.02 
(C19), 22.53 (C20), 27.70 (C21), 28.49 (C22), 30.64 (C23), 31.69 (C14), 43.00 (C15), 45.24 (C13), 54.88 
(C17), 59.96 (C12), 127.75-128.93 (C1, C2, C3, C4 and C6) 130.53 (C18), 135.90 (C5), 170.59 (C9); UV 
Peaks at 317 and 263 nm 
2.5. Tetrazine coupling 
4-((5-Methyl-3,4-dihydro-2H-pyrrol-4-yl)methyl)-3,6-di(pyridin-2-yl)-4,5-dihydropyridazine 
65 
19d (0.2 mol, 1 eq.) in solution in DMSO (200 µl) was mixed with Py2Tz 
64 (300 µl, 0.4mg/34 µl in DMF, 15 µmol, 70 eq.) in PBS buffer (1 ml). 
The mixture was stirred at r.t. for 48h and monitored by LC-MS. After 
24 hr a colour change was visible. After 48h, LC-MS was consistent with 
a 70% conversion. The mixture was diluted in EtOAc and washed with 
brine. The organic layer was dried and concentrated, but 65 could not be isolated pure. 
  
Chapter 7: Materials and Methods 
144 
 
2.6. Synthesis of PigE potential substrates 
Method A 
 
Method B 
 
 
Ethyl 2-acetylheptanoate 72 
Dry EtOH (0.6 ml) was added to Na (20 mg, 0.86 mmol, 1.1 eq.) under 
N2. After the first intense reaction, the mixture was heated to 60°C. After 
the total disappearance of Na, ethyl acetoacetate (100 mg, 0.77 mmol, 1 
eq.) was added slowly, followed by 1-iodopentane (182 mg, 0.91 mmol, 
1.2 eq). The solution was heated at reflux (80 °C) and stirred for 4 h, 
cooled and evaporated to dryness. The residue was partitioned between DCM and water. The 
organic phases were combined, dried (MgSO4) and evaporated. Purification by flash column 
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chromatography eluting with EtOAc 3% in hexane gave product 72 (109 mg, 50%). 1H NMR (400 
MHz, CDCl3):  0.87 (3H, t, J 7.0, H14), 1.22–1.31 (9H, m, H9, H11, H12 and H13), 1.73–1.88 (2H, m, 
H10), 2.20 (3H, s, H1), 3.35 (1H, t, J 7.0, H3), 4.15 (2H, q, J 7.0, H8); 13C NMR (100 MHz, CDCl3):13.3 
(C14), 14.1 (C9), 22.3 (C13), 27.1 (C10), 28.2 (C1), 28.7 and 31.4 (C11 and C12), 60.0 (C3), 61.2 (C8), 170.0 
(C5), 203.4 (C2) ; HRMS: m/z calcd for C11H20O3+H+: 201.1491 ; found 201.1487 
Ethyl 2-acetyl-2-allylheptanoate 73 
Na (180 mg, 7.74 mmol, 1.3 eq.) were dissolved under N2 in EtOH (4.8 ml) 
at r.t. and then heated up to 60°C. 72 (1.2 g, 6 mmol, 1 eq.) was added 
slowly, followed by allyl bromide (0.75 ml, 8.75 mmol, 1.45 eq.) and the 
mixture was stirred at 60°C for 2 h. A white precipitate appeared. The 
mixture was filtered and the solvent removed under reduced pressure. The 
residue was partitioned between water and DCM and the organic layer was dried (MgSO4) and 
the solvent removed under reduced pressure. Purification by flash chromatography 
(hexane/acetone 9:1) gave product 73 (870 mg, 60%). 1H NMR (400 MHz, CDCl3):  0.86 (3H, t, 
J 6.9 Hz, H14), 1.10 (2H, t, J 7.0 Hz, H9), 1.21–1.27 (7H, m, H11, H12 and  H13), 1.75-1.92 (2H, m, H10), 
2.11 (3 H, s, H1), 2.60 (1H, dd, J 8.0 & 15.0, H15a), 2.58 (1H, dd, J 8.0 & 15.0,H15b), 4.19 (2H, q, J 7.0, 
H8), 5.03 (1H, d, J 10.0, cis-H17), 5.07 (1H, d, J 17.0, trans-H17), 5.58 (1H, ddt, J 17.0 &  10.0 & 8.0, 
H16); 13C NMR (100 MHz, CDCl3, ATP used for assignments):  13.86, 14.04 (C9 and C14), 
22.27(C13), 23.19 (C12), 26.24 (C1), 31.25 (C10), 32.10 (C15), 35.8 (C11), 61.2 (C8), 63.4 (C3), 118.8 (C17), 
132 .6 (C16), 172.1 (C4), 204.8 (C2) ; HRMS: m/z calcd for C14H24O3+H+: 241.1804; found: 241.1798. 
3-Allyloctan-2-one 74 
Ester 73 (1.9 g, 7.9 mmol, 1 eq.) was dissolved in MeOH/H2O (4:1, 22.8 ml) 
and 1.3 g of KOH (1.3 g, 23.2 mmol, 3 eq.) was added. The mixture was stirred 
at 80°C overnight. H2SO4 was added until pH<5. Extraction with DCM and 
the organic layers were washed with aq. NaOH (1 M), dried (MgSO4) and the 
solvent was removed under reduced pressure. Purification by flash column 
chromatography (hexane/EtOAc 5:1) gave 74 (993 mg, 84%). 1H NMR (400 MHz, CDCl3):  0.87 
(3H, t, J 7.0 Hz, H9), 1.19–1.35 (6H, m, H6, H7 and H8), 1.42 (1H, m, H5a), 1.53–1.65 (1H, m, H5b), 
2.12 (3H, s, H1), 2.19 (1H, m, H10a), 2.30 (1H, m, H10b), 2.53 (1H, tt, J 6.0 & 8.0 Hz, H4), 4.97 (1H, 
d, J 10.0 Hz, cis-H12), 5.03 (1H, d, J 17.0 Hz, trans-H12), 5.70 (1H, ddt, J 17.0 & 10.0 & 7.0 Hz, H11); 
13C NMR (100 MHz, CDCl3):  13.94 (C9), 22.42 (C8), 26.86 (C5), 29.10 (C1), 31.11 (C6), 31.83(C10) 
35.71 (C7), 52.70 (C4), 116.61(C12), 135.62 (C11), 212.16 (C2); HRMS: m/z calcd for C11H20O+H+: 
169.1592; found: 169.1592 
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2-Allylheptanoic acid 74b 
Instead of the decarboxylated product, a deacetylated produced was 
sometimes formed during 74 synthesis. Its formation is the result of a retro 
Claisen mechanism. 1H NMR (400 MHz, CDCl3):  0.87 (3H, t, J 7.0 Hz, 
H8), 1.19–1.39 (6H, m, H9, H10 and H11), 1.49 (1 H, m, H12a), 1.61 (1H, m, H12b), 
2.24 (1H, m, H5a), 2.30-2.45 (2H, m, H3 and H5b), ,5.01 (1H, d, J 10.0 Hz, cis-H7), 5.06 (1H, d, J 
17.0 Hz, trans-H7), 5.76 (1H, m, H6). 
Dimethyl 2-(2-oxooctan-3-yl) malonate 77 
Dimethyl malonate (487µl, 4.2 mmol, 1 eq.) and K2CO3 (750 mg, 13.4 mmol, 
3.2 eq.) were added to 48 (1.5 g, 7.2 mmol, 1.7 eq.) in acetone (7.5 ml). The 
mixture was stirred at 80 °C overnight. DCM (20 ml) were added and the 
organic phase was washed with H2O and brine. The organic phase was dried 
(MgSO4) and the solvent removed under reduced pressure. Purification by 
flash column chromatography (hexane/EtOAc) gave 77 (755 mg, 2.9 mmol, 
40%). 1H NMR (400 MHz, CDCl3):  0.87 (3 H, t, J 6.0 Hz, H9), 1.2-1.34 (6H, m, H6, H7, H8), 1.52 
(2H, m, H5), 2.28 (3H, s, H1), 3.34 (1H, dt, J 11.0 & 6.0 Hz, H4), 3.69 (3H, s, H13 or H17), 3.75 (3H, 
s, H13 or H17), 3.83 (1H, d, J 11.0 Hz, H10) 13C NMR (100 MHz, CDCl3, HMQC and HMBC used for 
assignments)  13.9 (C9), 22.8 (C8), 25.6 (C6), 29.0 (C5), 30.5 (C1), 31.8 (C7), 50.6 (C4), 52.7 (C13 
and C17), 53.1 (C10), 169 (C11 and C15), 209.9 (C2);  IR (neat): max 2955w, 2862w, 1735s (C=O), 1713 
(C=O), 1265m, 1226m, 1151s (C-O) LC-MS: m/z calcd for C13H22O5+Na+: 281.14; found: 281.14 
Methyl 3-acetyloctanoate 79 
77 (191 mg, 0.74 mmol, 1 eq.), NaCl (120 mg, 2 mmol, 2.7 eq.), and H2O (54 l, 
3 mmol, 4 eq.) in DMSO (12 ml)) were stirred at 160 °C under a condenser for 
16 h. The mixture was diluted in EtOAc (20 ml) and washed with water and 
brine. The aqueous phase was reextracted with EtOAc. The organic layers were 
dried (MgSO4) and evaporated under reduced pressure, giving 79 (110 mg, 0.55 
mmol, 74%). 1H NMR (400 MHz, CDCl3):  0.88 (3H, t, J 12.0 Hz, H9), 1.26 
(6H, m, H6, H7 and H8), 1.41 (1H, m, H5a), 1.60 (1H, m, H5b), 2.23 (3H, s, H1), 2.35 (1H, dd, J  17.0 
& 4.0 Hz, H10a), 2.73 (1H, dd, J  17.0 & 10.0 Hz, H10b), 2.98 (1H, m, H4), 3.64 (3H, s, H14); 13C NMR 
(100 MHz, CDCl3)  14.0 (C9), 22.4 (C8), 26.6 (C6), 29.5 (C1), 31.3 (C5), 31.7 (C7), 34.9 (C10), 47.9 
(C4), 51.7 (C14), 173.0 (C11), 211.1 (C2). 
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2-(1-Oxooctan-3-yl) malonic acid 78 
KOH (67.2 mg, 1.2 mmol, 15 eq.) in solution in MeOH/H2O 4:1 (1 ml) was 
added to 77 (20 mg, 0.077 mmol, 1 eq.) and the mixture was stirred at 60°C 
overnight. The mixture was washed with DCM, acidified to pH 2 with HCl 1 
M and extracted with DCM. The organic layer was dried (MgSO4) and 
concentrated under reduced pressure to give 78 (15 mg, 0.065 mmol, 84%) 
1H NMR (400 MHz, D2O)  0.76 (3H, t, J  7.0 Hz, H9), 1.18 (6H, m, H6, H7 and 
H8), 1.55 (2H, m, H5), 1.96 (3H, s, H1), 3.08 (1H, m, H4), 3.67 (1H, d, J 10.0 Hz H10); 13C NMR (100 
MHz, D2O)  13.1 (C9), 21.7, 28.2, 30.9 (C6, C7, C8), 25.6 (C1), 53.5 (C10) 
3-Pentylpentane-1,4-diol 80 
LiAlH4 (1 M in THF, 2.1 ml, 2.1 mmol, 4 eq.) was cooled to 0°C. 69 (100mg, 0.53 
mmol, 1 eq.) in THF (1.25 ml) was added dropwise. The reaction was allowed to 
reach r.t. and stirred o/n. H2O (75 µl), NaOH (15% in H2O, 75 µl) and H2O (225 
µl) were added slowly at 0°C. The cold bath was removed, and the reaction 
stirred for 1 more hr. The mixture was diluted in THF, dried (MgSO4) and 
concentrated under reduced pressure to give 80 (80 mg, 0.46 mmol, 87%). 
NMR 1H(400 MHz, CDCl3) : 0.88 (3H, t, J 7.0 Hz, H9), 1.15 and 1.21 (3H, d, J 6.0 Hz, H1), 1.23-
1.35 (8H, m, H5, H6, H7 and H8), 1.46 (1/2H, m, H4a),  1.5-1.58 (1/2H, m, H10a1), 1.6-1.68 (1 H, m, 
H10a2 and H4b), 1.74-1.79 (1H, m, H10b), 3.65 (1H, m, H11a), 3.77 (1.5 H, m, H11b, H2a), 3.9 (m, 1/2H, 
H2b); 13C NMR (100 MHz, CDCl3)  14.1 (C9), 18.5 and 21.3 (C1), 22.62 (C8), 26.9 and 27.4 (C5), 
30.8 and 31.0 (C6), 32.1 and  32.2 (C7), 32.4 and 32.6 (C10), 43.2 and 43.3 (C4), 60.6 and 61.7 (C11), 
70.1 (C2); IR (neat): max 3306br (O-H), 2925s, 2857s, 1052s (C-O)  
3-Acetyloctanal 20 
Method A: Alkene 74 (990 mg, 5.9 mmol) was dissolved in DCM (15 ml). O3 
was bubbled in the solution until the solution turned blue. The ozonolizer 
was turned off and O2 was bubbled in the solution until the blue colour 
disappeared. The mixture was poured into a suspension of Zn in DCM (15 
ml) at 0 °C. Acetic acid (1 ml) was added slowly, and the solution was allowed 
to reach r.t. and to stir overnight. The mixture was filtered and washed with 
sat. aq, NaHCO3 and brine. The organic phases were dried (MgSO4) and the 
solvent was removed under reduced pressure. Product 20 was obtained (955 mg, 95%). 
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Method B: oxalyl chloride (675 µl, 7.8 mmol, 4.5 eq.) was added dropwise to a stirred solution 
of DMSO (755 µl, 10.6 mmol, 9 eq.), in DCM (10 ml) at -78°C. the mixture was stirred 10 min at 
-78°C and diol 80 (300 mg, 1.7 mmol, 1 eq.) in solution in DCM (5 ml) were added dropwise. 
The mixture was stirred a further 10 min at -78 °C. Et3N was added and the reaction was stirred 
at r.t. for approximately 30 min. The mixture was diluted in Et2O (20 ml) and washed with brine. 
The organic layer was dried (MgSO4) and concentrated under reduced pressure. Purification by 
flash column chromatography gave 20 (250 mg, 1.5 mmol, 88%) 1H NMR (400 MHz, CDCl3):  
0.87 (3H, t, J 7.0 Hz, H9), 1.22(6H, m, H6, H7 and H8), 1.42 (1H, m, H5a), 1.58(1H, m, H5b), 2.20 
(3H, s, H1), 2.45 (1H, dd, J 4.0 & 18.0 Hz, H10a), 2.92 (1H, dd, J 10.0 & 18.0 Hz, H10b), 3.02 (1H, m, 
H4), 9.70 (1H, s, H13); 13C NMR (100 MHz, CDCl3, HBQC used for assignments):  14.0 (C9), 22.4 
(C8), 26.6 (C6), 29.4 (C1), 31.2 ( C5), 31.7 (C7), 44.9 (C10), 45.9 (C4), 200.7 (C11), 210.7 (C2) ; IR 
(neat): max 2957m, 2958m, 2857m, 2750w (aldehyde C-H), 1713 (C=O); LC-MS: m/z calcd for 
C10H18O2+H+: 171.14; found: 171.14 
3-Acetyloctanoic acid 69 
Method A: NaClO2 80% (180 mg, 1.6 mmol, 1.3 eq.) in solution in water (2.1 
ml) was added dropwise to a solution of 20 (200 mg, 1.2 mmol, 1 eq.) in ACN 
(1.15 ml), buffered with NaH2PO4 (35 mg, 0.3 mmol) and 35% H2O2 (120 l, 1.2 
mmol, 1 eq.). The temperature was kept under 10°C. The reaction was stirred 
under 10 °C for two hours and Na2SO3 was added to destroy any unreacted 
oxidant. Aq. HCl (1 M) was added until pH=2. The solution turned green. The 
mixture was extracted with DCM. The organic phase was dried (MgSO4) and the solvent 
removed under reduced pressure to give 69 (109 mg, 50%). 
Method B: 79 (110 mg, 0.55 mmol, 1 eq.) was dissolved in MeOH/H2O 4:1 (4 ml) and KOH (270 
mg, 4.8 mmol, 8.7 eq.) was added. The mixture was heated up to 60°C and stirred for 4 hr. 
Hydrochloric acid 1 M was added slowly until pH<2. The mixture was extracted with DCM. 
Analysis of the organic phase showed presence of DMSO from the previous step and unreacted 
79 (less than 10% of the mixture). DCM was removed under reduced pressure and the mixture 
dissolved in NaHCO3 sat. and washed with DCM. The aqueous phase was then acidified by 
adding hydrochloric acid (1 M) an extracted with DCM. The organic extract was then dried, and 
the solvent removed under reduced pressure to give 69 (100 mg, 0.53 mmol, 96%). 1H NMR 
(400 MHz, CDCl3):  0.88 (3H, t, J 7.0 Hz, H9), 1.23-1.34 (6H, m, H6, H7 and H8), 1.42 (1H, m, 
H5a) 1.59 (1H, m, H5b), 2.20 (3H, s, H1), 2.39 (1H, dd, J 17.0 & 4.0 hz, H10a), 2.76 (1H, dd, J 17.0 & 
910.0 Hz, H10b), 2.93 (1H, m, H4); 13C NMR (100 MHz, CDCl3, HMQC used for assignments): 
 14.11 (C9), 22.57 (C8), 26.69 (C7), 29.41 (C1), 31.27 (C6), 31.89 (C5), 35.09 (C10), 47.94 (C4), 177.55 
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(C11), 210.74 (C2); IR (neat): max 2958m, 2928m, 2861 M, 1707s (C=O), 1374 (C-O carboxylic acid); 
UV Absorbance max at 276 nm; LC/MS m/z calcd for C10H18O3-H+: 185.12; found: 185.1. 
S-(2-Acetamidoethyl) 3-acetyloctanethioate 68 
Carboxylic acid 69 (50 mg, 0.27 mmol, 1 eq.) were dissolved in DCM (0.5 ml) 
and cooled on ice. EDC (57 mg, 0.36 mmol, 1.3 eq.) and DMAP (6 mg, 50 nmol, 
0.2 eq.) were added and the mixture stirred on ice for 15 min. N-
Acetylcysteamine (36 mg, 0.3 mmol, 1.1 eq.) was added and the mixture was 
allowed to reach r.t. and was stirred overnight. The solvent was removed under 
reduced pressure and the residue dissolved in CHCl3 (approx. 2 ml) and washed 
with hydrochloric acid (0.1 M) and brine. The aqueous layers were reextracted 
with CHCl3. The organic layers were combined and dried (MgSO4). The solvent 
was removed under reduced pressure. Purification by flash column 
chromatography (DCM/MeOH 9:1) gave 68 (13 mg, 16%).1H NMR (400 MHz, CDCl3):  0.88 
(3H, t, J 7.0 Hz, H9), 1.27 (6H, m, H6, H7 and H8), 1.43 (2H, m, H5), 1.96 (3H, s, H18), 2.21 (3H, s, 
H1), 2.63 (1H, m, H10a), 3.04 (4H, m, H4, H10b and H14), 3.42 (2H, m, H15); 13C NMR (100 MHz, 
CDCl3, HMQC and HMBC used for assignments):  14.09 (C9), 22.54 (C8), 23.30 (C18), 26.64 (C6), 
28.77 (C14), 29.39 (C1), 31.22 (C5), 31.87 (C7), 39.61 (C15), 44.69 (C10), 48.56 (C4), 170.51 (C17), 198.72 
(C11), 210.12 (C2); IR (neat): max  2948m, 2932m, 2854m, 1709s (C=O ketone), 1687s and 1657s 
(C=O amide and thioester), 1541 M (NH bend); LC-MS m/z calcd for C14H25NO3S+H+, 288.16; 
found: 288,16. 
2.7. Synthesis of potential substrate of PigD 
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Methyl (E)-oct-2-enoate (E)-90 
A RBF was charged with methyl 
(triphenylphosphoranylidene)acetate 91 (502 mg, 1.5 mmol, 1.5 
eq.), hexanal (0.12 ml, 1 mmol, 1 eq.) and water. The mixture was 
stirred at r.t. for 1 hr. The mixture was then extracted with DCM and the organic layer was dried 
(MgSO4) and concentrated under reduced pressure. Purification by flash column 
chromatography (hexane/Et2O) gave (E)-90 as a colourless liquid (97 mg, 0.6 mmol, yield 60%). 
1H NMR (400 MHz, CDCl3) : 0.86 (3H, t, J 7.0 Hz, H1), 1.23-1.36 (4H, m, H2 and H3), 1.45 (2H, 
m, H4), 2.19 (2H, m, H5), 3.72 (3H, s, H11), 5.81 (1H, d, J 16.0 Hz , H7), 6.97 (dt, 1H, J  16.0 &  7.0 
Hz , H6);  13C NMR (100 MHz, CDCl3)  13.95 (C1), 22.41, 27.70, 31.42, 32.20 (C2, C3, C4 and C5), 
51.38 (C11), 120.88 (C6), 149.95 (C7)  
Methyl (Z)-oct-2-enoate (Z)-90 
The conditions described for the formation of (E)-90 were repeated with increased 
quantity of hexanal (10 mmol) and ylid (15 mmol). Proton NMR of the crude was 
consistent with the formation of (Z)-90. The product was not isolated, but the 
NMR spectra was consistent with a ratio 1:4 (Z)/(E). The quantity of (Z)-90 could 
then be estimated (260 mg, 1.6 mmol, 16%) 1H NMR (400 MHz, CDCl3) 0.89 (3H, 
t, J 7.0 Hz, H1), 1.3 (6H, m , H2, H3 and H4), 2.6 (2H, qd, J 7.0 & 2.0 Hz, H5), 3.70 (3H, s, H11), 5.76 
(1H, dt, J 11.0 & 2.0 Hz, H7), 6.24 (1H, dt, J 11.0 & 7.0 Hz, H6) 
2-Octenoic acid 89 
LiOH (81 mg, 3.5 mmol, 6 eq.) in H2O (570 µl) was added slowly 
to methyl 2-octenoate E-90 (100 mg, 0.6 mmol, 1 eq.) in solution 
in THF (1.14 ml) and tBuOH (570 µl) at 0°C. The mixture was 
stirred overnight at r.t.. 5 ml of hydrochloric acid (1 M) were added to decrease the pH below 2. 
The mixture was extracted with 3x5ml DCM. The organic layer was dried with MgSO4 and the 
solvent removed under reduced pressure. The crude mixture was redissolved in sat. NaHCO3, 
washed with DCM and the pH was decreased to 2 by adding hydrochloric acid (1 M) before 
extracting with DCM. After drying (MgSO4) and concentrating under reduced pressure, 
carboxylic acid 89 was obtained (42 mg, 0.28 mmol, 47%) NMR 1H(400 MHz, CDCl3)  0.89 
(3H, t, J 7.0 Hz,  H1), 1.25-1.39 (4H, m, H2 and H3), 1.47 (2H, m, H4), 2.22 (2H, dt, J  7.0 & 7.0 Hz, 
H5), 5.82 (d, 1H, J 16.0 Hz, H7), 7.08 (dt, 1H, J  16.0 & 7.0 Hz , H6); 13C NMR (100 MHz, CDCl3) 
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 13.94 (C1), 22.41, 27.54, 31.29,32.28(C2, C3, C4 and C5), 120.42 (C6), 152.52(C7); LC-MS: m/z calcd 
for C8H14O2+H+ 143.21, found 143.2 
3-Octenoic acid 89b 
Demithylmalonate (502 mg, 5 mmol, 2.2 eq.) was added to a stirred 
solution of hexanal (270 µl; 2.25 mmol, 1 eq.) in pyridine (13 ml) and 
piperidine (2 ml). the mixture was stirred at 110 °C for 1h. the mixture 
was cooled to 0 °C in an ice bath and hydrochloric acid (1 M) was added until pH = 2. After 
extraction with DCM, the organic layers were dryied (MgSO4) and concentratedunder reduced 
pressure. Purification by flash column chromatography (hexane/EtOAc, 2:8) gave 89b (55 mg, 
17%). NMR 1H (400 MHz, CDCl3)  0.91 (3H, t, J 7.0 Hz,  H1), 1.24-1.45 (4H, m, H7, H3), 2.07 (2H, 
dt, J  7.0 & 7.0Hz, H4), 3.1 (2H, d, J 7.0 Hz, H7), 5.49-5.67 (2H, m, H5, H6)  
3-Methoxyoctanoic acid 89c 
LiOH (162 mg, 5.5 mmol, 3 eq.) in solution in H2O (1.14 ml) was 
added slowly to a solution of ester (E)-90 in THF (2.28 ml) and 
MeOH (1.14 ml) at 0 °C. The mixture was stirred overnight at r.t. 
After a wash with DCM, th pH was decreased to 2 with hydrochloric acid (1 M) and the product 
was extracted with DCM. The organic layer was dried (MgSO4) and concentrated under reduced 
pressure. NMR was consistent with a mixture of 89 and by-product 89b (ratio 4:1) but they could 
not be separated. NMR 1H (400 MHz, CDCl3)  2.56 (2H, m, H7), 3.41 (3H, s, H11), 3.66 (1H, m, 
H6); The rest of the protons were hidden in the spectra of the main carboxylic acid. 
S-(2-Acetamidoethyl) (E)-oct-2-enethioate 70 
2-octenoic acid 89 (34 mg, 0.24 mmol, 1 eq.) in DCM 
was poured in a dry flask under N2. At 0 °C N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (EDC HCl) (50 mg, 0.26 mmol, 1.1 eq.) 
and DMAP (0.05 eq.) were added. The mixture was stirred at 0°C for 15 min. H-SNAC was added 
and the mixture was allowed to reach r.t. The mixture was stirred overnight. The solvent was 
removed under reduced pressure and the crude redissolved in chloroform. The solution was 
washed with hydrochloric acid (10 mM) and brine. The organic layer was dried (MgSO4) and the 
solvent removed under reduce pressure. Purification by flash column chromatography gave 70 
(19 mg, 0.08 mmol, 30%) NMR 1H(400 MHz, CDCl3)  0.88 (3H, t, J 7.0 Hz, H12), 1.29 (4H, m, 
H13 and H14), 1.46(2H, tt, J  7.0 & 7.0 Hz, H15),1.95 (3H, s, H10), 2.19 (2H, dt, J 7.0 & 7.0 Hz, H16), 
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3.08 (2H, t, J 6.0 Hz, H6), 3.44 (2H, dt, J 6.0 & 6.0 Hz , H7), 6.11 (1H,d, J 15.0 Hz, H2), 6.92 (1H, 
dt, J 7.0 & 15.0 Hz, H1); 13C NMR (100 MHz, CDCl3)  13.91 (C12), 22.39 (C13), 23.20 (C10), 27.58 
(C15), 28.23 (C6), 31.31 (C14), 32.20 (C16), 39.82 (C7), 128.27 (C2), 146 (C1), 170.26 (C9), 190.41 (C3);  
LC-MS: m/z calcd for C12H21NO2S+H+: 244.14; found: 244.14 
2-(Triphenyl-l5-phosphanylidene)acetaldehyde 93 
A mixture of CHCl3 (2 ml) and chloroethanal 92 (45% in H2O, 160 mg, 0.92 
mmol, 1 eq.) were distilled at 73 °C to remove the water. When approx. 1.6 ml 
of the azeotrope had been removed, triphenylphosphine (260 mg, 0.92 
mmol, 1 eq.) was added to the yellow solution and the mixture was heated at 
reflux for 24 h. The solvent was removed under reduced pressure and the 
crude dissolved in water and washed with CHCl3. Activated charcoal was added and the mixture 
stirred for 30 min before removing the charcoal by filtration. NaOH (1 M) was added dropwise 
under vigorous stirring until pH 12. The resulting precipitate was filtered and dried (86 mg). No 
further purification was performed.  1H NMR (400 MHz, CDCl3)  3.67 (1H, dd, J 25.0 & 4.0 Hz, 
H2), 7.45-7.70 (15H, m, H3, H4 and H5), 8.96 (1H, dd, J 38.0 & 4.0 Hz, H1); 13C NMR (100 MHz, 
CDCl3)  54.7 (d, J 98.0 Hz, C2) 129.1, 132.3, 133.4 (C3, C4 and C5), 181.8 (C1); LC-MS: m/z calcd for 
C20H17NaOP+H+: 327.3, found 327.1 
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Appendix 
1. Bioinformatic of PigE 
1.1 Phyre alignement 
>PigE 1 MKFGFIAHPTSVGLKRYVKMIDLLQRNSTELHSGYKRDLWRRENLVPFMNFAKITSATGA 
>UniRef50_Q2S9J6         1 MKFGFIGHPTSIGLKRYVKMLDLLDRSSRDLQVGYQRDIWSHRNLVPFVDFGRIQSPAGV 
>UniRef50_A4FH75 1 MKFGFLAHPVNTGQRNYVRAAALLSSMADERTGRAPSGAARHT--VPMPMFGTVVSATGH 
>UniRef50_Q2LW66 1 ------------------------------------------------------------ 
    
>PigE 61 TCEGVIKYMPLVADEMLADARGIANRVVSGIEELVEDGAELVGLGGFTSIVGRRGEATAE 
>UniRef50_Q2S9J6         61 SCEGIVHYLPLTAEEMLSTPRAVQQRIFEGIESLQAQGAQLVGLGGFTSIIGKRGLVTAE 
>UniRef50_A4FH75 61 RCEGDLRYLPHTAEDLLRRATDAVDHVVAQVEDLRRAGAQLVGLGGATSIVGNRGLTTQR 
>UniRef50_Q2LW66 61 ------------------------------------------------------------ 
    
>PigE 121 KSPVPVTSGNSLTTYAGYKALMQIQSWLDIQPEQEPVAIVGYPGSICLALSRLLLAQGFS 
>UniRef50_Q2S9J6         121 RAGIPVTSGNSLTTYAGYTVLLQTLERLQLDPADAQVAIVGYPGSICLALAKLLLQLGCR 
>UniRef50_A4FH75 121 RVDVPLTSGNSLTTYSAHELLRTVIARLGRRPSDVEVGIVGFPGAIGLAMARLLLDDGCR 
>UniRef50_Q2LW66 121 ------------------------------------------------------------ 
    
>PigE 181 LHLLHRAGHKDEDELLSHLPEQYRSRVTLTSDPEDLYPRCKLFVAATSAGGVIDPYKLQP 
>UniRef50_Q2S9J6         181 LDLVHRGTADDAQLL-EHLPEHWRSRVTLLNSMDAAYERNRLFAAATSSGGVIDVSRLAP 
>UniRef50_A4FH75 181 LHLVHRKGRMRPEQLLDELPAAAHDRVTIGDDVAECLRRTRLIVAASSAGGLIDCDDLRP 
>UniRef50_Q2LW66 181 ------------------------------------------------------------ 
    
>PigE 241 GSVFIDVALPRDINSDTRPDRDDILIIDGGCVTATDAVKLGGESLNVTIKQQLNGCMAET 
>UniRef50_Q2S9J6         241 GSIVVDIALPRDAERPPTP-RTDVLVLDGGCVTASPATKLGGESMNMSIKQQINGCLAET 
>UniRef50_A4FH75 241 GSVVVDVALPRDVRRPVRERR-DVLVLDGGLVSASDAVVLDGM--ELATSEQINGCLAET 
>UniRef50_Q2LW66 241 ------------------------------------------------------------ 
    
>PigE 301 IVLALENRRENFSLGRYLALDNVLEIGELAEKHGFLVYPLASYGERIDRQRVINLKRYYH 
>UniRef50_Q2S9J6         301 MVLALEGRAECFSIGRDLPPEKVLEIGEIAERHGFRAFPLASYGERINIELINGLRRFHH 
>UniRef50_A4FH75 301 VVLALEERAESFSLGRELDPGRVREIGELARRHGFLPSAPSSWGRLVRLDRIDELPGWSA 
>UniRef50_Q2LW66 301 ------------------------------------------------------------ 
    
>PigE 361 HDIYSDEPDTEQPPASQLAFIDAIIAQDPAREDTLDRYHQFINPMMVEFLKLQHCDNVFR 
>UniRef50_Q2S9J6         361 RGNAQAPGYT-----PSDLAATEPDSGEARRSQTVQRYRSYINPMLADFLQMQRCDKVFE 
>UniRef50_A4FH75 361 -------------------------ERPDPAESTRRRFRDNVNPPLAGFYAVHGMDRVFT 
>UniRef50_Q2LW66 361 ---------------NSCSGTRMSKEGETMREDLVTRTQRLLAPSLVIHS-----DIVVK  
    
>PigE 421 RASGTQLFTADGEAFLDMVAGYGCINLGHNPQPIIDALKAYLDAQGPNFIQYISIPEQAA 
>UniRef50_Q2S9J6         421 RAEGCTLTDTDGERFLDMVSGYGCLNLGHNPQVVTEAIQKYVANMGPNFVQYVSLPEETS 
>UniRef50_A4FH75 421 RGSGSTLTTADGVEYLDFIGGYGSLNVGHNHPAVTAAVGQFLTAGEPTFVQYASIPHRTA 
>UniRef50_Q2LW66 421 RGHGVYLESVDGKRYLDFTSGLAVANVGHSHPKIVEAIKKQAEELVHAGCMFYY--EPLA  
    
>PigE 481 KLAEVLCHFAPGNMGRVFFSNSGTEAVEAAMKLAKASTGKAGIAYLKNSYHGKTLGALSI 
>UniRef50_Q2S9J6         481 KLAERLCAVAPGRFERVFFSNSGTEAVEAALKLAKAASRRSRFVFANNSYHGKTLGALSV 
>UniRef50_A4FH75 481 ELAERLCEIAPGGMRRAFFGNSGAEAVEAALKLARAATGRTRFVHAENSYHGKTFGALSV 
>UniRef50_Q2LW66 481 EYPERLKEVTPPGLDRFFFSNSGAEAIEGALKLARYFTGRQGILAFSGAFHGRTYGALSL 
    
>PigE 541 TGREKHRRHFKPLLASMIEVPFADIEALRQTLSRDDIGALMIEPIQGEGGVHVPPPGYLR 
>UniRef50_Q2S9J6         541 TGREKHQKHFRPLLPGCTGVPFGDLEALRVELEQGDVCAFIIEPIQGEGGVYLPPDGYLK 
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>UniRef50_A4FH75 541 TGRDHYRDPFRPMVPDCVGVPFGDENALREAIAG--AAAFIVEPVQGEGGVVLPPPGYLT 
>UniRef50_Q2LW66 541 TSNAKYRNRYAPLLPSVYHAPYPYCYRLNRLIAPEEIACAVIEPMLGEGGYVVPPARYLK 
    
>PigE 601 TVQEICRQTDTLLMVDEVQTGLGRTGKLFACEWEGIEPDVLMLSKSLSGGVMPIGATLCR 
>UniRef50_Q2S9J6         601 AAQELCRRTGTLLIVDEIQTGLGRTGRLFACEWEGVEPDIMVLSKSLSGGLIPIGATLSS 
>UniRef50_A4FH75 601 AAQRICREAGAVFIVDEIQTGLGRTGAMFACEHEGVEPDVLCLAKSLSGGLVPIAATLST 
>UniRef50_Q2LW66 601 KLRKLCDREGILLIFDEVQSGMGRTGRWFASEHFGIVPDIMTLAKGIANG-MPLSAVVSS 
    
>PigE 661 AIFGNGPYGTADRFLMHSSTFGGGNIAAVVALSALREILAQDLVGNAERLGTYFKQALTD 
>UniRef50_Q2S9J6         661 AQIWDAAYASTGRFLLHTSTFGGCNLAGVAGLAALEGVIEQDLPRRAQEMGDYFKAELQQ 
>UniRef50_A4FH75 661 AEVWDAAYGSSSGSLLHTSTFGGGNLASVAALATLDLIESEKLAARAEVMGRRLRDALTE 
>UniRef50_Q2LW66 661 GRIMD-----GWAPGTHGTTFGGNPVSLCAAAATLRVIEEERLLENAAVVGSKALERLES 
    
>PigE 721 VAARYPFVAEIAGRGLMLGIQFDQTFAGAVGASAREFATRLPGDWHTTWKFLPDPVQAHL 
>UniRef50_Q2S9J6         721 AVQAYPFIKEVRGRGLMLGIQFNNDFSGAVEACAREFGTRLPGDWHLAYRFFPDEVREHL 
>UniRef50_A4FH75 721 ACAPFEFVGEVRGIGLMNAIAFDARYDGAVRTAVEDMASRLPGDFRAIAELLPDPVREVL 
>UniRef50_Q2LW66 721 MKDRHPVIGDVRGRGLMIGVEFVREGK--------------------------------- 
    
>PigE 781 KAAMERMEQSLGEMFCMKFVTKLCQDHNILTFITANSSTVIRIQPPLTISKAEIDRFVSA 
>UniRef50_Q2S9J6         781 AAAVGKMEESLAEMFCMRFVTKLSNDHRILTFVTANSSTVIRIQPPLIISKEEVDHFVKS 
>UniRef50_A4FH75 781 RQAGSSVETALGDLLCLRFVAAMGRDHRILTFVTANRNQVVRLQPPLVVTEAEIDRFAES 
>UniRef50_Q2LW66 781 ----------EPDRATVEKIMKTCLDRGLLLVECGGDKNILRLIPPLVITREEMDHGLDI 
    
>PigE 841 FATVCDELSTFLE 
>UniRef50_Q2S9J6         841 FATVCEEMS----     
>UniRef50_A4FH75 841 ARAVCETAT----     
>UniRef50_Q2LW66 841 LEEAI--------    
 
1.2 BLAST 
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2. Bioinformatic of PigD 
>PigD 1 MTTMIGQTRQAGSSSYEQAWQAEQAPCPGMEPDTLTVGVVVVTRNPTFFQTGLSVLNDIR 
>UniRef50_Q2S9J7 1 ---------------------------------EITIGVIVVTRSRGFFETGLSVLSDIR 
>UniRef50_B9KBA0 1 ------------------------------------------------------------ 
>UniRef50_C6VV63 1 ------------------------------------------------------------ 
   
>PigD 61 DYVFNRVHIQSELPLKLSELASDPLYSEAREKAIHFLKNQSKALNIQVIQCASLAEATGK 
>UniRef50_Q2S9J7 61 GEVFQQVSLDADIEFEEKLPSTHPVYEEARDKAVRFLGKRKERISMRVIQADSLARAQDK 
>UniRef50_B9KBA0 61 ------------------------------------------------------------ 
>UniRef50_C6VV63 61 ------------------------------------------------------------ 
   
>PigD 121 IIYTHALEQQPEFQMGMLFYDQTSLGNVDDSIEKIDRDLDAFYSAMQRGGIPAFYTTFST 
>UniRef50_Q2S9J7 121 ILQAPLLGTN--FQVGMVYVDYADPQFEDLAPQQIDAQLRDFYAVLRQADIPVFQSSFST 
>UniRef50_B9KBA0 121 ------------------------------------------------------------ 
>UniRef50_C6VV63 121 ------------------------------------------------------------ 
   
>PigD 181 VTFIRDVRSSFRYLPQQYREIVRSEDPAIFQTELLCLWMDFFEMNYTNRRVKPIGALALH 
>UniRef50_Q2S9J7 181 VVYTLPQRPRIRHQPMEYIERQLPDDRSLLQADLLCLWMDFFEMSYANRRVKPAARVLPH 
>UniRef50_B9KBA0 181 -----------------------------------------------------------K 
>UniRef50_C6VV63 181 --------------------------------------------------PVVSVAKPEL 
   
>PigD 241 NTLAEQLIQFFERTAASRWLVSYYTGSIISNLIGYLDRHAEAHGALVLRGPNEHAIACGA 
>UniRef50_Q2S9J7 241 NTLGEHLINFLSARAGSEWLGFYFTGSLVSNMINYLEQEAAHRDVLLLRGPSEHSLACGA 
>UniRef50_B9KBA0 241 MKGSKMLFEAFLREGVDT--IFGIPGGAIINVYDELCNYED--KINFYLFRHEQGATHAA 
>UniRef50_C6VV63 241 INGSHAVIQSLIAEGVKT--IFGYPGGAIMPVYDAIYDYQDQ--IDHILVRHEQGAAHAA 
   
>PigD 301 MANWQLYRMPFLGVVTSGMMDEFKGTLINLKETAAQGIIVAAENRNNQWYSFQGTQTPTE 
>UniRef50_Q2S9J7 301 MANWQLYRRPFLIVVTSGMIDEFKGTIANLREARAQGFIVCAENRHDQWFAFQGTVSAEE 
>UniRef50_B9KBA0 301 DGYARVTGKPGVVIVTSGPgtNTVTGIATAYMDSIPLVVITGQVPTSFIG---TDAFQEV 
>UniRef50_C6VV63 301 EGFARISGEVGVCLVTSGPgtNLVTGIADAIIDSTPMVCIIGQVASHLLG---TDAFQET 
   
>PigD 361 DMRDVLAAKRIPYVYIDDVDGIADGLAEVFRLYHQAQGPVVILATQNVLESTLSLEPVPG 
>UniRef50_Q2S9J7 361 DSREVIKARGLPCLYLNDVDRLQEDLQKAMELYDAKRGPVVLLATQAVLEACSRFDIAYP 
>UniRef50_B9KBA0 361 DVTGITMPITKHNHLVTSIEELPYAIKEAFYVatGRPGPVVLDFPKDIQTAEGEFNYPDE 
>UniRef50_C6VV63 361 DVMGITIPITKWNYQITNADEIPEIIAKAFYIasGRPGPVLIDITKDAQ-QKLMTKPFVH 
   
>PigD 421 DLPPVSGLPAYDCPPISDSFEQAMALINEGPEKLVWQLGPVSDDEYALVHEIADAAGLAL 
>UniRef50_Q2S9J7 421 PAPEAPSDTI--PESVQPVLDQVMSLLNDGPDKLVWQCGAMDEEELELTLSIAERAGVAL   
>UniRef50_B9KBA0 421 IEILGYKPTVKGHP---KQIKKAMELLKESKRpvIVGGGANLSGAMDLVNRFIDKFGVPA 
>UniRef50_C6VV63 421 KKTETLLSYHPRVAPKEEQLAAAAKLINQAKRplFVGHGVQISGAEQELIQFIEKTDIPA 
   
>PigD 481 VDSLAHPGSAPKYYQGKRNPHYLGTLAIYGYSPRVYNFLHTNDKLNPMSDQSVFMIKSRV 
>UniRef50_Q2S9J7 481 VDSLTYPGSVPKFRHCQRNRNYLGALAVYGYSPRVYNFLHTNDKMNPQSEQCLFFIKSKL 
>UniRef50_B9KBA0 481 VSTLMGRGVNPSDER-----LYYDGIGMHGAYYGNYAV---------ANADLIIALGVRF 
>UniRef50_C6VV63 481 ASTLLGLSSVSVDH-----PNYVGWLGMHGNYGT---------NVLTNQCDLIIAVGMRF 
   
>PigD 541 AQITTPFSDGRLERKVHLVQLTHDERHLSPYADLKLHMDCLTFLRAVKANLHVDAALREK 
>UniRef50_Q2S9J7 541 HQVCTPFSDGRLQRKLQIVQLTDNPEHISPYTDFPLVLEHKQFLRYVDKHLAPSPELVAR 
>UniRef50_B9KBA0 541 SDRILG-NPRTFTRNARIVHVDIDPAEIGKnvDVPIVGDLRNVLEEFLKY--DLDTDFSE 
>UniRef50_C6VV63 541 DDRVTGDLS-RYAKQAKVVHIEIDPAEIDKIvdAPVVGDAKKALELLLPLVNENNH---- 
   
>PigD 601 RKALIAAYLDSPSDVVSQLPSLPMSANYFFCQLNRVIENLIKTENFDFTGVYDVGRCGIS 
>UniRef50_Q2S9J7 601 RYQAIASVPDSPSDMASRLPTTPMTPNYFFARLNKLMEKLIVEHGYDYTGLYDVGRCGIS 
Appendix 
175 
 
>UniRef50_B9KBA0 601 WIEELQEVKKKYPLTYK-RDGKLIKPQY-------IVEKVNEVFPDDTIVVADVGQNQMW 
>UniRef50_C6VV63 601 -EAWKAEFKKYDAIEDEKITQPELAPTTEKIKMAEVIRTLSDKTKGEAVIVADVGQHQMM 
   
>PigD 661 AVRNVAKTRRGFSGWYGRALMGDALLATSYLAHTSPTHVVAFIGDGAKGIVPDILPAFID 
>UniRef50_Q2S9J7 661 AVRNLARTRRGFSGWYGRALMGDALMASISLAFTSPSNVVAFIGDGAKGLTPDVLPSLLE 
>UniRef50_B9KBA0 661 VAQYYRFKHQrfLCSGGLGTMGYALPAGIGAKiaPDREVVIFAGDGGFQMNIQELMTV-- 
>UniRef50_C6VV63 661 TARYYQFKKpsFITSGGLGTMGYALPASFGAKvaPDREVVAMIGDGCFQMTIQELGTIAQ 
   
>PigD 721 NILTHPQLLNKSITIFYFCNGGLSVINTYQERILFNRTSRQMRLVNVDQPAFEQTVDDFH 
>UniRef50_Q2S9J7 721 NALSYPGRMNRNLTIFYFCNGGHSVINTYQERILFNYTSRQMRLVNVTDQDWEDELGGLR 
>UniRef50_B9KBA0 721 ------KRYNLPVKIIVMDNKALGMVRQWQQLFFNCRYSATILA---DNPDFAKIAEAVG 
>UniRef50_C6VV63 721 S--------GLPVKIIILNNNFLGMVRQWQQLFHQKRYS----FVELQNPDFITIAKGFG 
   
>PigD 781 IQGKTLTHFDEDTIRHALMTPKRLNLFSVVLGHNNEGDGISLATAKGWQRDPSDREALQE 
>UniRef50_Q2S9J7 781 FTSRTLTTFDPAALTSALLRPGCVNLFSVMVSHNNEGDGISLATATGWQRDP----ATQP 
>UniRef50_B9KBA0 781 IKAMRIEKPDerAVEE-LARSKEPMLIHAVVDPAENVLPMVPPGG--------------- 
>UniRef50_C6VV63 781 INGHTCSKREdaSLDTMLA-SDKPYLLEVIVEKEENVFPMVPTGA--------------- 
   
>PigD 841 RKDWAARQPESTSTSFDQGQNKEAIS 
>UniRef50_Q2S9J7 841 QAEAKAQTATGTDTETDK--------     
>UniRef50_B9KBA0 841 -------------------------- 
>UniRef50_C6VV63 841 -------------------------- 
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